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Despite 50+ years of use as anxiolytics, anti-convulsants, and sedative/hypnotic agents, the 
mechanisms underlying benzodiazepine (BZD) tolerance are poorly understood. BZDs potentiate 
the actions of GABA, the primary inhibitory neurotransmitter in the adult brain, through positive 
allosteric modulation of γ2 subunit containing GABA type A receptors (GABAARs). Sustained 
treatment with BZD drugs is intimately associated with the development of tolerance, dependence, 
withdrawal and addiction. BZD efficacy diminishes after prolonged or high dose acute exposure, 
with tolerance to the sedative/hypnotic effects forming most quickly. We investigated the adaptive 
mechanisms occurring during initial exposure to the classical BZD, Diazepam (DZP), and the 
molecular signature of the mouse brain during established sedative tolerance. We found cultured 
neurons treated 24 h with DZP presented no change in surface or synaptic levels of γ2-GABAARs. 
In contrast, both γ2 and the key inhibitory synaptic scaffolding protein gephyrin levels were 
decreased after a single DZP treatment in vitro and in vivo. Live-imaging and label-free 
quantitative proteomics further revealed alterations in γ2 subunit surface trafficking, 
internalization and lysosomal targeting. In comparison, mice treated seven days with DZP had 
altered GABAAR subunit composition, reduced responsiveness to DZP, and tonic inhibition was 
diminished. Furthermore, DZP increased excitatory NMDA receptor subunit levels and function. 
State of the art mass spectrometry experiments revealed increased CaMKII subunits, which are 
positive regulators of NMDA receptors and involved in tolerance to other drugs. Downstream 
bioinformatics analysis confirmed robust synaptic plasticity after DZP. Together, we describe a 
time-dependent downregulation of synaptic GABAAR function after initial DZP exposure 
 v 
followed by an adaptive increase in excitatory neurotransmission, neuronal remodeling and altered 
synaptic GABAAR composition. 
 vi 
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1.0 Introduction 
Chapter adapted from:  
 
1) Lorenz-Guertin, J. M. and T. C. Jacob (2017). GABA type a receptor trafficking and the 
architecture of synaptic inhibition. Develop Neurobiol  
(1) https://doi.org/10.1002/dneu.22536 License Number: 4611921510881 
1.1 The GABA Type A Receptor 
GABAA receptors (GABAARs) are ligand-gated ionotropic chloride (Cl-) channels 
responsible for most fast inhibitory neurotransmission in the mature central nervous system (CNS). 
Ubiquitous expression supports their central role in regulating most aspects of CNS function. 
Binding of the neurotransmitter GABA induces GABAAR ion channel opening, Cl- influx, and 
subsequent membrane hyperpolarization (Fig. 1A). These receptors are heteropentameric 
structures typically composed of two α (α1-6), two β (β1-3), and either a γ (γ1-3) or a δ subunit 
(2). Subunits share a common structure consisting of a large N-terminal extracellular domain 
(ECD) that participates in GABA binding, transmembrane domains (TM) comprised of four α-
helical regions (TM1-4) and a small extracellular C-terminus (Fig. 1C). The TM regions are 
connected by a small intracellular loop between TM1-TM2 and a much larger intracellular domain 
(ICD) between TM3 and TM4 that undergoes extensive post-translational modifications and is 
key for protein trafficking and function (Fig. 1C). The most common GABAARs providing fast 
synaptic inhibition in the mature mammalian cerebral cortex contain α1β2γ2 subunits (Fig. 1B) 
(3). As viewed from outside the cell GABAARs are arranged in a counterclockwise subunit 
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configuration of γ-β-α-β-α (Fig. 1B) (4, 5). Despite the great diversity of GABAAR subunits (α1-
6, β1-3, γ1-3, δ, ɛ, θ, π, ρ1-3) and possible configurations, these receptors produce two types of 
currents: synaptic (phasic) and tonic. Presynaptic terminal release of GABA onto post-synaptically  
 
Figure 1. GABAAR Structure and Subunit Topology.  
A) A representation of the heteropentameric GABAAR composed of αβγ subunits. Binding of the neurotransmitter 
GABA (yellow circle) at the αβ interface triggers ion channel opening and allows the rapid influx of Cl− and membrane 
hyper polarization in the mature nervous system. (B) Extracellular representation of the receptor showing all five 
subunits contributing to the central ion pore and the general binding sites of GABA (yellow circle) and 
benzodiazepines (BZs) (red square). BZs bind at the interface of an α1/2/3/5 and γ subunit. (C) All subunits have a 
common topology including an extracellular N-terminal domain, short C-terminal tail, and four transmembrane 
domains (TM1–4). GABAAR subunit TM2 (blue) contributes to formation of the receptor ion channel pore, while the 
intracellular domain (ICD) between TM3 and TM4 contain sites of phosphorylation and protein interactions that 
modulate channel function and/or trafficking. Adapted from: Lorenz-Guertin, J. M. and T. C. Jacob (2017). GABA 
type a receptor trafficking and the architecture of synaptic inhibition. Develop Neurobiol.. 
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clustered GABAARs triggers fast, transient synaptic currents, while ambient “spill over” GABA 
generates a persistent tonic current via activation of extrasynaptic receptors. GABAAR subunit 
composition therefore determines receptor cell surface localization, electrophysiological 
properties and drug sensitivities. 
In addition to their inhibitory function in the mature CNS, GABAARs are of fundamental 
importance in organization of newly forming circuits by promoting dendritic outgrowth and 
synaptogenesis. Synapses develop first with the emergence of excitatory GABAergic synaptic 
signals that drive the subsequent establishment of glutamatergic synapses, before GABA 
neurotransmission shifts to functioning as an inhibitory signal (6-9). Underlying deficits in 
GABAergic neurotransmission occur in a wide variety of neurological disorders such as epilepsy, 
psychiatric disorders (anxiety (10, 11), depression (12, 13), post-traumatic stress disorder (14-17)) 
and neurodevelopmental disorders including autism (18-21), Fragile X (22, 23) and schizophrenia 
(24-26). Importantly, pathophysiological events including seizures (27), ischemic stroke (28-30), 
traumatic brain injury (31) and stress can cause adaptive changes in GABAAR neurotransmission, 
compromising GABAergic inhibition and further hampering recovery.  
1.2 GABAAR Pharmacology 
 GABAAR Clinical Agents 
The ubiquitous expression of GABAARs in the CNS makes these receptors key drug targets 
to enhance inhibition and globally dampen neuronal activity. Multiple clinically recognized agents 
exert actions at GABAARs specifically or non-specifically including barbiturates, benzodiazepines 
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(BZDs), benzodiazepine-site ligands, barbiturates, intravenous and volatile anesthetics, ethanol 
and neuroactive steroids (32). In general these drugs induce distinct conformational states of 
GABAARs thereby altering the efficacy of GABA-mediated receptor activation. The site of 
GABAAR drug action is highly dependent on GABAAR subunit composition and binding site 
interfaces. For example, BZDs bind between the interface of a γ2 subunit and a directly adjacent 
α1/2/3/5 subunit at the ECD (Fig. 1B) (33). In contrast, transmembrane domain interactions 
between non α/γ subunit interfaces mediate binding drugs like etomidate, propofol, barbiturates, 
volatile anesthetics, octanol, and neuroactive steroids (34). Importantly, a recent surge in high-
resolution GABAAR structural findings (35-40) have dramatically expanded our molecular 
understanding of drug binding sites and the physical changes in receptor conformation that mediate 
downstream signaling and clinical effects. GABAAR structures for the human β3 homopentamer 
bound to benzamidine (35), chimeric α5TM/β3ECD bound to the neurosteroid allopregnanolone 
(37), human α1β2γ2 heteropentamer bound to the benzodiazepine site antagonist Flumazenil (36), 
the human α1β3γ2 GABAAR in a lipid bilayer (38), as well as full-length α1β3γ2L bound in 
different conformations in the presence of a channel-blocker, agonist or competitive antagonist, or 
the BZDs alprazolam and DZP (39) have all been recently resolved. One notable finding from this 
work is the physical identification of an additional second low-affinity DZP binding site between 
the β3/α1 receptor interface (39), consistent with the biphasic response seen in electrophysiology 
studies using high DZP concentrations (41). 
 BZD Clinical Use and Tolerance 
No GABAAR drug class has been more heavily utilized clinically or subject to more 
intensive research efforts than BZDs. The BZD drug class was first introduced in the 1960’s by 
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the company Hoffman-La Roche with the release of the revolutionary drug chlordiazepoxide 
(Librium) (42). As compared to the widely-used CNS depressant barbiturate agents, 
chlordiazepoxide demonstrated significantly less dangerous side effects, most notably respiratory 
depression. By 1963, the second and more potent BZD, diazepam (DZP; Valium), also entered the 
marketplace. Before long, DZP became one of the top selling drugs in the history of mankind (43). 
The wide-spread use of these drugs propagated a need to characterize their pharmacological target 
and mechanism of action, ultimately leading to the discovery of the GABAAR (also referred to as 
the “BZD receptor” up until the early 2000s). Clinically, BZDs are used for their sedative, 
myorelaxant, anticonvulsant and short term memory loss effects. Multiple BZD type drugs exist 
with differing pharmacokinetic/pharmacodynamics profiles and some selectivity for specific 
GABAAR subtypes.  
The classical BZD, DZP, belongs to a subclass of non-selective, long-acting BZDs that 
includes the drug flurazepam (Dalmane). Intermediate-acting BZDs (example: alprazolam; Xanax) 
have relatively shorter half-lives compared to DZP and flurazepam and their metabolites, where 
the elimination half-life may take up to 48 h in humans. A subclass of short-acting BZDs with 
half-lives of 1-4h are also available, namely midazolam (Versed) and triazolam (Halcion). These 
differences in half-lives, as well as other characteristics including peak onset time and drug 
administration options, provide clinicians multiple BZD therapy options to suit the preferred 
therapeutic outcome. This catalog of BZD drugs is heavily utilized in medicine; in 2008 
approximately 5.2% of US adults aged 18-80 used BZDs according to one study (44). Additionally, 
a more recent survey from 2015-2016 found 12.6% of adults reported BZD use in the last year 
(45). Shockingly, 25.3 million individuals reported taking the drug as prescribed, while 5.3 million 
were reported to be misusing the drugs. 
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The chronic use of BZD drugs manifests in a number of behavioral and physical symptoms 
including tolerance, withdrawal, addiction and dependence. Requiring a higher dose of a drug to 
achieve the same therapeutic effect overtime is known as tolerance, and is a hallmark of BZD use. 
At the molecular level, positive allosteric modulation by BZD enhances GABAAR inhibition by 
increasing the binding affinity of GABA and increasing ion channel opening frequency (33). This 
potentiating effect of BZD is lost after prolonged or high dose acute exposure in animal models 
and humans, characterized first by a loss of sedative/hypnotic activity followed by the anti-
convulsant and potentially anxiolytic properties (46). 2-Deoxyglucose quantitative 
autoradiography in BZD-treated rats suggests that tolerance initiates in the cerebral cortex (47), a 
region with diverse roles in sensory and motor processing, anxiety  (48), memory (49) and sleep 
(50). The induction of BZD tolerance occurs in part due to the uncoupling of allosteric actions 
between GABA and BZD, leading to diminished potentiation of BZD on GABA-induced current 
and a loss in the ability of GABA to potentiate BZD binding (51, 52).  Resolving the 
neuroadaptations that occur after BZD treatment and the molecular mechanisms regulating 
GABAAR function and drug responsiveness will provide a critical step in building towards new 
treatment paradigms that limit the harmful side effects of BZD agents. 
1.3 GABAAR Regulation and Surface Localization 
 Key GABAergic Synapse Components 
The confinement of GABAARs at synaptic sites is a key step in tuning the strength of phasic 
inhibition, receptor function and drug response (53) (Fig. 2). The postsynaptic inhibitory 
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scaffolding protein gephyrin is the main organizer of GABAAR synaptic localization and density 
(54), as gephyrin knock out mice exhibit a robust loss of GABAAR clustering (55), although 
gephyrin-independent synaptic clustering does occur (56, 57). Gephyrin is a highly conserved 93 
kDa protein that is hypothesized to form multimeric complexes which associate with a number of 
cytoskeletal proteins (58), contributing to its scaffolding function (59). The architecture of 
gephyrin scaffolding arises from the N-terminal or G-domain of gephyrin participating in dimer-
dimer self-associations, while the C-terminal or E-domain forms trimer interactions, likely to 
create a hexagonal lattice (60, 61). This structure tethers freely-diffusing receptors at synaptic sites 
through binding GABAAR α1, α2, α3, α5, β2, and β3 subunits (62-65).  The GABAAR γ2 subunit 
also plays an important role in gephyrin-receptor attachment, as γ2-knockout mice demonstrate 
diminished clustering of gephyrin and GABAARs (66, 67). Importantly, synaptic GABAAR 
clustering can occur independent of γ2 in some cases (68). Functionally, gephyrin acts to confine 
receptors undergoing diffusion at the cell surface membrane and limit their escape into the 
extrasynaptic space, a process that is influenced by neuronal activity and GABAAR specific drugs 
including DZP (69, 70).  
Gephyrin’s scaffolding ability is regulated by extensive post-translational modifications. 
Mass spectrometry studies alone have revealed 22 sites of phosphorylation in gephyrin’s C-domain 
and 1 additional threonine 324 (Thr324) site in the E-domain (71-73). Yet, the exact role of 
gephyrin phosphorylation is complex and controversial, highlighted by the bidirectional effect of 
altering gephyrin phosphorylation at the serine (S) 270 site. Initial findings by Tyagarajan et al. 
(2011) (74)  identified phosphorylation of this site by Glycogen Synthase Kinase 3β (GSK3β) to 
negatively modulate gephyrin clustering via enhanced Ca2+-dependent protease calpain-1 
mediated degradation. Accordingly, overexpression of a phosphodeficient S270A gephyrin mutant 
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enhanced both the amplitude and frequency of miniature inhibitory postsynaptic currents 
(mIPSCs), suggesting increased functional GABAAR clustering. It was later revealed that the S270 
site was also a substrate for the proline-directed serine/threonine kinase, cyclin-dependent kinase 
5 (CDK5) (72, 75). Gephyrin synaptic clusters were found to be basally phosphorylated at Ser270 
in a CDK5-dependent manner (72), with CDK5 knockdown or inhibition leading to loss of 
phosphorylated gephyrin clusters and postsynaptic γ2-containing GABAA receptors (75). To 
further complicate these findings, S270 is cross-regulated by phosphorylation of a neighboring 
S268 residue targeted by extracellular signal-regulated kinase 1/2 (ERK1/2) (73) (role for ERK 
also described in (76)). This study suggested these serine residues control distinct gephyrin 
clustering dynamics including postsynaptic cluster size and number, again in conjunction with 
calpain activity. Expanding the role of gephyrin serine site regulation, phosphomutant studies and 
in vitro kinase assays indicate that increased phosphorylation of gephyrin on S305 (mass 
spectrometry identification by Tyagarajan et al) by the kinase CAMKII is required for activity-
dependent inhibitory plasticity (77). Considering the number of additional gephyrin 
phosphorylation sites identified in vivo and the challenges of gephyrin point mutant studies 
(overexpression concerns), continued multidisciplinary efforts are necessary to resolve the 
functional relevance of these modifications.  
Transynaptic proteins are also key to GABAergic synapses formation and stability. One of 
the most well characterized trans-synaptic interactions crucial for GABAAR synapse development 
is that of neuroligins and neurexins (78) (Fig. 2). Neurexins are found presynaptically and induce 
differentiation of GABAergic and glutamatergic postsynaptic densities during maturation and 
plasticity (79, 80), although overexpression of neurexins leads to reduced GABAergic 
neurotransmission (81). Postsynaptically, different neuroligins (NL1-4) are found at either 
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glutamatergic or GABAergic synapses and play important scaffolding and receptor recruitment 
roles. GABAergic synapses primarily rely on NL2 for synapse integrity, and when expressed with 
recombinant GABAARs in HEK cells, NL2 supports formation of functional GABAergic synapses 
in neuron co-culture systems (82). Moreover, NL2 is critical for GABAergic synapse formation 
and coding in the retina (83), while enhanced expression of this protein in cerebellar granule cells 
can accelerate GABAAR synapse development (84, 85) and strengthen inhibitory synaptic function 
in hippocampal neurons (86).  
Our current overall understanding of the proteins involved in inhibitory synapse stability 
and clustering remains incomplete, as highlighted by two in vivo inhibitory synapse proteomic 
screenings using α2-pHluorin (pH-sensitive GFP) tagged subunit knock-in mice (87) or viral 
expression of inhibitory fusion proteins including gephyrin (88). These mass spectrometry 
methods revealed 140 (Uezu, et al. 2016) and 149 (Nakamura, et al.  2016) novel protein 
components of GABAAR/inhibitory synapses spanning multiple trafficking, stability, and 
regulatory pathways. Collectively, these studies further validated molecular interactions between 
GABAAR intracellular loops and the metabotropic glutamate receptor subunit mGluR5, the Dbl 
family GEF Ephexin, the metabotropic GABA B receptor (GABABR) auxiliary subunit KCTD12, 
and initiated characterization of a novel inhibitory synaptic regulator inhibitory synaptic protein 1 
(InSyn1). Our lab recently found DZP-induced changes in γ2-GABAAR using label-free 
quantitative proteomics (details in Chapter 3), identifying new key interactor proteins and changes 
in their association by a common clinical agent. Future investigations will need to dissect the exact 
roles of these identified proteins in GABAAR regulation and function.  
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 Extrasynaptic GABAARs 
While synaptic receptors participate in phasic inhibition, extrasynaptic GABAARs are 
responsible for setting the inhibitory tone of a neuron through the generation of a constant tonic 
current. Receptors composed of α4βδ or α6βδ subunits are found extrasynaptically and respond to 
low concentrations of ambient or “spillover” GABA (89-94) (Fig. 2). While hippocampal tonic 
currents are largely generated by synaptic spillover (95), other GABA sources include astrocytes 
(96, 97), and neurogliaform cells (98). Furthermore, extrasynaptic GABAARs can be 
spontaneously open in the absence of GABA (99). GABAARs incorporating the α5 subunit with 
βγ2 also represent a large pool of extrasynaptic GABAergic signaling (100, 101), although this 
receptor subtype can be found clustered both synaptically (63, 102, 103) and extrasynaptically 
(104). Scaffolding of α5βγ2 GABAARs extrasynaptically occurs due to interaction with the ERM 
(ezrin, radixin, moesin) family protein radixin (104), whereas α5 was recently shown to interact 
with gephyrin at synaptic sites (63).  
It is important to note that GABAARs undergo Brownian motion at the surface membrane 
and are continuously diffusing into and out of the synaptic and extrasynaptic space (105), meaning 
δ containing GABAARs can impact synaptic current, and γ2 GABAARs participate in extrasynaptic 
tonic current. GABAAR subtype specific protein interactions regulate the degree of confinement 
at a given location and GABAAR diffusion dynamics and localization are highly influenced by 
activity-dependent changes and various signaling cascades (Section 1.5). For instance, radixin acts 
in a phospho-dependent manner to scaffold α5βγ2 receptors to the actin cytoskeleton ultimately 
reducing diffusion rates and concentrating channel activity away from axon terminals (106). 
Bidirectional control of radixin phosphorylation state by the RhoA GTP- and Rho-kinase (ROCK) 
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dependent pathway is contingent on GABAergic versus glutamatergic activity (Fig. 2). 
Application of GABA favors radixin phosphorylation and retention of α5-GABAARs 
extrasynaptically, while AMPA treatment leads to dephosphorylation and increased percentage of 
α5-subunit receptors found synaptically (106). Additional GABAAR subtypes are also subject to 
synaptic/extrasynaptic exchange following manipulations of the excitatory/inhibitory balance 
and/or kinase signaling. Gerrow & Triller (2014) identified GABABR activity increases α2-
GABAARs diffusion from synapses via PKC activity, allowing α5-GABAAR synaptic 
accumulation due to available synaptic binding slots (107). PKC-activation also promotes synaptic 
accumulation of α4-containing GABAARs (108), while PKA-activation shifts α4-receptors 
extrasynaptically (Fig. 2) (109). These findings highlight the dynamic nature of GABAAR 




Figure 2. GABAAR Synapse Structure. 
GABAARs composed of α(1–3)βγ subunits are largely synaptically localized via gephyrin interactions and contribute 
to phasic currents, whereas α(4/6)βδ receptors are extrasynaptic and generate tonic current. α5βγ receptors are found 
in both locations due to binding with gephyrin at synapses and radixin extrasynaptically. Proteomics and other modern 
strategies have significantly enriched the complexity of the inhibitory synapse, however the functions of many new 
components have yet to be defined. Key synaptic adhesion, scaffold and signaling proteins shown. Adapted from: 
Lorenz-Guertin, J. M. and T. C. Jacob (2017). GABA type a receptor trafficking and the architecture of synaptic 
inhibition. Develop Neurobiol. 
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1.4 GABAAR Intracellular Trafficking 
 Assembly and Forward Trafficking 
GABAAR biogenesis is controlled via regulated assembly of subunits into heteropentamers 
within the endoplasmic reticulum (ER). Due to the diversity of receptors generated in recombinant 
systems during multiple independent subunit transfections, studies on assembly of concatenated 
subunit constructs have been a major route for determining receptor configuration. GABAAR 
studies using heterologous cells show that a β subunit is required for receptor cell surface 
expression, while the αβ interface that forms the GABA binding site is required for functional 
responses. Although unlikely to occur in vivo, β1 or β3 homomeric channels form, while other 
individual subunit expression leads to ER retention (110, 111). Co-expression of γ2 subunits with 
αβ leads to preferential assembly of αβγ2 receptors (112, 113). Receptor complex formation begins 
with αβ heterodimer formation, with the N-terminal domains controlling this process. Studies of 
α1β2γ2 recombinant receptors demonstrate that the N-terminal putative α helical region of the α1 
subunit is critical for surface receptor expression, while deletion of the other subunits N-terminal 
extensions had minimal effects on surface expression (114). Rather, deletion of the β2 α-helix 
decreased GABA sensitivity and receptor desensitization, while γ2 N-terminal deletions reduced 
incorporation of γ2 in receptors.  
The exit of GABAARs from the ER is negatively regulated by constitutive ER-associated 
degradation (ERAD) (115-117). ERAD recognition of misfolded proteins leads to their dislocation 
from the ER membrane, ubiquitination via E3 ligases, and proteosomal degradation in the 
cytoplasm. Chronic neuronal blockade via 24 h tetrodotoxin (TTX) treatment increases β3 subunit 
GABAAR ubiquitination and ERAD, leading to reduced receptor cell surface expression and 
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decreased inhibition (117). Conversely, enhanced neuronal activity diminished β3 subunit 
ubiquitination and improved receptor stability. Reduced calcium entry via voltage-gated calcium 
channels (VGCC) also contributes to ubiquitination and degradation of receptor subunits (118), 
while enhanced VGCC activity promotes β3 S383 phosphorylation and receptor insertion (119), 
suggesting a mechanistic link to activity-dependent changes. GABAAR subunit mutations that 
result in enhanced ERAD contribute to genetically determined epilepsies, or idiopathic generalized 
epilepsies (IGEs) (120, 121) and altered GABAAR ERAD is indicated in autism spectrum disorder 
(ASD) subjects (122) 
Once assembled, GABAARs undergo transport from the ER to the Golgi apparatus, 
followed by translocation to the plasma membrane. In the Golgi, the γ2 subunit is subject to 
palmitoylation by the Golgi-specific DHHC zinc finger enzyme (GODZ), a process important for 
synaptic GABAAR maintenance and surface expression (123-125). During Golgi forward 
transport, GABAARs are segregated into distinct vesicles from excitatory glutamatergic AMPA 
receptors, and are subsequently inserted at the cell surface via specialized Rab GTPases and 
SNARE complexes SNAP23–syntaxin1A/B–VAMP2 and SNAP25–syntaxin1A/B–VAMP2, 
respectively (126). Proteins contributing to GABAAR trafficking from the Golgi to the plasma 
membrane include Big2 (brefeldin A-inhibited GDP/GTP exchange factor 2) (127), GABARAP 
(GABA receptor-associated protein) (128), GRIP (Glutamate receptor interacting protein) (129, 
130), PRIP1/2 (phospholipase C-related catalytically inactive proteins 1 and 2) (131, 132), GRIF-
1 (133), Macoco (134), and NSF (135). Vesicular GABAAR transport from the trans-Golgi 
network (TGN) to the plasma membrane relies on the microtubule-dependent molecular motor 
kinesin KIF5 family (KIF5A, KIF5B, KIF5C) (136).  
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 Internalization, Recycling and Lysosomal Degradation 
Regulated internalization of cell surface receptors is a universal cellular response to 
moderate signaling and function. GABAAR internalization occurs through clathrin-mediated 
endocytosis dependent on dynamin (the GTPase that is responsible for fission of endocytic vesicles 
from the plasma membrane) and binding of the adaptor protein AP2 to specific GABAAR subunits 
(Fig. 3) (137), although clathrin-independent endocytosis occurs in heterologous cells and in C. 
elegans (138, 139). The interaction of AP2 with GABAARs is partly regulated by PKA and PKC 
mediated-phosphorylation of serine residues within a highly basic ten amino acid sequence motif 
in the intracellular loop of the β subunits (S409 in β1, S410 in β2, S408/409 in β3), with increased 
phosphorylation reducing AP2 and GABAAR interaction and endocytosis (Fig. 3) (140-144). Two 
additional motifs in the β-subunit appear important for AP2 interactions: 1) a dileucine motif is 
critical for receptor internalization in HEK cells (145) and 2) three arginine residues (405RRR407) 
within the β3-subunit intracellular domain are important for AP2-stabilization of receptors at 
dendritic endocytic zones (146). The importance of phosphoregulation of these residues was 
revealed by S408/409A homozygous mice (the S/A mutation reduces AP2 interaction, mimicking 
phosphorylation (147)), which exhibit increased phasic but decreased tonic inhibition, and 
demonstrate the core phenotypes of autism spectrum disorders (148). Moreover, a common model 
of fragile X syndrome and autism spectrum disorders, the Fmr1 KO mouse, demonstrates enhanced 
S408/409 phosphorylation, further providing evidence for deregulation of these sites in disease 
(148). Accordingly, BZD resistance in epileptic mice undergoing sustained seizures is linked to 
reductions in PKC phosphorylation of β phosphorylation (148). How specific PKC isoforms 
participate in phosphoregulation of GABAAR surface levels and internalization is still unclear. For 
instance, ethanol induced internalization of α1-containing GABAARs is PKCγ dependent (149), 
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while PKCε reduces GABAAR sensitivity to ethanol and BZDs by acting at a γ2 S327 residue 
(150). 
The intracellular loop of the γ2 subunit also contains two AP2 interaction domains, a 12 
basic amino acid region similar to the β-subunits and a YGYECL motif (144). The Tyr 365/367 
within the YGYECL motif are targets of Fyn and other Src family kinases (Fig. 3) (151, 152), and 
phosphorylation at these sites reduce AP2 binding (153). Tyrosine to phenylalanine mutations 
inhibits AP2 binding to the γ2 subunit, and heterozygous Y365/7F knock-in mice demonstrate 
surface and synaptic accumulation of GABAARs and spatial memory deficits (154). Importantly, 
homozygous Y365/7F knock-in mice are developmentally lethal, highlighting the importance of 
these residues in regulating GABAAR activity. BDNF-induced phosphorylation of the γ2 subunit 
Y365/7 residues was recently implicated as a promoter of receptor surface expression during 
hippocampal neurogenesis (155). The authors found heterozygous Y365/7F mice demonstrated an 
antidepressant-like phenotype and enhanced neurogenesis that could not be further enhanced by 
BDNF. 
A number of noxious stimuli trigger GABAAR endocytosis including seizure models (156-
158), oxygen-glucose deprivation (OGD) conditions (159), and prolonged agonist application 
(160). Protein phosphatases (Fig. 3) have an important role in regulating receptor endocytosis 
under these conditions. For example, inhibition of the calcium-sensitive phosphatase calcineurin 
(CaN) by FK506 or serine/threonine protein phosphatase 1 (PP1) and 2A (PP2A) by okadaic acid 
reverses reduction of surface γ2-subunit containing GABAARs and mIPSC amplitude induced by 
status epilepticus treatments in slice preparations (161). NMDA receptor mediated calcium entry 
and CaN activation was further shown to decrease surface α2-containing receptors during in vitro 
epileptiform activity by live-cell imaging techniques (162). Activation  
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Figure 3. GABAAR Intracellular Trafficking. 
GABAARs composed of α(1-3)βγ subunits are largely synaptically localized via gephyrin interactions and contribute 
to phasic currents, whereas α(4 or 6)βδ receptors are extrasynaptic and generate tonic current. α5βγ receptors are found 
in both locations due to binding with gephyrin at synapses and radixin extrasynaptically. Proteomics and other modern 
strategies have significantly enriched the complexity of the inhibitory synapse, however the functions of many new 
components have yet to be defined. Reproduced from: Lorenz-Guertin, J. M. and T. C. Jacob (2017). GABA type a 
receptor trafficking and the architecture of synaptic inhibition. Develop Neurobiol. 
 
of the transient receptor potential cation channel subfamily V member 1 (TRPV1) also appears to 
cause GABAAR endocytosis in the dentate gyrus of rodents dependent on calcium influx, CaN, 
and dynamin-activity (163). In addition, inflammation and release of the proinflammatory cytokine 
tumor necrosis factor-α (TNFα) stimulates GABAAR internalization (α1/2/5, β3, γ2) in a CaN-
independent pathway in cultured hippocampal neurons (164). Recent evidence has also recognized 
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the amyloid β (Aβ) peptide, most commonly associated with the pathogenesis of Alzheimer’s 
disease, as a stimulator of GABAAR endocytosis (165).  
Surface biotinylation assays suggest the majority of constitutively-internalized GABAARs 
rapidly recycle back to the cell surface (70% in 1 h), while significant degradation occurs over 
longer time scales (6 h) (166). The recycling of GABAARs is partly mediated by huntingtin 
associated protein 1 (HAP1) direct association with the β subunits (Fig. 3) (136, 166). HAP1 
functions as a kinesin adaptor and localizes to early endosomes containing GABAAR, and thus 
overexpression of HAP1 promotes receptor surface levels and reverses intracellular accumulation 
of receptors by constitutive (166) and OGD-induced endocytosis (167). Mutation of the HAP1 
protein resulting in polyglutamine expansion, as seen in Huntington’s Disease, results in 
dysregulated transport of GABAARs to the cell surface and compromised inhibitory 
neurotransmission (136). The recycling activity of HAP1 likely arises from its association with the 
kinesin KIF5 (Fig. 3). Purified complexes of β3-GABAAR/KIF5 and HAP-1/KIF5 are readily 
immunoprecipitated from rat brain tissue, while acute blockade of KIF5 reduces GABAAR 
synaptic levels and signaling strength (136). The integral membrane protein CAML (calcium-
modulating cyclophilin ligand) has also been implicated in GABAAR forward trafficking and 
recycling via interaction with the γ2 subunit cytoplasmic and fourth transmembrane domain 
regions (168). CAML-deficient neurons have reduced recycling of internalized GABAARs and 
decreased GABAergic neurotransmission in electrophysiological recordings. 
GABAARs undergoing constitutive internalization from the cell surface may be subjected 
to lysosomal-mediated degradation (Fig. 3), a process blocked by the lysosomal proteolytic 
inhibitor leupeptin (166). Acute leupeptin treatment also increases the size, number, and strength 
of GABAergic synapses in cortical slices (159). Certain stimuli can also accelerate degradation of 
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surface GABAARs. For instance, cultured hippocampal neurons undergo enhanced lysosomal-
mediated degradation of α2-containing receptors in response to BZD treatment (169). 
Ubiquitination of 7 lysine residues within the intracellular loop of the γ2 subunit plays a key role 
in GABAAR lysosomal targeting (159). Mutation of these lysines to arginine (K7R) reduced 
colocalization of receptors at late endosomes, made receptors impervious to leupeptin treatment in 
heterologous cells, and blocked an OGD-induced loss of surface receptor clusters in neurons (159).  
The ubiquitin E3-ligase, ring finger protein 34 (RNF34), directly interacts with the intracellular 
loop of γ2, co-immunoprecipitates with this subunit from brain extracts, and can be found 
colocalized at GABAergic synapses (Fig. 3) (170). Overexpression of RNF34 enhances the rate 
of γ2-GABAAR degradation and reduces GABAAR synaptic cluster size and strength. 
Interestingly, expression of the γ2 K7R mutant in these experiments did not reverse RNF34-
induced degradation of GABAARs in co-transfected HEK293 cells, but mutation of additional 
lysine residues in a K8R, K9R, and K10R mutant did. Moreover, RNF34 mediated ubiquitination 
appears to contribute to both proteasomal and lysosomal degradation of GABAARs in these cells. 
The ARF GEF, Brefeldin A-inhibited guanine nucleotide-exchange protein 3 (BIG3), may also be 
important for lysosomal trafficking of GABAARs (Fig. 3). BIG3 is primarily expressed in 
pancreatic islets and the brain, and is found colocalized with lysosomes in neurons. BIG3 KO mice 
demonstrate increased GABAAR synaptic size and current, suggesting this protein is involved in 
negative regulation of GABAAR levels (171). The exact role of specific GABAAR subunits, 
associated E3-ligases and ubiquitination patterns, and lysosomal trafficking proteins that regulate 
the transition of surface receptors to lysosomes is an important area of future research.  
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1.5 Activity-Dependent Plasticity of GABAAR Synapses 
Synapse plasticity refers to strengthening or weakening of individual synapses in response 
to changes in stimuli at a local or system level. Two decades of research have uncovered various 
forms of short and long term plasticity of GABAergic neurotransmission in different brain regions, 
with underlying cellular and molecular mechanisms being identified both pre- and post-
synaptically (172).  Persistent changes in synaptic efficacy are generally referred to as long-term 
potentiation (LTP) and long-term depression (LTD). Traditionally this described excitatory 
synapse plasticity that produced a respective increase or decrease in synapse strength. However, 
with growing awareness of GABAergic synapse plasticity, these terms now refer to changes in the 
gain of either synapse type (for GABAergic synapses, iLTD and iLTP).  
GABAAR postsynaptic plasticity is encompassed by changes in channel function, receptor 
number or clustering/lateral diffusion, and altered chloride homeostasis (changing the GABA 
reversal potential/EGABA). Tonic inhibition generated by extrasynaptic receptors is also dynamic, 
with acute and chronic stress inducing changes in cell surface trafficking and subunit specific 
expression (173). Receptor phosphorylation state is a key means for altering channel function or 
receptor trafficking via activation of protein kinases (including PKC, PKA, CaMKII, and Src) or 
phosphatases (CaN, PP1, PP2A) (Fig. 2) (174). Investigation of GABAergic postsynaptic 
plasticity has largely focused on excitation driven changes. Early plasticity studies identified that 
intracellular application of CaMKII (175) and experimental epilepsy kindling models (176) 
elevated GABAAR surface levels and potentiated the inhibitory response. Later studies revealed 
that moderate NMDA activation of hippocampal neurons promote CaMKIIα translocation to 
inhibitory synapses and CaMKIIα-dependent insertion of GABAARs with concomitant 
phosphatase-mediated AMPAR (GluR1) removal (177, 178). Aside from NMDAR stimulation, 
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enhanced VGCC (voltage-gated calcium channel) activity promotes CaMKII phosphorylation of 
the β3 subunit S383 residue and receptor insertion (Fig. 3) (119), suggesting multiple routes for 
calcium signaling to enhance GABAAR surface levels. In addition, a quantum dot single-particle 
tracking study showed that NMDA-induced iLTP required CaMKII phosphorylation of β3 S383 
to reduce GABAAR lateral diffusion and enhance recruitment of the synaptic scaffold protein 
gephyrin (179). More recently, this experimental approach revealed additional glutamate- and 
calcium-evoked plasticity of GABAergic synapses. Low glutamate levels stimulate mGluR-driven 
calcium store release via PKC and IP3 receptors and stabilization of surface GABAARs, while 
robust NMDAR activation promoted CaN phosphatase activity and destabilization of postsynaptic 
GABAAR (180). This is consistent with earlier findings where glutamate application promotes 
CaMKIIα translocation to excitatory synapses, enhanced AMPAR surface levels, and reduced 
plasma membrane GABAAR levels (178, 181). Glutamate, high levels of neuronal activity, or 
strong NMDAR activation also reduces plasma membrane GABAAR cluster size, stimulates 
receptor lateral mobility, and decreases mIPSC amplitude via CaN (182) and dephosphorylation 
of the γ2 subunit S327 residue (183). These molecular studies in neuronal culture are consistent 
with earlier slice and in vivo studies showing LTD of GABAergic inhibition via NMDAR 
activation requires CaN (184) and the γ2 subunit (185). Similar mechanisms for iLTD and iLTP 
that rely on GABAAR trafficking are supported by studies in other brain regions such as the deep 
cerebellar nuclei (186, 187). Together these plasticity studies show that glutamate receptor 
activation and calcium-sensitive signaling pathways can generate either iLTP or iLTD. Moderate 
or ambient glutamate signaling promotes kinase activity that stabilizes GABAARs, while strong 
stimulation leads to CaN phosphatase activation and receptor diffusion. Ultimately, glutamatergic 
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activity dictates bidirectional modulation of GABAergic postsynaptic strength and receptor 
clustering.  
Structural reorganization of gephyrin scaffolding is now emerging as a key mechanism of 
rapid inhibitory synaptic plasticity with changes occurring on a minute timescale (188). Gephyrin 
post-translational modifications such as phosphorylation and ubiquitination are likely to be central 
in regulating synapse architecture. A recent organotypic slice culture study of gephyrin dynamics 
identified that activity patterns promoting NMDAR LTP (carbachol treatment or theta burst 
stimulation) increase gephyrin cluster size and formation in a CaMKII-dependent manner (77). 
Furthermore this gephyrin plasticity was associated with enhanced phosphorylation of gephyrin 
S305, a CaMKII phospho site identified by in vitro kinase assay. 
On the other spectrum of neuronal activity level, early studies using chronic activity 
blockade (24 - 48 h TTX treatment) resulted in homeostatic pre- and post-synaptic GABAergic 
plasticity with decreased GABAAR synaptic clusters, mIPSC amplitude and frequency (189). In 
vivo chronic sensory deprivation via whisker trimming decreases GABAAR number and weakens 
inhibitory synapses (190-192). In contrast, whisker training promotes GABAergic synaptogenesis 
on dendritic spines, while not on dendritic shafts (193). Analogous findings in the visual cortex 
(194) indicate that a pool of dynamic GABAergic spine synapses support changes to network 
activity levels. These chronic in vivo protocols reveal how neuronal adaptation operates across a 
continuum of GABAAR synaptic plasticity, where reductions in activity lead to loss of inhibition, 
while learning or heightened neuronal activity strengthens existing GABAergic synapse or initiates 
new synapse formation. However, some sensory modulation can occur in an inverse fashion, as 
brief monocular deprivation potentiates iLTP (195), concurrent with increasing gephyrin and 
GABAAR perisomatic accumulation (179). Other visual cortex studies indicate that GABAAR 
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endocytosis contributes to LTD occurring with repetitive firing, while slow membrane oscillations, 
comparable to activity during sleep state, promote iLTP via exocytosis (196). Similarly, 
acquisition of a fear response is accompanied by surface GABAAR decreases (197) and extinction 
of fear requires GABAAR insertion (198). Collectively, GABAergic synapse plasticity and 
rewiring is fundamental for sensory experience adaptation and behavior, with functional changes 
in inhibition matching structural changes. 
1.6 Advancing our Understanding of Dynamic GABAAR Trafficking and Regulation 
Considerable scientific progress has revealed a network of molecular mechanisms 
underlying GABAergic plasticity. Yet, advancement of new and existing methods is promoting 
major inroads for our understanding of GABAAR signaling and trafficking. Recent proteomic 
strategies from other labs has vastly expanded the protein repertoire of GABAergic synapses to 
nearly 200 proteins by targeted purification of GABAARs, NL2, or gephyrin and their respective 
interactomes (87, 88, 199, 200). Microscopy-based approaches encompass the fastest growing 
means of discovery in vitro and in vivo, including optogenetically controlled GABAARs (201, 
202), two-photon based GABA photolysis (203), single-particle-tracking of receptor diffusion 
(204), quantitative super-resolution imaging of gephyrin (205) and gephyrin recombinant 
antibody-like proteins (206, 207) or fluorescent super-binding peptides (208). Additionally, 
proximity ligation assays allow for researchers to detect native protein interactions utilizing 
widely-available primary antibodies (209, 210), while emerging fluorescence resonance energy 
transfer methods (FRET) have begun to be applied, as in our recent publication (211). Herein we 
validate and characterize a new tool to address multiple GABAAR trafficking questions within a 
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single assay using a dual fluorescent sensor GABAAR γ2 subunit to advance our knowledge of 
basal receptor trafficking and drug-induced neuroadaptive changes. 
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2.0 Designing an Optical Tool to Measure Multistage GABAAR Trafficking 
Chapter adapted from: Lorenz-Guertin, J. M., et al. (2017). A versatile optical tool for studying 
synaptic GABAA receptor trafficking. J Cell Sci 130: 3933-3945; doi: 10.1242/jcs.205286 
(212) https://jcs.biologists.org/content/130/22/3933.long  
 
JL-G performed the biochemistry, fixed- and live-imaging acquisition and analysis. Madeleine 
R. Wilcox performed the electrophysiology and Madeleine R. Wilcox and Jon W. Johnson 
performed electrophysiology data analysis.  
2.1 Introduction 
The majority of GABAARs are composed of two α, two β, and a γ2 subunit forming a 
heteropentamer, but considerable subunit heterogeneity may exist (α1-6, β1-3, γ1-3, δ, ɛ, θ, π, ρ1-
3) (53). The γ2 subunit plays a critical role in GABAAR function, as it is necessary for receptor 
synaptic targeting and cluster maintenance (67, 213-216), coassembles with nearly all α and β 
subunits (217), and is the only subunit characterized to undergo ubiquitination leading to 
lysosomal degradation (159). The degree of γ2-GABAAR synaptic clustering directly impacts the 
strength of GABAergic synaptic inhibition and is dynamically regulated by changes in receptor 
trafficking (53, 218). A number of endogenous and pharmacological agents including GABA, 
neurosteroids, ethanol, and BZDs are known to influence receptor trafficking (149, 219-226). 
Despite this knowledge, precise GABAAR trafficking mechanisms induced by these and other 
clinically relevant compounds remain underexplored at the molecular level.  
Real-time receptor trafficking measurements typically rely on genetically encoded 
fluorophores to track single protein localization and movement within living cells. In contrast to 
immunofluorescence based live-cell techniques which require reliable antibodies and are restricted 
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to measurements of surface proteins (227), fluorescent tags allow for identification of a protein 
from synthesis through degradation. Despite this advantage, traditional fluorophores still remain 
limited in their ability to spatially resolve  surface from internal populations without the use of 
total internal reflection fluorescence (TIRF) imaging approaches (228). This issue led to the 
generation of pH-sensitive fluorescent proteins, such as pHluorin (pHGFP), which exhibit 
fluorescence in extracellular environments with alkaline pH (pH ~ 7.4), but not in more acidic 
areas like intracellular vesicles (229). pHGFP is not without limitations, as some discernable signal 
can be observed in the E.R. where pH can be roughly 7.2 (230). One possible way to resolve 
protein trafficking occurring at the cell surface from the intracellular space is to use compartment 
specific high-affinity labeling techniques. We previously described a labeling method utilizing a 
GABAAR subunit genetically tagged with an α-bungarotoxin binding site which selectively binds 
cell-excluded fluorescent bungarotoxin, allowing for selective monitoring of receptor insertion and 
internalization (231). Unfortunately, the inherent fluorescence of Alexa dye coupled 
bungarotoxins necessitates extensive washing after labeling to reduce background signal. 
Furthermore, bungarotoxins were recently shown to function as antagonists of the GABAAR, 
further complicating the use of this reagent (232). To overcome these obstacles associated with 
GABAAR imaging we have employed an innovative paired optical reporter system where two 
individually non-fluorescent components become highly fluorescent upon binding: a genetically 
encoded fluorogen-activating peptide (FAP tag) and exogenously applied malachite green (MG) 
dyes. FAPs are antibody single chain variable fragments (scFvs) which have been characterized to 
selectively bind MG synthetic dyes with high specificity and affinity (233). These synthetic dyes 
are non-fluorescent in solution until bound by their respective FAP and can be modified to have 
distinct characteristics including cell permeability, pH-sensitivity, and various fluorescence 
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properties (234-238). The FAP-dye system offers many advantages for live-imaging: (i) the dyes 
can be added directly to a culture dish and saturate the target FAP in seconds; (ii) a number of 
distinct dyes can be used for the same genetically encoded FAP; and (iii) the dyes are highly 
specific for their target FAP. Moreover, high affinity MG-FAP binding forms a stable fluorescent 
module that allows for measurements of receptors undergoing internalization and recycling (239-
241). Measuring drug-induced changes in FAP-tagged receptor trafficking has proven largely 
successful (234, 236, 241-244) placing this technique at the forefront of pharmacological 
screening. 
In order to design a tool to track synaptic GABAAR internalization and trafficking, we 
engineered a γ2 subunit encoding a pHGFP and the fluorogen-activating peptide dl5 (γ2pHFAP) 
(233, 240, 245, 246). We find that γ2pHFAP containing GABAARs are trafficked to the cell surface 
in both HEK293 cells and primary neurons, and are localized appropriately at synapses. We further 
demonstrate how this construct can be combined with malachite green (MG) dye derivatives to 
measure alterations in surface localization and intracellular trafficking using high-resolution 
confocal microscopy approaches. Finally, using these FAP based methods we found that an in 
vitro seizure model induced rapid loss of dye-labeled synaptic GABAARs concomitant with 
enhanced targeting of internalized receptors to lysosomal compartments, key results that were not 
detectable using pHGFP signal alone. We therefore demonstrate an innovative tool to monitor 
multistage synaptic GABAAR trafficking.  
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2.2 Methods and Materials 
 Cell culture and Transfection 
All procedures were approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee. Cortical neurons were prepared from embryonic day 18 Sprague Dawley rats 
and nucleofected (Lonza, Switzerland) at plating (54). HEK293 cells were maintained in DMEM 
with 10% FBS (Life Technologies, Carlsbad, CA) and were transfected by nucleofection. 
 DNA Constructs and Antibodies 
The α2, β3, and pH-sensitive GFP tagged γ2 subunit (γ2pHGFP) plasmids have been 
previously described (54, 65, 247, 248). The flurogen-activating peptide dl5 (240) was inserted 
upstream of pHGFP (γ2pHFAP) separated by a G-A-P-P-A amino acid linker. The EEA1-GFP was 
a gift from Silvia Corvera (Addgene plasmid #42307) (249). All constructs were sequenced to 
confirm the fidelity of final plasmids. The following primary antibodies were used: mouse anti-β-
actin (1:2000, A1978, Sigma); rabbit anti-GFP (1:1000, A11122, Invitrogen); rabbit anti-VGAT 
(1:1000, 131002, Synaptic Systems); mouse anti-EEA1 (1:1000, 610457, BD Biosciences) and 
immunofluorescence secondary antibodies: goat anti-rabbit Alexa Fluor 641 (1:1000, A21245, 
Invitrogen); goat anti-mouse Alexa Fluor 405 (1:1000; A31553, Invitrogen). 
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 MG Dyes 
MG dyes were kindly provided by Dr. Alan S. Waggoner, Dr. Ming Zhang, Dr. Marcel P. 
Bruchez, and Dr. Brigitte F. Schmidt at CMU. The MG dye MG-BTau was synthesized as 
described in (236, 239) and the MG dye Cy3pH(S/SA)-MG was prepared by the method of (238). 
The IUPAC name for Cy3pH(S/SA)-MG is 2-((E)-3-((Z)-3,3-dimethyl-5-sulfoindolin-2-
ylidene)prop-1-en-1-yl)-1-(6-((3-(4-((4-(dimethylamino)phenyl)(4-(dimethyliminio)cyclohexa-
2,5-dien-1-ylidene)methyl)phenoxy)propyl)amino)-6-oxohexyl)-3,3-dimethyl-5-sulfamoyl-3H-
indol-1-ium. Structural, synthetic and analytical details for MG-BTau are as described previously 
(239, 241, 250). 
 Immunocytochemistry and Confocal Microscopy 
Primary cortical neurons grown on glass coverslips were fixed at days in vitro (DIV) 13-
14. Neurons were permeabilized and stained with anti-VGAT antibody. Images were taken on a 
Nikon Ti-E A1 Confocal microscope equipped with a motorized Z-stage and perfect focus system 
(PFS) using a 60x oil immersion objective (NA 1.49) at 3x zoom. Data were analyzed using NIS 
Elements software (Nikon, NY). Thresholds were set using binary masks to selectively identify 
brightly fluorescent objects above background (54). Three dendritic 10 µm regions of interest 
(ROI) were drawn per neuron to measure synaptic colocalization of pHGFP signal with VGAT in 
γ2pHFAP characterization studies. γ2pHGFP control and γ2pHFAP expressing neuron pixel intensity 
and sum area of synapses in µm2 was measured and values were normalized to control mean. Fixed 
EEA1 early endosome studies utilized a 2 min 100 nM MG-BTau dye pulse-labeling protocol in 
HBS at room temperature. After live cell MG dye incubation steps, cells were washed 5 times to 
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remove all unbound dye prior to returning the cells to 10°C or 37°C solution for 30 min followed 
by fixation and immunostaining. Total pixel intensity of MG-BTau labeled receptors colocalized 
with EEA1 was measured within a cell body ROI. Laser settings were held constant across 
experiments. The researcher was blinded during image acquisition and data analysis. 
 Live-Cell Imaging  
Transfected DIV 12-14 cortical neurons or HEK293 cells were plated on MatTek glass-
bottom dishes (Ashland, MA). Imaging was performed in HEPES-buffered saline (HBS): 135 mM 
NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 10 mM HEPES, 2.5 mM CaCl2, 11 mM glucose, pH 7.4 (169). 
Low pH HBS (pH 6.4-6.8) was similarly prepared, while pH 4.8 saline was a MES-buffered saline: 
(135 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 10 mM MES, 2.5 mM CaCl2, 11 mM glucose). All 
dye pulse-labeling steps were performed in HBS at room temperature. Following dye incubation 
steps, cells were washed 5 times to remove all unbound dye prior to treatment or imaging. All 
images were taken at room temperature using a 60x objective at a 3x zoom within 10 min of dye 
washout. Perfusion assays utilizing different pH saline buffers monitored a single cell per assay, 
while 2-3 cells were imaged in each experimental dish for all other experiments. Researchers were 
blinded during data analysis where applicable. 
Cy3pH(S/SA)-MG dye was used for neuron constitutive trafficking assays. Neurons were 
pre-incubated in DMSO vehicle control (t0, t30) or 80 µM dynasore (2897, Tocris) 30 min prior 
to pulse-labeling. After dye exposure, neurons were either immediately imaged (t0) or returned to 
conditioned media ± the continued presence of dynasore for 30 min at 37°C prior to imaging. 
Cy3pH(S/SA)-MG dye acquisition was taken sequentially to measure Cy3pH (561 nm excitation) 
induced MG emission (680 nm) followed by MG (640 nm excitation) induced MG emission (680 
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nm). Laser settings were then switched to allow for capture of pHGFP (488 nm excitation; 510 nm 
emission). Individual vesicles were identified using the NIS Elements Spot Detection tool and 
thresholding analysis. A ROI was drawn around the cell body and binary thresholds were set to 
selectively capture only pHGFP clusters and MGex640 (MG signal excited by 640 nM) signal above 
background. Next, spot detection thresholds were set to selectively identify MGex561 (signal excited 
by 561 nM) fluorescent objects with a minimum circular area of 0.55 µm2 and signal above 
threshold. Colocalization of MGex561 spot signal and MGex640 binary signal was considered a 
γ2pHFAP positive vesicle. To remove contributions of surface synaptic GABAARs from these 
vesicle measurements, MGex561 and MGex640 signals colocalized with pHGFP signals were 
subtracted. The values reported reflect the total number of MGex561 and MGex640 positive objects 
(vesicles) identified and the MG561/MG640 ratio of each vesicle. Early endosome characterization 
assays measured colocalization of Cy3-MG objects with EEA1-GFP vesicles to determine the 
MG561/MG640 ratio in these compartments, while all non-associated Cy3-MG objects were placed 
in the “other” category. A ROUT outlier test (Q = 1.0%) was used in this experimental analysis. 
For surface Cy3pH(S/SA)-MG pH characterization perfusion assays, the ratio of MG561/MG640 
was determined by selectively measuring synaptic clusters of γ2pHFAP GABAARs. 
Neuron surface and lysosomal-association assays utilized MG-BTau dye for surface 
receptor pulse-labeling. For bicuculline-induced seizure assays, neurons were either immediately 
imaged following 100 nM MG dye incubation (t0) or returned to conditioned media in the presence 
of 50 µM (-)-bicuculline methiodide (2503, Tocris) or DMSO vehicle control. To label lysosomes, 
neurons were incubated at 37°C in 50 nM LysoTracker Blue DND-22 (Life Technologies) in 
conditioned media 30 min prior to imaging. For image analysis, independent ROIs were drawn to 
capture the soma, three 10 µM sections of dendrite, and the whole cell. Binary thresholds and 
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colocalization measurements were performed as above to identify MG-BTau, pHGFP synaptic 
GABAAR clusters, and lysosomes. Total surface pHGFP expression was determined by taking the 
entire cell surface signal following background subtraction.  
 Western Blot 
Transfected and non-transfected DIV 13-14 cortical neurons were lysed using RIPA buffer 
containing: 50 mM Tris-HCl (pH 8.0), 50 mM NaCl, 1 mM EDTA, 1% Igepal, 0.5% sodium 
deoxycholate, 0.1% SDS, 10mM NaF, 2 mM sodium orthovanadate, and protease inhibitor 
cocktail (Sigma, St. Louis, MO), solubilized for 15-30 min at 4°C, and spun at 13,500xg for 15 
min to remove the nuclear pellet. BCA protein assay was performed on the supernatant, and 
equivalent amounts of protein were loaded for SDS-PAGE analysis. After electrophoresis and 
transfer to nitrocellulose membrane, samples were probed with primary antibody overnight 
followed by the appropriate HRP-coupled secondary antibody. Blots were visualized using a 
Biorad Chemicdoc XRS+ following ECL development (Thermo Scientific). 
 Electrophysiology 
Whole-cell voltage-clamp recordings were performed on HEK293 cells 12-48 h after 
nucleofection with GABAAR subunits. Cells were transfected with (a) EGFP:α2:β3:γ2pHGFP or 
(b) EGFP:α2:β3:γ2pHFAP  in a 1:1:1:3 ratio to favor the production of γ2 subunit-containing 
receptors. Pipettes were pulled from borosilicate capillary tubing (Sutter Instruments) to a 
resistance of 2 – 5 MΩ on a Sutter Instruments-Flaming Brown P-97 electrode puller and fire 
polished. Unless otherwise indicated, the extracellular solution contained (in mM): 140 NaCl, 4.7 
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KCl, 1.2 MgCl2, 2.5 CaCl2, 10 HEPES and 11 D-glucose, and was pH adjusted to 7.4 ± 0.05 with 
NaOH. The intracellular solution contained (in mM): 140 CsCl, 0.1 CaCl2, 10 HEPES, 1.1 EGTA, 
2 MgCl2, 2.5 phosphocreatine, 2 ATP-Mg and 1 GTP-Na, and was pH adjusted to 7.2 ± 0.05 with 
CsOH. Recordings were made from cells expressing EGFP identified by epifluorescence 
illumination on an inverted Zeiss Axioscope microscope. Cells were held at a membrane potential 
(Vm) of -50 mV for all experiments. Vm was corrected for an empirically determined liquid junction 
potential between the extracellular and intracellular solution of -4 mV. Whole-cell currents were 
recorded using an Axopatch 200A patch-clamp amplifier (Molecular Devices), low-pass filtered 
at 5 kHz and sampled at 10 kHz in pClamp10.7 (Molecular Devices). Series resistance was 
compensated with the prediction and correction circuitry to at least 75% in all experiments. Rapid 
solution exchange was achieved using an in-house-fabricated 10-barrel fast perfusion system 
connected to gravity-fed reservoirs similar to the system previously described (251). All 
experiments were performed at room temperature. Peak currents were measured relative to 
baseline current prior to agonist application using Clampfit 10.7. 
 Statistics 
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, San  
Diego, CA) or Microsoft Excel. Unpaired Student’s t-tests or one way ANOVA with subsequent 
post hoc Tukey’s test were used to determine significance in indicated imaging studies. Significant 
differences in data distribution for Cy3pH(S/SA)-MG experiments were determined using the 
Mann-Whitney test. Paired or unpaired two-tailed Student’s t-tests were used to determine 
significance of differences in electrophysiological studies. All data are reported as mean ± S.E.M. 
unless otherwise indicated in the text. 
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2.3 Results 
 Expression and Function of γ2pHFAP in HEK293 Cells 
We began by introducing the dl5 FAP into a previously characterized N-terminal pHGFP 
γ2-construct (γ2pHGFP) that functions comparably to wild-type γ2 (54, 183, 247, 252) (Fig. 4A). 
The FAP will selectively bind MG dyes with distinct biophysical and fluorescence properties. For 
example, the MG derivative (2-((4-[(2,5-dioxopyrrolidin-1-yl)oxy]-4-
oxobutanoyl}amino)ethanesulfonate; MG-BTau) is cell impermeant, binds to dl5 FAP with high 
binding affinity (Kd value less than 0.5 nM), and is non-fluorescent until dl5 FAP binding occurs, 
which causes activation of fluorescence in the far red spectral region (680 nm) (239-241, 250) 
(Fig. 4B). We first examined if the full length γ2pHFAP construct was appropriately expressed in 
HEK293 cells. GABAAR β3 subunits were coexpressed in these experiments as a β subunit is 
required for trafficking of receptors to the cell surface (253). Western blot analysis of non-
transfected, γ2pHGFP control, and γ2pHFAP expressing cells reveal γ2pHFAP is ~25 kDa larger than 
γ2pHGFP, consistent with the molecular weight of the dl5 FAP (240) (Fig. 4C). Next, we evaluated 
surface expression and specificity of MG-BTau dye labeling of GABAARs in cells transiently 
transfected with β3 + γ2pHFAP or β3 + γ2pHGFP. Addition of MG-BTau to a live-cell culture 
should swiftly and selectively label surface GABAARs containing γ2pHFAP. To test this dye based 
labeling approach, living cells plated on glass-bottom Mattek dishes were pulse-labeled with 250 
nM MG-BTau in HEPES-buffered saline (HBS) for 1 min at room temperature, washed 5x times 
with saline, and then immediately imaged by confocal microscopy. We found that HEK293 cells 
expressing γ2pHFAP demonstrate selective receptor surface labeling by MG-BTau, while γ2pHGFP 
control cells show no cell membrane MG-BTau fluorescence (although occasional low-level 
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background MG-BTau binding can occur with cellular debris (239)) (Fig. 4D). The majority of 
cells express heteromeric receptors composed of β3 + γ2 subunits, although a few cells express the 
γ2 subunit alone, leading to subunit retention in the endoplasmic reticulum (ER) and no MG-BTau 
signal in γ2pHFAP cells (Fig. 4D, yellow arrowheads). These results highlight key advantages of 
FAP-fluorogen labeling over pHGFP alone: 1) higher signal-to-noise ratio and 2) the removal of 
pHGFP intracellular background fluorescence generated by ER localized receptors where pH can 
be roughly 7.2 (230).  
We further investigated the ability of γ2pHFAP to assemble into functional heteromeric 
α2β3γ2 GABAARs with normal chloride channel activity in response to the endogenous agonist 
GABA which binds between α and β subunits. Patch clamp recordings were used to determine the 
GABA dose-response curve for HEK293 cells expressing receptors composed of α2β3γ2pHGFP or 
α2β3γ2pHFAP. Concentration-response analysis revealed these receptors exhibit similar GABA 
EC50 values (α2β3γ2pHGFP, 22.0 ± 6.2 µM; α2β3γ2pHFAP, 14.3 ± 8.9 µM; p > 0.05) and Hill 
coefficients (α2β3γ2pHGFP, 1.14 ± 0.26; α2β3γ2pHFAP, 0.90 ± 0.29; p > 0.05) (Fig. 5A). The EC50 
values are consistent with previously reported values for receptors containing this subunit 
composition (254). To directly test if addition of the FAP tag altered drug binding and functional 
properties of the γ2 subunit, we compared the potentiation response the induced by the BZD, 
diazepam (DZ/DZP), a GABAAR positive allosteric modulator that binds at  
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Figure 4. Novel Optical GABAAR Paired Reporter System.  
(A) The fluorogen activating peptide (FAP) dl5 was inserted upstream of an N-terminal pH-sensitive GFP tag 
(pHGFP) in a γ2-subunit construct. Cartoon schematic of γ2pHFAP subunit. Model not to scale. (B) The MG dye, MG-
BTau, is cell impermeant and dark in solution. Fluorescence is generated when MG dye binds to surface receptors 
containing the γ2pHFAP subunit. (C, D) HEK293 cells were transfected with β3 + γ2pHGFP control or β3 + γ2pHFAP 
(β3 subunits are needed to form surface targeted receptors). (C) Representative western blot from NT (non-
transfected), β3 + γ2pHGFP control and β3 + γ2pHFAP expressing cells (n = 2 experiments). (D) HEK293 cells 
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transfected with β3 + γ2pHGFP control or β3 + γ2pHFAP were pulse-labeled with 250 nM MG-BTau dye for 1 min 
prior to live-cell imaging. pHGFP fluorescence is shown in green and MG-BTau is shown in blue in the Merge panels 
and boxed areas enlarged below. MG-BTau signal is selectively localized at the cell surface in γ2pHFAP expressing 
cells and is absent in γ2pHGFP control cells. Note that with double transient transfection (β3 + γ2pHFAP), some cells 
contain the γ2pHFAP subunit alone (yellow arrowheads), leading to intracellular retention and a pHGFP signal (green) 
but no MG dye labeling (blue). Scale bars = 20 μm.  
 
Figure 5. Recombinant GABAARs Containing γ2pHFAP Maintain Responsiveness to GABA and the 
Benzodiazepine Drug Diazepam in HEK293 Cells. 
(A) The GABA concentration response curve in α2β3γ2pHGFP and α2β3γ2pHFAP expressing cells is equivalent. 1s 
GABA applications were made at ≥120 s intervals and peak response was measured. Curves were fit with the Hill 
equation, and the EC20 was determined. (B) GABA currents are equivalently potentiated by 1 μM DZ (at the GABA 
EC20). Representative traces show responses to application of GABA (black) and of GABA with DZ (DZP) (red). (C) 
Quantification of DZ potentiation (n = 5-8 cells per treatment). (D) DZ potentiation of the GABA response in 
α2β3γ2pHFAP expressing cells is not altered by the presence of 100 nM MG-BTau dye (n = 4 cells per treatment). 
(C,D) Data presented as mean ± S.E.M., Student’s t-tests. 
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the interface of γ2 and specific α subunits (α1, 2, 3 or 5) (Fig. 5B) (217). We found no significant 
difference in the DZ potentiation of the EC20 GABA response between α2β3γ2pHGFP or 
α2β3γ2pHFAP expressing cells (Fig. 5C, Fold DZ potentiation α2β3γ2pHGFP = 3.1 ± 0.5, 
α2β3γ2pHFAP = 2.8 ± 0.6; p > 0.05). Finally, we tested if binding of a MG dye to the γ2pHFAP 
subunit would interfere with receptor function. We compared the DZ potentiation response of 
γ2pHFAP before and after co-application of MG-BTau. Binding of MG-BTau to the receptors did 
not alter the response to DZ (Fig. 5D, Fold DZ potentiation γ2pHFAP without dye = 4.0 ± 0.4, 
γ2pHFAP with dye = 3.9 ± 1.0; p > 0.05). Taken together these results suggest GABAARs 
incorporating γ2pHFAP maintain normal receptor function and responsiveness to GABA and DZ 
in the presence of MG dye. 
 γ2pHFAP is Clustered at Synapses in Neurons and Can be Used to Monitor 
Multistage Receptor Trafficking 
To confirm that γ2pHFAP is fully expressed in cultured neurons, we compared non-
transfected rat cortical neurons to those transfected with γ2pHFAP or γ2pHGFP control at plating 
(Fig. 6). Neurons were lysed 14 days after transfection and subsequently immunoblotted with anti-
GFP antibody (Fig. 6A), revealing robust expression of γ2pHFAP and γ2pHGFP as seen in HEK293 
cells (Fig. 4C). We then tested if neurons with γ2pHFAP GABAARs could selectively bind and 
activate MG-BTau dye fluorescence. Days in vitro (DIV) 12 cortical neurons expressing γ2pHGFP 
or γ2pHFAP were pulse-labeled with 250 nM MG-BTau dye for 1 min at room temperature, then 
immediately washed and used for live-cell imaging. Only γ2pHFAP expressing neurons 
demonstrate dye activation and colocalization with pHGFP surface synaptic clusters (Fig. 6B). 
Furthermore, it is evident that MG-BTau labeling in neurons also has a higher signal-to-noise ratio 
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than pHGFP due to 1) the continually generated pHGFP signal of diffuse newly inserted 
extrasynaptic γ2pHFAP receptors that are not yet clustered at synapses, which contrasts with the 
small MG-BTau pulse-labeled extrasynaptic population (if the MG dye was continually present 
rather than being washed away, its extrasynaptic signal would be more similar to pHGFP) and 2) 
the low but observable pHGFP background from ER resident γ2pHFAP subunits, whereas there is 
no ER signal from MG-BTau labeling. These data establish MG dyes as a selective label for 
synaptic γ2pHFAP containing GABAAR populations in living primary cortical neurons.  
Synapse formation and receptor clustering are critical for neuronal development and 
regulation of inhibitory neurotransmission. To determine if γ2pHFAP clusters normally at 
GABAergic synapses in mature neurons, we transfected cortical neurons at DIV 0 with γ2pHGFP 
control or γ2pHFAP and fixed the cells for immunofluorescence studies at DIV 15. We assessed 
receptor synaptic localization by measuring colocalization of the pHGFP tagged receptors with the 
vesicular GABA transporter (VGAT), a presynaptic marker of GABAergic synapses (Fig. 6C). 
Expression of γ2pHFAP did not alter presynaptic GABAergic input as indicated by unchanged 
VGAT levels (intensity) and area compared to control (Fig. 6D). Additionally, the size of 
postsynaptic GABAergic synapses was not significantly different between constructs, although the 
mean intensity of γ2pHGFP synapses was 20.7% (95% confidence interval) greater than γ2pHFAP, 
likely due to higher overall expression of the control subunit. These results indicate that the full 
length γ2pHFAP construct is expressed, assembles with endogenous subunits into receptors, traffics 




Figure 6. γ2pHFAP is Fully Expressed in Neurons and Appropriately Clustered at GABAergic Synapses. 
(A) Detection of γ2pHGFP control and γ2pHFAP receptors via western blot in cortical neurons 14 days post-
transfection. NT = non-transfected. (n = 3 neuronal cultures). (B) DIV 12 neurons expressing γ2pHGFP control or 
γ2pHFAP were pulse-labeled with 250 nM MG-BTau dye for 1 min prior to live-cell imaging. Surface GABAARs are 
selectively labeled in γ2pHFAP neurons as evidenced by extensive colocalization of the pHGFP signal (green, Merge) 
and MG-BTau signal (blue, Merge). Note that in γ2pHGFP control neurons, surface GABAARs are not labeled by MG-
BTau dye. Boxed areas enlarged below. (C) Confocal fixed immunofluorescence images of γ2pHGFP control and 
γ2pHFAP expressing neurons with presynaptic GABAergic terminals labeled with VGAT antibody. pHGFP 
fluorescence (green in Merge) shows intracellular γ2 subunit and synaptically localized receptors on dendrites that are 
colocalized with VGAT (red in Merge). Boxed areas enlarged below. (D) VGAT and surface γ2 containing receptor 
synaptic clusters were quantified. Scatter plot graphs showing mean area and mean fluorescence intensity in neurons 
transfected with γ2pHGFP control or γ2pHFAP. No changes were observed in GABAergic presynaptic terminals as 
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measured by VGAT area and intensity. Synaptic γ2 GABAAR measurements were determined from pHGFP signal 
colocalized with VGAT: synaptic γ2 GABAAR fluorescence area was equivalent, while the intensity was slightly 
lower in γ2pHFAP neurons (***p < 0.001, Student’s t-test; n = 54-57 neurons from 3 cultures for each condition; error 
bars represent ± 95% confidence interval). Scale bars: main panels = 20 μm, enlargements = 1 μm.  
 
Having validated and established the application of FAP technology to generate a synaptic 
GABAAR reporter system, we first explored the experimental flexibility afforded by the distinct 
characteristics of available MG dyes to study receptor trafficking. First we examined if MG-BTau 
labeled surface receptors could be identified in endosomal pathways following internalization. 
DIV 12-13 γ2pHFAP neurons were pulse-labeled with 100 nM MG-BTau, transferred to 10°C or 
37°C HBS for 30 min, and then fixed and immunostained with the early endosome marker EEA1 
(Fig. 7A). Neurons maintained at 37°C demonstrated greater mean intensity and area of MG-BTau 
colocalized at EEA1 vesicles compared to those kept at 10°C to inhibit internalization, indicating 
MG-BTau labeling can also be used to track GABAAR internalized pools (Fig. 7B).  
We next investigated the adaptability of γ2pHFAP with other MG dye applications in live-
imaging intracellular trafficking assays. The Cy3pH(S/SA)-MG dye is a dichromophore consisting 
of a pH-sensitive forester-resonance energy transfer (FRET) donor Cy3pH molecule and an 
acceptor MG (Fig. 8A) (238). Excitation of Cy3pH (561 nm excitation) results in highly efficient 
FRET to MG and emission is observed at 680 nm, while direct stimulation of MG (640 nm 
excitation) also results in 680 nm emission, allowing calculation of an emission ratio of 
MG561/MG640 (Fig. 8A). Increasingly acidic environments such as endosomes and lysosomes lead 
to protonation of Cy3pH and increased fluorescence intensity, enhancing FRET, and the ratio of 
MG561/MG640 (236, 238, 255, 256) The pH sensor dye is cell impermeant like MG-BTau and thus 
allows for selective labeling of surface γ2-containing GABAARs. To characterize the pH-
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sensitivity of Cy3pH(S/SA)-MG in our γ2pHFAP neuronal system, we first performed live-cell 
imaging perfusion experiments using different pH solutions to simulate receptor progression 
through an increasingly acidic endolysosomal pathway, as similarly performed in other cell culture 
methods using Cy3pH(S/SA)-MG (238). Neurons were pulse-labeled with pH sensor dye and then 
first imaged with pH 7.4 physiological saline, followed by pH 6.8 and pH 4.8 solutions, 
demonstrating a clear shift in the ratio of MG561/MG640 across treatments (Fig. 8B). Quantification 
of MG561/MG640 mean ratios at surface synaptic cluster sites revealed pH 7.4 (0.58 ± 0.01), pH 6.8 
(0.69 ± 0.01), and pH 4.8 (0.99 ± 0.02) conditions were significantly different from one another 
(Fig. 8C). Therefore, Cy3pH(S/SA)-MG labeled γ2pHFAP receptors can be readily identified in 










Figure 7. MG-BTau Dye Signal Shows Trafficking of γ2pHFAP GABAARs to Early Endosomes. 
(A)  DIV 12 γ2pHFAP expressing neurons were pulse labeled with 100 nM MG-BTau dye for 2 min, then incubated 
in HBS at 37°C or 10°C  for 30 min prior to fixation. MG-BTau (blue) labeled neurons were permeabilized and stained 
with early endosome marker EEA1 antibody (red). pHGFP (green) is visible throughout the cell after fixation. Boxed 
area is enlarged to the right with EEA1 (red), MG-BTau (blue), and Merge panels. Yellow circles show colocalized 
EEA1 and MG-BTau signal. (B) The intensity and area of MG-BTau labeled receptors colocalized with EEA1-positive 
intracellular vesicles is increased when endocytosis is not inhibited by 10°C. (*p≤0.05, **p < 0.01, Student’s t-test; n 




Figure 8. Cy3pH(S/SA)-MG Dye Bound to Surface γ2pHFAP Receptors Displays a pH-Sensitive FRET Signal. 
(A) pH sensor dye Cy3pH(S/SA)-MG is a fluorogen FRET sensor. Increasingly acidic environment enhances Cy3pH 
fluorescence intensity and FRET. A higher MG561/MG640 ratio indicates lower pH. (B) DIV 12-13 γ2pHFAP expressing 
neurons were pulse labeled with 100nM pH sensor dye Cy3pH(S/SA)-MG for 2 mins, then were immediately used 
for live-imaging. Cells were first perfused with pH 7.4 HBS, then pH 6.8 HBS, and finally MES-buffered saline pH 
4.8. Zoomed dendrite images below highlight MG561/MG640 ratios at surface synaptic clusters across different 
acidities. All ratiometric images are on a scale from 0.1 to 2. Scale bars: whole image = 10 μm; zoom image = 2.5 μm. 
(C) The MG561/MG640 ratio of individual surface γ2pHFAP GABAAR synaptic clusters were quantified at each pH 
(****p≤0.0001, one way ANOVA followed by post hoc Tukey’s test; n = 41 synaptic clusters from 4 cells; error bars 
represent ± S.E.M. 
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Following pH characterization of Cy3pH(S/SA)-MG, we then utilized this dye to identify 
localization of internalized γ2pHFAP receptors in the endosomal-lysosomal system. Acidity 
increases as intracellular receptors undergo transition from early endosomal/recycling pathways 
to late endosomal/lysosomal pools (Fig. 9A). We therefore anticipated differences in mean 
MG561/MG640 ratios between these vesicular populations. To examine this effect, we cotransfected 
γ2pHFAP neurons with the early endosome marker EEA1-GFP for live-imaging experiments. At 
DIV 12-13, 10 nM Cy3pH(S/SA)-MG was added directly to the cell culture media and neurons 
were incubated for 30 min at 37°C prior to imaging. Cells were first perfused with pH 7.4 HBS to 
acquire MG561/MG640 data, then with pH 6.4 solution to eliminate surface γ2pHFAP (pHGFP) 
signal (orange stars; Fig. 9B) to isolate intracellular EEA1-GFP for image analysis. Cy3pH(S/SA)-
MG vesicles colocalized with EEA1-GFP (yellow arrows; Fig. 9B) demonstrated a mean 
MG561/MG640 ratio of 0.824 ± 0.012, while all other identified vesicles not-associated with EEA1-
GFP (white triangles; Fig. 9B) displayed a significantly higher ratio of 0.918 ± 0.016 (Other; Fig. 
9C). The Cy3pH(S/SA)-MG found in non-EEA1 intracellular sites typically displayed the lowest 
pH and was in comparably larger vesicular bodies, suggesting lysosomal compartments. These 
results indicate Cy3pH(S/SA)-MG labeled γ2pHFAP receptors can be used to decipher the 
localization of internalized GABAAR pools along the endosome-lysosome axis. 
Next we wanted to elucidate if Cy3pH(S/SA)-MG could be used to monitor the constitutive 
endolysosomal trafficking of GABAARs by using conditions that limit internalization. We 
compared γ2pHFAP neurons pulse-labeled with 100 nM Cy3pH(S/SA)-MG dye either immediately 
after washing (t0) or 30 min later ± the dynamin inhibitor, dynasore (80 µM) at 37°C. Importantly, 
GABAARs have been previously characterized to undergo constitutive dynamin-dependent 
clathrin mediated endocytosis (137, 257). Images of neurons allowed 30 min of trafficking show 
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enhanced dye-labeled GABAAR accumulation within the cell body compared to t0 and to t30 + 
dynasore (Fig. 9D). The number of GABAAR-positive vesicles inside the neuronal cell body was 
measured using the spot detection feature in NIS Elements. Quantification confirmed that the total 
number of vesicles identified at t30 is 78.7 ± 20% greater than at t0 and that vesicle internalization 
is blocked by dynasore co-treatment (Fig. 9E). To better understand the receptor population 
distribution along the endosomal-lysosomal trafficking axis, we examined each measured vesicle’s 
respective MG561/MG640 ratio using a histogram plot (Fig. 9F). This analysis revealed that the 
increase in vesicles found at t30 were primarily at lower MG561/MG640 ratios, suggesting early 
endosomal trafficking. Moreover, the vesicle median MG561/MG640 ratios were significantly 
different between all conditions: t0 = 1.31; t30 = 0.767; and t30 + dynasore = 0.826. Interestingly, 
we found that while dynasore reduced the number of internalized receptors detected back to t0 
levels, dynasore treated neurons demonstrated a unique vesicular MG561/MG640 ratio profile (Fig. 
9E). Dynasore inhibition of clathrin-coated pit formation and endocytosis generates half formed 
“U” and “O” shaped pits/vesicles associated with the plasma membrane (258). The few vesicles 
present in t30 + dynasore treated neurons (Fig. 9D) are likely to be these structures undergoing 
partial acidification during the 30 minute experimental period. In summary, γ2pHFAP and the 
Cy3pH(S/SA)-MG dye reveal significant constitutive clathrin-dependent endocytosis of 







Figure 9. Constitutive Endolysosomal Trafficking of GABAARs can be Measured using the pH-Sensitive Dye 
Cy3pH(S/SA)-MG and γ2pHFAP. 
(A) Application of pH sensor dye to visualize and distinguish intracellular vesicle targeting of internalized GABAAR. 
Once internalized, the pHGFP signal is immediately quenched, and the increasingly acidic environment enhances 
Cy3pH fluorescence intensity and FRET. A higher MG561/MG640 ratio indicates vesicular acidification. 
Recycling/early endosomal vesicle signal represented as green, late endosome/lysosomes as red to match the 
MG561/MG640 ratio heatmap in images. (B) Neurons transfected with γ2pHFAP and EEA1-GFP were incubated in the 
continuous presence of 10nM Cy3pH(S/SA)-MG dye for 30 min in conditioned media at 37°C and then washed and 
rapidly imaged. After initial images were taken at pH 7.4, pH 6.4 HBS was perfused onto cells to quench surface 
pHGFP signal of γ2pHFAP and selectively identify EEA1-GFP positive vesicles. Yellow arrows indicate vesicles 
where EEA1-GFP is colocalized with Cy3pH(S/SA)-MG; white triangles indicate larger Cy3pH(S/SA)-MG vesicular 
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structures not colocalized with EEA1-GFP (Other); orange stars represent γ2pHFAP pHGFP surface signal that is 
eliminated after pH 6.4 saline perfusion. Scale bar = 10 μm. (C) Quantification of individual intracellular vesicles 
MG561/MG640 ratio at either EEA1-GFP positive sites or other internal compartments (n = 243 EEA1-GFP; 511 Other 
from 9 cells and 2 neuronal cultures; Student’s t-test; error bars represent error bars represent ± S.E.M.). (D) Confocal 
images of pH sensor dye-labeled GABAARs at t0, t30 and t30 + dynasore (Dyn, 80 μM), with cell body indicated by 
yellow outlined region of interest (ROI). Zoomed images of timepoints are shown to right. Scale bars: whole image = 
10 μm; zoom image = 5 μm. (E) More intracellular vesicles are quantified at t30 than t0 or t30 + dynasore (one way 
ANOVA followed by post hoc Tukey’s test; error bars represent ± S.E.M.). (F) Histogram analysis reveals most t30 
vesicles had lower MG561/MG640 ratios and the median values between all conditions were significantly different 
(Mann-Whitney test) (n = 14 neurons per treatment from 3 independent cultures). All ratiometric images are on a scale 
from 0.1 to 2. p values for (C,E,F): *p≤0.05, **p≤0.01, ***p≤0.001, and ****p≤0.0001 
 γ2pHFAP Reveals Enhanced GABAAR Synaptic Turnover in an In Vitro 
Bicuculline Seizure Paradigm  
We last set out to investigate if the γ2pHFAP-dye system could be used to measure 
pharmacologically-induced changes in GABAAR trafficking in living neurons. Prolonged 
exposure of the GABAAR antagonist bicuculline is proconvulsant due to sustained dampening of 
network inhibition, leading to seizure-type activity in vitro and in vivo (259-262). Multiple 
hyperexcitable neuronal states have previously been reported to enhance γ2-containing GABAAR 
internalization and reduce total surface levels at 1 h post induction (156-158, 263). We investigated 
if the γ2pHFAP construct could be used to simultaneously examine multiple stages of receptor 
trafficking including receptor surface, synaptic, and lysosomal levels following a bicuculline-
induced seizure paradigm. At DIV 12-14 γ2pHFAP neurons were pulse-labeled with MG-BTau dye 
and then returned to conditioned media +/- 50 µM bicuculline at 37°C for 1 h. 50 nM LysoTracker 
was added 30 min prior to the end of treatment to identify association of receptors with lysosomes. 
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Representative images indicate MG-BTau labels synaptic GABAAR clusters on the surface of 
dendrites as seen by colocalization of MG-BTau (blue) and pHGFP (green) (Fig. 10A,B). MG-
BTau also reveals internalized receptors within the cell body in lysosomes (Fig. 10C, Lysotracker 
in red). These data demonstrate that the binding of MG-BTau to γ2pHFAP GABAARs and its 
resulting fluorescence is stable even in very low pH environments such as lysosomes, consistent 
with previous findings using different FAP-tagged receptors colocalized with LysoTracker in cell 
culture (236). Image analysis uncovered no significant difference in total surface expression of 
γ2pHFAP between DMSO control and bicuculline treated cells when measuring pHGFP signal 
(Fig. 10D). There was a trend towards a decrease in synaptic levels of γ2pHFAP in bicuculline 
treated neurons (75 ± 13% of control), determined by pHGFP cluster fluorescence, but this was 
not significant. In contrast, (Fig. 10E) shows bicuculline treatment reduced total and synaptic MG-
BTau signal by 41 ± 10% and 67 ± 8%, respectively, indicating the population of pulse-labeled 
γ2pHFAP receptors had decreased. In support of enhanced receptor turnover, we found that 
bicuculline treatment increased association of labeled receptors with lysosomes by 107 ± 41% 
compared to control. These findings suggest that bicuculline-induced seizure activity leads to 
augmented GABAAR synaptic turnover, lysosomal targeting, and a compensatory increase in new, 
non-recycled GABAAR insertion to  
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Figure 10. γ2pHFAP Imaging Reveals Increased Internalization and Enhanced GABAAR Turnover Rates 
Following a Bicuculline-Induced Seizure Paradigm. 
(A) γ2pHFAP neurons were pulse-labeled with 100 nM MG-BTau for 2 min then returned to 37°C conditioned media 
+/- 50 µM bicuculline for 1 h. LysoTracker (50 nM) was added directly to the media after 30 min to label lysosomes. 
pHGFP fluorescence is shown in green, LysoTracker in red, and MG-BTau in blue in the Merge panels. Smaller boxed 
areas in Merge panel identify surface synaptic receptors (enlarged in B). Larger boxed area identifies internalized 
receptors present in endosomes and lysosomes in cell body of neuron (enlarged in C). (B) Surface synaptic receptors 
on dendrites are seen with colocalization of MG-BTau and pHGFP signals. (C) Enlargements of cell body area show 
colocalization of internalized MG-BTau labeled GABAARs and lysosomes. (D) Quantification of pHGFP signal 
showed synaptic and total surface levels were not changed following bicuculline treatment. (E) In contrast, 
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quantification of MG-BTau signal revealed reductions in total and synaptic receptor levels after the bicuculline seizure 
paradigm. Bicuculline treatment also enhanced the ratio of MG-BTau labeled receptors associated with lysosomes 
over total MG-BTau signal. (*p < 0.05, ****p < 0.0001, Student’s t-test; synaptic measurements performed on three 
10 μm regions located on dendrites; n = 13 neurons per treatment from 3 independent cultures; error bars represent ± 
S.E.M.). Scale bars: 20 μm in A and 2 μm in B,C. 
mitigate this response. These results robustly demonstrate the versatility of the γ2pHFAP-dye system and its ability to 
measure numerous trafficking events to address complex questions. 
2.4 Discussion 
Live-cell receptor tracking approaches offer critical information by revealing real-time 
alterations in protein trafficking. Here we describe a flexible paired GABAAR γ2-subunit optical 
reporter system that can be used to monitor multi-stage receptor trafficking. Compared to 
previously available methods that require reliable antibodies, conventional fluorophore tagging, or 
fluorescent α-bungarotoxin labeling, the γ2pHFAP-dye system can allow for simultaneous 
monitoring of surface, synaptic, and intracellularly trafficking GABAARs in real-time. The 
strength of this method lies in the ability to simply alternate FAP-compatible MG dyes to address 
the specific experimental question of interest. 
We applied the pH sensor dye, Cy3pH(S/SA)-MG, to monitor internalization and 
constitutive endosomal and lysosomal trafficking of GABAARs in neurons. We found that 
Cy3pH(S/SA)-MG labeled surface γ2pHFAP receptors can be tracked to small EEA1-positive early 
endosomes (MG-BTau labeled receptors also identified at EEA1 endosomes; Fig. 7) and also to 
larger vesicular structures with low pH (likely lysosomes), generating high MG561/MG640 ratios 
(Fig. 9B,C). Synaptic GABAAR endocytosis occurs primarily in a dynamin-dependent manner 
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(257) and can be identified within 30 minutes using an antibody feeding approach (137). Our 
results in Fig. 9 demonstrate rapid internalization of receptors in endosomal/lysosomal pathways 
on this same time scale, a process reduced by the dynamin-inhibitor dynasore. As a result of the 
vesicle-level pH-sensitive measurement afforded by this tool, we were able to  
further generate a histogram plot identifying differences in the trafficking stages of γ2pHFAP-
positive vesicles. These analyses suggest internalized receptors favor early endosomal pathways, 
a finding supported by a previous study that determined over 70% of internalized GABAARs are 
recycled back to the cell surface within 1 h (143). Furthermore, dynasore treated neurons displayed 
vesicles with a distinct MG ratio profile, possibly resulting from acidification of endocytic 
pits/vesicles not released from the plasma membrane, non-dynamin dependent endocytosis of 
receptors, or dynasore off-target effects. GABAARs undergo both clathrin-dependent and -
independent endocytosis pathways in heterologous cells (138), with both mechanisms being 
recently identified in neurons for glutamateric AMPA receptors (264, 265). Dynasore has also 
been shown to disrupt lysosomal fission by inhibiting dynamin-2 (266) as well as have other non-
specific, dynamin independent effects (267, 268) that could result in different vesicle 
MG561/MG640 ratio profiles. Further studies investigating additional time points are necessary to 
identify the rate, equilibrium, and overall population dynamics of constitutive GABAAR 
internalization.  
To test the utility of γ2pHFAP in detecting pharmacologically-induced changes in GABAAR 
trafficking, we exposed neurons to a bicuculline-induced seizure paradigm following a MG-BTau 
pulse-labeling protocol (Fig. 10). This unique dye labeling approach readily detected enhanced 
synaptic receptor turnover rates and lysosomal targeting that were not detectable by pHGFP 
fluorescence alone. Previous work has shown that more aggressive seizure protocols relying on 
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depolarization via high external potassium and/or agonist application targeting highly calcium 
permeable NMDA receptors reduces total surface GABAARs in cultured neurons (157). It is likely 
that the mild seizure paradigm used here does not affect total surface receptor levels, but instead 
enhances surface turnover that is offset by increased receptor insertion rates. In support of this 
argument, another recent study (160) found that 1 h treatment with GABAAR antagonists did not 
lead to a reduction in surface GABAAR levels.  
This paper lays the groundwork for future investigations of GABAAR trafficking using the 
γ2pHFAP sensor.  Importantly, this technique can be further extended toward pharmacology 
focused efforts in high throughput screenings (234, 244), assay development based on flow 
cytometry (235, 243) or high resolution 96-well plate assays (250), and for in vivo protein labeling 
(237, 269). In summary, our γ2pHFAP is the first protein-FAP conjugate characterized in primary 
neurons, providing a unique tool to monitor multistage GABAAR trafficking in living cells with 
relevance both for basic science research and applied pharmacology. 
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3.0 Early Diazepam Exposure Alters GABAAR Intracellular Trafficking and Accelerates 
Synaptic Exchange 
Chapter adapted from: Lorenz-Guertin, J. M., et al. (2019). Diazepam Accelerates GABAAR 
Synaptic Exchange and Alters Intracellular Trafficking. Front Cell Neurosci  
(270) https://doi.org/10.3389/fncel.2019.00163  
 
JL-G performed the biochemistry, immunoprecipitation, bioinformatics analysis and fixed and 
live imaging acquisition and analysis. Matthew J. Bambino performed the FRET imaging and 
analysis. Joshua Lorenz-Guertin, Tija C. Jacob and Susan T. Weintraub designed the Mass 
spectrometry experiments. The Weintraub lab performed mass spectrometry and data was 
analyzed by Joshua Lorenz-Guertin, Tija C. Jacob and Susan T. Weintraub. 
3.1 Introduction 
The most prevalent synaptic GABAAR subtype is composed of two α, two β, and a γ2 
subunit forming a heteropentamer (32). BZDs are a widely used clinical sedative-hypnotic drug 
class that selectively bind between the interface of a GABAAR γ2 subunit and either an α1/2/3/5 
subunit (33). Receptors containing these α subunits are considered to be primarily synaptic, with 
the exception of α5, which is localized both synaptically and extrasynaptically (63). Positive 
allosteric modulation by BZD enhances GABAAR inhibition by increasing the binding affinity of 
GABA and increasing channel opening frequency (32). It is known that the potentiating effect of 
BZDs are lost after prolonged or high dose acute exposure (271, 272), characterized first by a loss 
of sedative/hypnotic activity followed by the anti-convulsant properties behaviorally (46, 273-
275). The induction of BZD tolerance occurs in part due to the uncoupling of allosteric actions 
between GABA and BZD (276, 277), a process that appears to rely on GABAAR receptor 
internalization (278, 279). We have previously shown that 24 h BZD treatment leads to decreased 
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surface and total levels of the α2 subunit in cultured hippocampal neurons that was dependent on 
lysosomal-mediated degradation (169); however, the process by which the α2 subunit is selectively 
targeted to lysosomes is still unknown. GABAAR subunit ubiquitination and subsequent 
degradation at proteasomes or lysosomes modulates cell surface expression of receptors (117, 159, 
170, 280, 281). Ubiquitination of the γ2 subunit is the only currently known mechanism identified 
to target internalized surface GABAARs to lysosomes (159).  
Another major regulator of GABAAR efficacy is postsynaptic scaffolding. Confinement at 
synaptic sites maintains receptors at GABA axonal release sites for activation. Furthermore, this 
limits receptor diffusion into the extrasynaptic space where internalization occurs (282, 283). The 
scaffolding protein gephyrin is the main organizer of GABAAR synaptic localization and density, 
as gephyrin knock-down and knock-out models show dramatic reductions in γ2- and α2-GABAAR 
clustering (54, 55). Evidence suggests gephyrin interacts directly with GABAAR α1, α2, α3, α5, 
β2, and β3 subunits (62, 63, 65, 284-286). Gephyrin recruitment is involved in inhibitory long term 
potentiation (iLTP) (77, 287), while its dispersal coincides with GABAAR diffusion away from 
synapses (54, 182). Extensive post-translational modifications influence gephyrin function (288, 
289). Accordingly, expression of gephyrin phosphorylation site mutants revealed complex effects 
on GABAAR diffusion and gephyrin ultrastructure and scaffolding (289, 290). Phosphorylation at 
the gephyrin serine 270 (Ser270) site has been particularly characterized to negatively modulate 
scaffold clustering and density, in part by enhancing calpain-1 protease mediated degradation of 
gephyrin (73). Given the well-established interdependent relationship between gephyrin and the 
γ2 subunit in maintaining receptor synaptic integrity (54, 55, 67, 215, 291, 292), impaired 
postsynaptic scaffolding should affect both pre-existing and newly inserted GABAAR clustering 
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and ultimately the efficacy of inhibitory neurotransmission. Thus a central unanswered question is 
if BZD exposure causes changes in gephyrin phosphorylation or protein levels. 
Here we demonstrate that 12-24 h treatment with the BZD diazepam (DZP) leads to a 
reduction in total γ2 subunit and full-length gephyrin levels in vitro and in vivo. This reduction 
occurred coincident with enhanced γ2 subunit ubiquitination, but resulted in no significant change 
in overall γ2 surface levels. Using our recently published dual fluorescent BZD-sensitive 
GABAAR reporter (γ2pHFAP), we further show that cell surface γ2-GABAARs are more frequently 
targeted to lysosomes after DZP exposure. Forester resonance energy transfer (FRET) experiments 
further confirmed specific loss of synaptic α2/γ2 GABAAR levels following DZP treatment. The 
scaffolding protein gephyrin also demonstrated augmented phosphorylation at Ser270, increased 
cleavage and was significantly decreased in membrane and cytosolic compartments. Fluorescence 
recovery after photobleaching (FRAP) assays identified that DZP treatment increased the 
simultaneous recovery of γ2-GABAAR and gephyrin at synaptic sites, indicating reduced receptor 
confinement and accelerated exchange between the synaptic and extrasynaptic GABAAR pool. 
This process was reversed by the BZD site antagonist Ro 15-1788. Lastly, co-
immunoprecipitation, quantitative mass spectrometry and bioinformatics analysis revealed shifts 
in the γ2-GABAAR interactome towards trafficking pathways in vivo. Together, these data suggest 
that DZP exposure causes a compensatory decrease in inhibitory neurotransmission by reducing 
BZD-sensitive GABAAR and gephyrin confinement at synapses and via ubiquitination and 
lysosomal targeting of γ2 by reducing BZD-sensitive GABAAR and gephyrin confinement at 
synapses, and via ubiquitination and lysosomal targeting of γ2. 
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3.2 Methods and Materials 
 Cell Culture, Transfection, Expression Constructs and Mice 
Cortical neurons were prepared from embryonic day 18 Sprague Dawley rats and 
nucleofected with constructs at plating (Amaxa). The γ2pHFAP construct was characterized in 
(212) and RFP-gephyrin was described in (63). The γ2RFP construct was generated by PCR cloning 
and fully sequenced: the red fluorescent protein mCherry replaced pHluorin in the previously 
published γ2pHGFP construct (54). GFP-ubiquitin was a gift from Nico Dantuma (Addgene plasmid 
# 11928) (293). 8-10 week old male C57BL/6J mice (Jackson Laboratory) were maintained on a 
reverse 12 h dark/light schedule. Mouse cortical brain tissue was collected and flash frozen 12 h 
after I.P. injection with either vehicle or diazepam (in 40% PEG, 10% EtOH, 5% Na Benzoate, 
1.5 % Benzyl alcohol (Hospira)). All procedures were approved by the University of Pittsburgh 
Institutional Animal Care and Use Committee.  
 Reagents, Antibodies, and MG Dye 
Diazepam (cell culture, Sigma; injections, Hospira); Ro 15-1788 (Tocris Bioscience); 
calpain-1 inhibitor MDL-28170 (Santa Cruz); L-glutamic acid (Tocris Bioscience). Primary 
antibodies: rabbit GAPDH (WB) (14C10, Cell Signaling); guinea pig GAD-65 (IF) (198104, 
Synaptic Systems); rabbit γ2 GABAAR subunit (IF, WB, IP) (224003, Synaptic Systems); rabbit 
gephyrin (WB) (sc-14003, Santa Cruz); rabbit gephyrin (IF, total) (147002, Synaptic Systems); 
mouse gephyrin mAb7a (IF, phospho) (147011, Synaptic Systems); chicken GFP (WB) (GFP-
1020, Aves); rabbit (P)ERK (WB) (4370, Cell Signaling); mouse ERK (WB) (9107, Cell 
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Signaling); rabbit (P)GSK3β (WB) (9322, Cell Signaling); rabbit GSK3β (WB) (9315. Cell 
Signaling); rabbit CDK5 (WB) (2506, Cell Signaling). MG-BTau dye prepared as in (212). 
 Fixed and Live-Imaging 
Measurements were made on days in vitro (DIV) 15–19 cortical neurons. Live-imaging 
performed in Hepes-buffered saline (HBS), containing the following (in mM): 135 NaCl, 4.7 KCl, 
10 Hepes, 11 glucose, 1.2 MgCl2, and 2.5 CaCl2 (adjusted to pH 7.4 with NaOH). Images were 
acquired using a Nikon A1 confocal microscope with a 60× oil objective (N.A., 1.49) at 3× zoom. 
Data were analyzed in NIS Elements software (Nikon, N.Y.). Measurements were taken from 
whole cell or averaged from three dendritic 10µm regions of interest (ROI) per cell. For fixed 
imaging, media was quickly removed and coverslips were washed twice with Dulbecco’s 
Phosphate Buffered Saline (DPBS) and immediately fixed with 4% paraformaldehyde and then 
blocked in PBS containing 10% fetal bovine serum and 0.5% bovine serum albumin. Surface 
antibody staining was performed under non-permeabilized conditions overnight at 4°C. 
Intracellular staining was performed overnight at 4°C following 0.2% Triton-X permeabilization 
for 10 min in blocking solution. Synaptic sites were determined during analysis by binary 
thresholds and colocalization with GAD-65. Extrasynaptic intensity was measured by taking the 
total dendrite ROI sum intensity minus background and synaptic fluorescence intensity. Dendritic 
fluorescence was measured using binary thresholds. Experimental conditions were blinded during 
image acquisition and analysis. The ROUT test (Q=1%) or Grubbs’ Test (alpha=0.05) was used to 
remove a single outlier from a data set. 
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 Lysosomal Targeting Assay 
Neuron surface and lysosomal-association assays utilized MG-BTau dye for surface 
receptor pulse-labeling. DIV 15-16 neurons were treated with vehicle or DZP for 8-12 h, then 
pulse labeled with 100 nM MG-BTau for 2 min at room temperature in HBS. Neurons were then 
washed 5x times with HBS and returned to conditioned media +/- DZP for 1 h. To identify 
lysosomal targeting, 50 nM LysoTracker Blue DND-22 (Life Technologies) and the lysosomal 
inhibitor, Leupeptin (200 µM Amresco), was added 30 min prior to imaging. Following 
incubation, neurons were washed and imaged in 4°C HBS. Two-three neurons were immediately 
imaged per culture dish within 10 min of washing. For image analysis, independent ROIs were 
drawn to capture the soma, three 10 μm sections of dendrite and the whole cell. Binary thresholds 
and colocalization measurements were performed to identify MG-BTau, pHGFP synaptic 
GABAAR clusters and lysosomes. Total surface pHGFP expression was determined by taking the 
entire cell surface signal following background subtraction. 
 NH4Cl Intracellular Imaging 
DIV 15-16 neurons were washed and continuously perfused with HBS + treatment at room 
temperature. Multiposition acquisition was used to image 2-3 neurons per dish. An initial image 
was taken to identify surface γ2pHFAP GABAARs. Neurons were then perfused with NH4Cl 
solution to collapse the cellular pH gradient and were reimaged. NH4Cl solution (in mM): 50 
NH4Cl, 85 NaCl, 4.7 KCl, 10 Hepes, 11 glucose, 1.2 MgCl2, and 2.5 CaCl2 (adjusted to pH 7.4 
with NaOH). pHGFP intensity was measured following background subtraction and smoothing. 
Surface/total levels were determined by dividing the first image (surface only) from the second 
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image (total). The spot detection tool in Nikon Elements was used to selectively count larger 
intracellular vesicles positive for γ2pHFAP. A stringent threshold was set to identify brightly 
fluorescent circular objects with a circumference of approximately 0.75 µm. Values reflect new 
vesicle objects that were only seen after NH4Cl perfusion (second image – first image). 
 Intermolecular FRET Imaging, Characterization and Analysis 
The α2 pHGFP (α2pH) construct was previously published (65) and the γ2RFP construct was 
generated by PCR cloning and fully sequenced.  DIV 15-16 neurons were treated with Veh or DZP 
for 20-28 h, then washed and continuously perfused with HBS at room temperature. Images were 
acquired with a 60x objective at 2x zoom. For each cell, an initial image was acquired containing 
two channels to identify surface α2pH (excited by 488 laser, emission band pass filter 500-550) and 
γ2RFP participating in FRET (excited 488 FRET, emission band pass filter 575–625 nm, FRET 
channel). A second, single channel image was taken immediately following with only 561 nm 
excitation to reveal total γ2RFP levels (excited by 561 laser, emission band pass filter 575–625 nm). 
For synaptic quantifications, binary thresholding based on intensity was applied with smoothing 
and size exclusion (0-3 μm) factors. FRET and 561 channel binaries shared identical minimum 
and maximum binary threshold ranges. Individual synaptic ROIs were created to precisely target 
and measure synaptic clusters containing both α2pH and γ2RFP. Manual trimming and single pixel 
removal were used to remove signal not meeting the criteria of a receptor cluster. Restriction 
criteria were applied in the following order: 1) at least 15 synapses measured per cell, 2) FRET 
γ2RFP: raw γ2RFP sum intensity ratio must be less than one, 3) synaptic α2pH mean intensity of at 
least 500, and 4) α2pH sum intensity limit of 300% of average sum intensity. ROI data was then 
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normalized to vehicle control as percent change. The percentage of RFP participating in FRET 
was also calculated using FRET RFP:Total RFP ratio.  
FRET activity was directly assessed by acceptor (γ2RFP) photobleaching. Photobleaching 
ROIs were implemented on 2 synapses per cell. Pre-bleaching images were acquired every 5 
seconds, followed by a γ2RFP photobleaching event using 80% 561 nm laser power. After 
photobleaching, image capturing resumed without delay using pre-bleach laser power settings for 
2 minutes.  Image analysis incorporated background subtraction and the measurement of percent 
change in α2pH/FRET γ2RFP ratio over the time course. FRET efficacy measurements compared 
directly adjacent α2pH and γ2RFP subunits in a GABAAR complex. Live-imaging with perfusion of 
pH 6.0 extracellular imaging saline solution (MES) was used to quench the pH-dependent GFP 
fluorescence from the α2pH donor fluorophores and show the dependence of FRET on surface α2pH 
fluorescence.  Acidic extracellular saline solution, MES solution pH 6.0 (in mM): 10 MES, 135 
NaCl, 4.7 KCl, 11 glucose, 1.2 MgCl2, and 2.5 CaCl2 (adjusted to pH 7.4 with NaOH). Images 
were collected under HBS conditions for 1 minute at 20 second intervals, and then followed by a 
2 minute MES wash with the same imaging interval to quench donor emissions. FRET RFP mean 
intensity was measured under both conditions and normalized to HBS. Percent or fold change in 
FRET RFP emissions were reported. We confirmed loss of α2pH donor lead to 90% loss of FRET 
γ2RFP emissions. γ2RFP emission from 488 laser excitation in the absence of donor was not tested. 
Measurements did not correct for channel bleed through. 
 Synaptic Exchange Rate FRAP Imaging 
Neurons were washed and media was replaced with HBS + treatment. Imaging was 
performed in an enclosed chamber at 37°C. An initial image was taken for baseline 
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standardization.  Photobleaching was performed by creating a stimulation ROI box encompassing 
two or more dendrites. This stimulation region was photobleached using the 488 and 561 lasers at 
25% power for 1 minute. The same stimulation ROI was used for every cell in an experiment. 
Immediately following photobleaching, 10 nM MG-Tau dye was added to the cell culture dish to 
re-identify surface synaptic GABAAR clusters. Time-lapse imaging was then started every 2 min 
for 60 min. During image analysis, objects were only considered synaptic if they demonstrated 
colocalization with γ2pHFAP pHGFP signal, RFP-gephyrin signal and had obvious surface MG-
BTau fluorescence. ROIs were drawn measuring the rate of fluorescence recovery at 4-8 synaptic 
sites and one extrasynaptic site (10μm long region; Bezier tool) per cell. For data analysis, synapse 
post-bleach fluorescence intensity time point data was first normalized to pre-bleach fluorescence 
intensity (post-bleach/pre-bleach). Normalized synapse post-bleach data was then calculated as 
percent change from t0 ((tx/t0)*100, where x = min). Individual synapses were then averaged to 
calculate fluorescence recovery and statistically significant changes across time points. 
 Quantitative PCR 
RNA was extracted from primary cultured neurons purified using a RNeasy mini kit 
(Qiagen). RNA concentration and purity were assessed using a Nanodrop spectrophotometer 
(Thermo Scientific). cDNA was synthesized from 320 ng of total RNA per reaction using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The Quantitative Polymerase 
Chain Reaction (qPCR) was performed using SYBR Green and the 7300 RealTimePCR system 
(Applied Biosystems Corp.), starting with 50°C for 2 min and 95°C for 10 min, followed by 40 
cycles at 95°C for 15 s and 60°C for 1 min, and concluding with 15 s at 95°C, 60°C for 1 min and 
95°C for 15 s to ensure a single product on melting curves; 1 μl of cDNA was used per well. All 
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data were analyzed using the ΔΔCt approach as described previously (294). GABAAR β3 subunit 
primers: CATGTCCTTTGTGAAGGAGACG, GTCAAGCGTGAGGTTGAGAGG, product 
length 229 base pairs (BP); GABAAR γ2 subunit primers GCGCAGTTCTGTTGAAGTGG, 
CCATTGCTGTGACATAGGAGAC, product length 338 BP; Gephyrin primers: 
GCAGGGTATCTTGGATCCTCG, GCTCTGTCTTTGGAGGTAGC, product length 215 BP; 4) 
β-actin primers: AGCCATGTACGTAGCCATCC, ACCCTCATAGATGGGCACAG, product 
length 115 BP. 
 Western Blot and Immunoprecipitation 
Protein concentration was determined by BCA protein assay for all biochemistry. Neurons 
were lysed in denaturing buffer for immunoprecipitation: 50mM Tris HCl, 1mM EDTA, 1% SDS, 
2mM Na₃VO₄, 10mM NaF, 50mM N-ethylmaleimide, protease inhibitor cocktail (Sigma). 
Lysates were sonicated and heated at 50°C for 20 min, then diluted 1:5 in RIPA buffer (50mM 
Tris HCl pH 7.6, 150mM NaCl, 1% Igepal, 0.5 % Sodium deoxycholate, 1mM EDTA, 2mM 
Na₃VO₄, 10mM NaF, 50mM N-ethylmaleimide, protease inhibitor cocktail). Standard 
immunoprecipitation procedures were performed using overnight incubation with γ2 subunit 
antibody or rabbit IgG (sci2027; Sigma), 1 h incubation with Protein A Sepharose 4B beads 
(Invitrogen), three RIPA buffer washes, and loading for SDS-PAGE. After electrophoresis and 
transfer to nitrocellulose membrane, samples were probed with primary antibody overnight 
followed by the appropriate horseradish peroxide (HRP)-coupled secondary antibody.  
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 Membrane and Subcellular Fractionation 
Cultured neurons were lysed using fractionation buffer: 50mM Tris-HCl, 50mM NaCl, 
1mM EDTA, 2mM Na₃VO₄, 10mM NaF, 320mM sucrose, 0.25% igepal, and protease inhibitor 
cocktail. Lysates were spun at 88,881g for 30 min at 4°C to separate pellet (membrane) from 
supernatant (cytosol). Fraction integrity was tested by localization specific markers in all 
experiments (270). 
 Co-immunoprecipitation 
Mice were intraperitoneally (I.P.) injected with vehicle control or 10mg/kg DZP and 
sacrificed 12 h post-injection (n = 4 mice per treatment). Mouse cortical tissue was homogenized 
in co-IP buffer (50mM Tris HCl pH 7.6, 50mM NaCl, 0.25% Igepal, 1mM EDTA, 2mM Na₃VO₄, 
10mM NaF, 50mM N-ethylmaleimide, and Sigma protease inhibitor cocktail) using a Dounce 
homogenizer. Tissue was solubilized with end-over-end mixing at 4°C for 15 min, and then spun 
at 1,000g to remove non-solubilized fractions. Each immunoprecipitation tube contained 375µg of 
tissue lysate brought up to 1ml volume using co-IP buffer. Lysates were precleared using Protein 
A Sepharose 4B beads (Invitrogen) for 1 h at 4°C. Lysate was then immunoprecipitated overnight 
with 2.5µg rabbit γ2 subunit antibody (224003, Synaptic Systems) or 2.5µg rabbit IgG (2027, 
Santa Cruz). The next day, 40 µl Protein A Sepharose slurry was added and mixed for 2 h at 4°C 
on a nutator. Beads were then washed 3x at 4°C on a nutator in 1ml co-IP buffer. Beads were 
denatured with SDS-PAGE loading buffer [Laemmli Sample buffer (Biorad) + β-mercaptoethanol] 
with heat at 70°C for 10 min and intermittent vortexing. Two immunoprecipitation reactions were 
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performed per animal and were pooled into a single tube without beads to be used for downstream 
in-gel digestion. 
 Mass Spectrometry and Data Processing 
Immunoprecipitated proteins were separated by electrophoresis in Criterion XT MOPS 
12% SDS-PAGE reducing gels (Bio-Rad), with subsequent protein visualization by staining with 
Coomassie blue. Each gel lane was divided into six slices. After de-staining, proteins in the gel 
slices were reduced with TCEP [tris(2-carboxyethyl)phosphine hydrochloride] and then alkylated 
with iodoacetamide before digestion with trypsin (Promega). HPLC-electrospray ionization-
tandem mass spectrometry (HPLC-ESI-MS/MS) was accomplished by data-dependent acquisition 
on a Thermo Fisher Orbitrap Fusion Lumos Tribrid mass spectrometer. Mascot (Matrix Science; 
London, UK) was used to search the MS files against the mouse subset of the UniProt database 
combined with a database of common contaminants. Subset searching of the Mascot data, 
determination of probabilities of peptide assignments and protein identifications, were 
accomplished by Scaffold (v 4.8.4, Proteome Software). MS data files for each entire gel lane were 
combined via the “MudPIT” option. Identification criteria were: minimum of two peptides; 96% 
peptide threshold; 1% FDR; 99% protein threshold. One vehicle- and one DZP-treated animal were 
removed from analysis due to insufficient γ2 subunit pulldown relative to all other groups. N = 3 
animals per condition were used for downstream analysis. Protein clustering was applied in 
Scaffold and weighted spectrum values and exclusive unique peptides were exported for manual 
excel analysis. Student’s t-test analysis was performed using relative fold change (ratio) of DZP 
compared to vehicle group. In some cases peptides were only detected in vehicle or DZP treated 
groups, resulting in DZP/V ratio values of zero or undefined error (cannot divide by zero). These 
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were annotated as NF-DZP (not found in DZP samples) or NF-V (not found in vehicle samples) 
in the tables.  
 Bioinformatics Analysis 
Ingenuity Pathways Analysis (IPA) (Ingenuity Systems) was used for cellular pathway 
analysis. Relative fold levels of DZP proteins compared to vehicle were used for analysis. To be 
suitable for IPA analysis, proteins NF-DZP were assigned a value of -1E+99, while proteins NF-
V were assigned a value of 1E+99. Significant enrichment in protein networks were calculated by 
right tailed Fisher's exact test. Z-score analysis is a statistical measure of an expected relationship 
direction and observed protein/gene expression to predict pathway activation or inhibition. IPA 
core analysis was searched to determine direct and indirect relationships within 35 molecules per 
network and 25 networks per analysis. All data repositories available through IPA were used to 
determine experimentally observed and highly predicted interactions occurring in mammalian 
tissue and cell lines. Ratio data were converted to fold change values in IPA, where the negative 
inverse (-1/x) was taken for values between 0 and 1, while ratio values greater than 1 were not 
affected. Proteins found to be enhanced in their association with γ2 (Table 1) were searched in the 
Mus musculus GO Ontology database (released 2018-10-08) for GO biological process and GO 
molecular function and analyzed by the PANTHER overrepresentation test; significance was 
determined using Fisher’s Exact with Bonferroni correction for multiple testing.  
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 Statistics 
Relevant statistical test information is described in the figure legends or within the 
individual methods sections. p values are reported in the results section if significance is between 
0.01 and < 0.05 or if the data is approaching significance.  
3.3 Results 
 12-24h Diazepam Decreases the GABAAR γ2 Subunit and Gephyrin through 
Post-Translational Mechanisms 
We first examined if DZP exposure reduced surface levels of γ2-GABAARs and altered 
gephyrin Ser270 phosphorylation in cortical neurons by immunofluorescence (Fig. 11A). Cortical 
neurons were treated for 24 h with vehicle or 1 µM DZP, then immunostained for surface γ2, 
followed by permeabilization and immunostaining with GAD65 (glutamic acid decarboxylase 65, 
a marker for presynaptic GABAergic terminals) and the phospho-Ser270 specific gephyrin mAb7a 
antibody (72, 75).  Image analysis identified no sizable change in surface synaptic (91.6 ± 5.3%) 
or extrasynaptic (93.3 ± 3.8%) γ2 intensity in DZP treated neurons relative to control, but DZP 
induced a significant 18.9 ± 7.4% (p = 0.033) increase in synaptic phospho-gephyrin (Fig. 11B). 
No change in extrasynaptic phosphorylated Ser270 gephyrin was measured. We repeated this DZP 
treatment and examined total and phospho-gephyrin levels in dendrites (Fig. 11C). Again DZP 
significantly enhanced phospho-Ser270 gephyrin compared to vehicle (132 ± 12%; p = 0.013), 
while a decrease in overall gephyrin levels was found (69.7 ± 5.4%) (Fig. 11D). 
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Figure 11. DZP Downregulates Gephyrin Independent of γ2 Surface Levels. 
(A) Cortical neurons were treated for 24 h with vehicle or 1 µM DZP, then immunostained for surface γ2 GABAAR 
(green), followed by permeabilization and immunostaining for (P)Ser270 gephyrin (red), and GAD65 (blue). Panels 
below show enlargements of GABAAR synapses on dendrites. (B) Dendrite surface synaptic and extrasynaptic γ2 
levels are not significantly altered by DZP. Synaptic phospho-gephyrin was enhanced in response to DZP (n = 69-74 
neurons; 4 independent cultures). (C) Neurons were treated as in A followed by antibody staining for total gephyrin 
(green) and (P)Ser270 gephyrin (red). Panels below show enlargements of dendrite region. (D) The dendritic pool of 
gephyrin was decreased, while (P)Ser270 gephyrin levels were augmented, resulting in a dramatic increase in the ratio 
of phosphorylated gephyrin to total gephyrin (n = 52-59 neurons; 3 independent cultures). Int. = fluorescence intensity. 
Image scale bars: main panels = 5 μm, enlargements = 1 μm. *p ≤ 0.05, **p < 0.01, ***p < 0.001, Student’s t-test; 




Accordingly, the mean ratio of phospho/total gephyrin was 78.1± 21% higher following DZP (Fig. 
11D). Complimentary biochemical studies using membrane fractionation were used to compare 
cytosolic, membrane, and total protein pools in cortical neurons. In agreement with 
immunofluorescence data, membrane levels of γ2 (0.929 ± 0.06) were not reduced after 1 µM 
DZP, although the total pool of γ2 was diminished (0.793 ± 0.07) (Fig. 12A,B) compared to 
vehicle. Cytosolic levels of γ2 (1.03 ± 0.06) were also unchanged. Comparatively, DZP reduced 
full-length gephyrin in every compartment measured relative to control (cytosol: 0.871 ± 0.03; 
membrane: 0.722 ± 0.06, total: 0.695 ± 0.05). We confirmed the integrity of our fractions using 
cytosolic and membrane specific markers (Supplemental Figure 2; (270)). 
Next we assessed if the decrease in gephyrin and γ2 total levels at 24 hours was a result of 
altered gene expression. qRT-PCR experiments revealed no difference in gephyrin (p = 0.206), γ2, 
or control GABAAR β3 subunit mRNA levels between vehicle and DZP treated neurons (Fig. 
12C). To determine if post-translational modification of γ2 also occurs coincident with decreased 
γ2 protein levels, we examined ubiquitination of γ2 in response to DZP exposure. We reasoned 
that changes in ubiquitination of γ2 would likely precede the loss of total γ2 seen at 24 h (Fig. 
12A,B). GFP-ubiquitin transfected cortical neurons were treated with vehicle or 1 µM DZP for 12 
h. Neurons were lysed under denaturing conditions to isolate the γ2 subunit from the receptor 
complex. Immunoprecipitation of the γ2 subunit revealed a 2.13 fold increase (p = 0.015) in 
ubiquitination in DZP treated neurons relative to vehicle (Fig. 12D,E). Furthermore, just as 
observed with 24 h DZP treatment, a reduced total pool of γ2 was also found at 12 h (p = 0.020) 
(Fig. 12D,E). Notably, this is the first demonstration of endogenous γ2 ubiquitination occurring in 
neurons (previous findings were of recombinant receptors in HEK cells) (159, 170). To investigate 
mechanisms underlying reduced full-length gephyrin levels, we examined gephyrin cleavage. 
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Gephyrin is degraded post-translationally by the protease calpain-1 (73, 295, 296), and gephyrin 
Ser270 phosphorylation promotes cleavage by calpain-1 (73). Consistent with the enhanced 
gephyrin Ser270 phosphorylation (Fig.11) and reduced full-length levels (Fig. 11,12) we found a 
significant increase in the ratio of cleaved/full length gephyrin after 24 h DZP in vitro (Fig. 
12F,G). We confirmed the identity of the gephyrin cleavage product using a well-characterized 
glutamate stimulation protocol that induces gephyrin cleavage in cultured neurons (295, 296), a 
process blocked by calpain-1 inhibition (Fig. 13). 
Finally, we wanted to determine if similar mechanisms occur in vivo following DZP 
treatment. Prior publications show BZDs and metabolites are not present 24 h post-injection due 
to rapid drug metabolism in rodents (297-300). Furthermore, BZD uncoupling does not persist 24 
h after a single dose (15 mg/kg) or 2 week daily DZP treatment, whereas uncoupling can be seen 
12 h after a single injection, indicating this is the appropriate time point for measuring in vivo loss 
of γ2-GABAAR function (271). Accordingly, mice were given a single intraperitoneal (IP) 
injection of 10 mg/kg DZP or vehicle control, and cortex tissues were harvested 12 h later. We 
found DZP significantly reduced the total pool of γ2 (87.3 ± 3.0%) and full-length gephyrin (73.9 
± 9.1%; p=0.046) relative to vehicle treated mice at 12 h post injection (Fig. 12H,I). Plasma 
membrane compartment specific loss of these proteins was further assessed using subcellular 
fractionation of mouse cortical tissue. Synaptic (Fig. 14A) and extrasynaptic (Fig. 14B) membrane 
fractions were unable to detect a robust loss of γ2 subunit or gephyrin at either localization after 
DZP treatment although a near significant decrease in extrasynaptic γ2 levels was found (-12.8% 
± 4.0; p=0.053) (Fig. 14C). These findings indicate both BZD-sensitive GABAARs and full-length 
gephyrin are downregulated by post-translational mechanisms after initial DZP treatment in vitro 




Figure 12. DZP Induces Degradation of γ2 and Gephyrin In Vitro and In Vivo.  
(A) Cortical neurons exposed to 1 µM DZP or vehicle for 24 h were subjected to membrane fraction and western 
blot analysis. (B) Total γ2 subunit and cytosolic, membrane, and total gephyrin were significantly reduced after DZP 
(n=4 independent cultures). (C) Quantitative RT-PCR revealed no change in γ2 subunit, β3 subunit or gephyrin 
mRNA expression following 24 h DZP in vitro (n=5 independent cultures). (D) GFP-ubiquitin transfected neurons 
were treated with vehicle or DZP for 12 h. Lysates were immunoprecipitated with control IgG or γ2 antibody, 
followed by blotting with anti-GFP, γ2 and GAPDH. (E) DZP treatment increased the levels of γ2 ubiquitin 
conjugates and decreased  γ2 total levels. (F,G) DZP treatment enhanced the ratio of cleaved gephyrin fragments/full 
length gephyrin (n=4 independent cultures). (H) Representative western blots of cortical tissue collected from mice 
12 h after a single IP injection of 10 mg/kg DZP or vehicle. Three mice shown from each treatment. (I) γ2 subunit 
and gephyrin totals are significantly reduced in DZP-treated animals (6-7 mice per condition). (*p ≤ 0.05, **p < 
0.01, ****p < 0.0001, Student’s t-test; error bars ± S.E.M.) 
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Figure 13. Calpain-1 Dependent Gephyrin Cleavage upon Glutmate Stimulation.  
DIV 16 neurons were treated with vehicle or 100µM glutamate for 30min in HBS +/- 10µM calpain-1 inhibitor MDL-
28170 (MDL). Neurons were then returned to conditioned media for 1.5 h prior to lysis. MDL-28170 treated neurons 
were in presence of inhibitor throughout experiment. Calpain-1 inhibition mitigates glutamate induced cleavage of 
gephyrin. Top band indicates full length gephyrin (95 kDa), bottom band indicates cleaved gephyrin (~50 kDA). 
 
 
Figure 14. Subcellular Fractionation of DZP Treated Mice.  
Cortical tissue collected from mice 12 h after a single IP injection of 10 mg/kg DZP or vehicle were subjected to 
subcellular fractionation to separate synaptic (A) and extrasynaptic fractions (B). Representative blots shown from 
animals 1-3 for each treatment. Western blot analysis was used to examine γ2 subunit and gephyrin levels. KIR 3.2, 
an inward-rectifier  potassium channel present at equal distribution in the plasma membrane (at both synaptic and 
extrasynaptic regions) was used as loading control. (C) Quantification of synaptic and extrasynaptic  γ2 subunit and 
gephyrin (6-7 mice per condition). (*p ≤ 0.05, Student’s t-test; error bars ± S.E.M.). 
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 GABAAR Composition and Intracellular and Surface Trafficking are Changed by 
DZP In Vitro 
We then investigated if surface γ2-containing GABAARs are more frequently targeted to 
lysosomes after DZP exposure by live-imaging. For these experiments we used our recently 
characterized optical sensor for synaptic GABAAR (γ2pHFAP). This dual reporter is composed of 
a γ2 subunit tagged with an N-terminal pH-sensitive GFP, myc, and the fluorogen-activating 
peptide DL5 (212). The pH-sensitive GFP tag selectively identifies cell surface GABAARs and the 
DL5 FAP binds malachite green (MG) dye derivatives including MG-BTau (233, 240, 301). MG-
BTau is cell impermeable and non-fluorescent until bound by DL5. Upon binding, MG-BTau 
fluoresces in the far red spectral region (~670 nM). This FAP-dye system allows for selective 
labeling of surface γ2-containing GABAARs which can then be tracked through various phases of 
trafficking (212). As previously shown, γ2pHFAP GABAARs are expressed on the neuronal 
surface, form synaptic clusters, do not perturb neuronal development and show equivalent 
functional responsiveness to GABA and DZP both in the absence and presence of MG dyes (212). 
We transfected neurons with γ2pHFAP and treated them with DZP for 8-16 h. Neurons were then 
pulse-labeled with 100 nM MG-BTau dye and returned to conditioned media at 37°C +/- DZP for 
1 h. The lysosomal inhibitor leupeptin (200 µM) and the lysosomal specific dye, Lysotracker (50 
nM), were added after 30 min. At the end of the incubation, neurons were washed in 4°C saline to 
inhibit trafficking and immediately used for live-imaging experiments. Representative images 
demonstrate MG-BTau labeled γ2pHFAP-GABAARs localized on the cell surface (Fig. 15A) and 
at synaptic clusters on dendrites (Fig. 15B) based on colocalization with surface specific pHGFP 
signal. MG-BTau further reveals internalized receptors at lysosomes (Fig. 15C). Image 
quantification showed synaptic γ2-GABAAR intensity remained largely unchanged (Fig. 15D). 
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Importantly, we found a significant 8.0 ± 2.5% (p = 0.015) enhancement in the mean intensity of 
GABAARs labeled with MG-BTau at lysosomes following DZP (Fig. 15E). The area of GABAARs 
colocalized at lysosomes trended towards an increase in DZP treated cells (140.2 ± 23.6%; p = 
0.144) but did not reach significance.  
We complemented these lysosomal targeting studies with an NH4Cl live-imaging approach 
that allows us to compare the ratio of cell surface vs. intracellular GABAARs in living neurons. 
γ2pHFAP expressing neurons were treated with vehicle or DZP for 24 h. Additional control groups 
included the BZD antagonist Ro 15-1788 (1-2 h) to reverse the effects of DZP. Neurons were 
actively perfused with HEPES buffered saline (HBS) treatment and an initial image was taken of 
surface pHGFP receptor signal (Fig. 15F). Neurons were then exposed to pH 7.4 NH4Cl solution 
to neutralize the pH gradient of all intracellular membrane compartments, revealing internal pools 
of γ2 containing GABAARs. Analysis revealed no change in surface γ2 levels between treatments 
(Fig. 15G) consistent with Fig. 11 and 12. However, the number of large intracellular vesicles 
(circular area ~0.75 µm) containing receptors was significantly enhanced (p = 0.047) (Fig. 15H), 
consistent with increased localization in intracellular vesicles. Ro 15-1788 and DZP + Ro 15-1788 
treated neurons were not significantly different from vehicle. Overall, these findings suggest γ2-
GABAAR ubiquitination, intracellular accumulation, lysosomal targeting and degradation are part 
of the adaptive response to DZP. 
To determine if γ2 subunit ubiquitination is key for lysosomal targeting of GABAARs 
following DZP exposure, we created lysine to arginine mutated γ2 subunits to block ubiquitination. 
Importantly, the lysine residues in the large intracellular domain have been implicated in γ2 subunit 
degradation (159, 170). We created a construct of the γ2 long isoform where eight closely 
compacted lysine residues previously found to be important for ubiquitination were mutated 
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(γ2pHFAPK8R). Two additional lysine residues in the ICD at more distant locations may also be 
subject to ubiquitination; therefore an additional γ2pHFAPK10R construct with these residues 
mutated was generated. First we examined if the γ2pHFAPK8R and γ2pHFAPK10R constructs could 
be expressed in primary cultured neurons (Fig. 16 A,B) and HEK293 cells (Fig. 16 C,D). We 
found that full length γ2pHFAPK8R and γ2pHFAPK10R are expressed in both cell types but at 
significantly lower levels in neurons (K8R: -65.0%; K10R: -70.8%) and in HEK293 cells (K8R: -
22.3%; K10R: -35.1%) relative to wild type. This suggests that the eight closely encoded lysine 
residues in the γ2 subunit may have a role in subunit stability during biosynthesis. 
Given the similar expression levels of γ2pHFAPK8R and γ2pHFAPK10R in our biochemical 
data, we proceeded with the γ2pHFAPK10R construct with two additional lysine residues mutated 
as it should conceivably be more resistant to ubiquitination. Cultured neurons expressing wild-
type γ2pHFAP and γ2pHFAPK10R were exposed to DZP for 20-28 h and then pulse-labeled with 
MG-BTau dye and returned to conditioned media at 37°C +/- DZP for 1.5 h. At the end of the 
incubation, neurons were washed in 4°C saline to inhibit trafficking and immediately used for live-
imaging experiments. Lysotracker (50 nM), was added 10 min prior to imaging. Representative 
images demonstrate MG-BTau labeled γ2pHFAP and γ2pHFAPK10R GABAARs localized on the 
cell surface (Fig. 16E) and at synaptic clusters on dendrites (Fig. 16F) indicating the 
γ2pHFAPK10R traffics to the plasma membrane. As seen previously in Fig. 15, DZP increases 
MG-BTau labeled γ2pHFAP GABAAR colocalization at lysosomes (Fig. 16G). Enhanced 
association of γ2pHFAPK10R with lysosomes was also observed after DZP. Image quantification 
(Fig. 16H,I) confirmed that DZP caused a significant increase in the intensity (+174.0% ± 72.5) 
and near significant increase in the area of (+153.1% ± 65.5) of MG- 
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Figure 15. Lysosomal Targeting and Vesicular Accumulation of γ2-GABAARs in Response to DZP.  
(A) γ2pHFAP neurons were pretreated for 12-18 h with 1 µM DZP, then pulse-labeled with 100 nM MG-BTau dye for 
2 min, and returned to conditioned media at 37°C +/- DZP for 1 h. 50 nM Lysotracker dye was added at the 30 min 
mark to identify lysosomes. MG-BTau = blue; pHGFP = green; Lysotracker = red. (n=37-42 neurons; 5 independent 
cultures). (B) Dendrite zoom images show MG-BTau labeling at γ2pHFAP synapses. (C) Cell body zoom images 
highlighting colocalization of MG-BTau labeled GABAARs (yellow trace) at lysosomes (purple trace). (D) pHGFP 
and MG-BTau measurements reveal surface synaptic γ2-GABAAR levels are not altered by DZP. (E) The pool of 
internalized MG-BTau GABAARs colocalized at lysosomes was enhanced in DZP treated neurons as measured by 
intensity (*p ≤ 0.05, Student’s t-test; error bars ± S.E.M.). (F) Neurons treated 20-28 h with vehicle or DZP. The DZP 
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site antagonist Ro 15-1788 (5 µM) was added 1-2 h prior to imaging to inhibit DZP binding at GABAARs. Neurons 
were first imaged in HBS, and then perfused with NH4Cl (pH 7.4) to reveal intracellular γ2pHFAP receptors. DZP 
treated neurons accumulated more γ2-GABAARs in large vesicular structures compared to vehicle. (n=20-27 neurons; 
3-4 independent cultures). (G) Surface intensity of γ2pHFAP was not different between treatments (one-way ANOVA; 
error bars ± S.E.M.). (H) DZP-treated neurons more frequently demonstrated accumulation of γ2pHFAP in large 
vesicles (*p ≤ 0.05 Kolmogorov-Smirnov statistical test). Scale bars in μm: A=10; B=1;C=2, F=5. 
 
BTau labeled γ2pHFAP GABAARs at lysosomes compared to vehicle wild type. Dye-labeled 
γ2pHFAPK10R receptors also demonstrated an increase in intensity (+128.2% ± 63.8) and area 
(+81.1% ± 35.4) of colocalization with lysosomes relative to vehicle control. No significant 
difference in synaptic cluster measurements were found for either group. This data suggests that 
redundant ubiquitination of other GABAAR subunits in complex with γ2 likely mediates DZP-
induced lysosomal targeting and that γ2 ubiquitination alone is not a key step in this process. 
Despite the increase in ubiquitination and lysosomal targeting of γ2-GABAARs after DZP, 
we did not detect decreased overall surface or synaptically localized surface γ2 levels.  This 
suggested two possibilities, one being that DZP treatment only reduced total γ2 levels to 80% of 
control in cultured cortical neurons and 85% in vivo, making a slight decrease in surface γ2-
GABAARs challenging to detect with current methods. Alternatively, there could be an increase 
in γ2 subunit assembly with BZD-insensitive α subunits (γ2α4β) (302) with a concomitant 
reduction in surface levels of BZD-sensitive receptors (γ2α1/2/3/5β). Our previous work showed 
24 h BZD exposure in hippocampal neurons causes decreased total and surface levels of the α2 
GABAAR subunit via lysosomal mediated degradation, without any changes in receptor insertion 
or removal rate (169). To determine if α2/γ2 GABAARs are specifically decreased by DZP 




Figure 16. Characterization and Lysosomal Targeting of Lysine Mutant γ2 in Response to DZP.   
(A) Cortical neurons transfected with wild type (WT), K8R or K10R γ2pHFAP constructs were assessed for full-length 
protein expression. NT = non-transfected. (B) Quantifcation revealed the K8R and K10R γ2pHFAP were expressed at 
a signifgantly lower level than wild-type (n = 3 independent cultures; one-way ANOVA with post-hoc Tukey’s Test; 
error bars ± S.E.M.; ***p ≤ 0.001). (C) Western blot analysis of HEK293 cells transfected with GABAAR β3 subunit 
along with WT, K8R or K10R γ2pHFAP subunits or NT negative control. (D) Quantification determined full-length 
K8R and K10R γ2pHFAP subunits are also expressed at lower levels in HEK293 cells relative to WT γ2pHFAP (n = 2 
independent cultures). (E) WT γ2pHFAP and K10R γ2pHFAP transfected neurons were pretreated for 12-18 h with 1 
µM DZP, then pulse-labeled with 100 nM MG-BTau dye for 2 min, and returned to conditioned media at 37°C +/- 
DZP for 1.5 h. 50 nM Lysotracker dye was added 10 min prior to live-imaging to identify lysosomes. MG-BTau = 
blue; pHGFP = green; Lysotracker = red. (n = 16-24 neurons; 4 independent cultures). (F) Dendrite zoom images 
show MG-BTau labeling at γ2pHFAP synapses. (G) Cell body zoom images highlighting colocalization of MG-BTau 
labeled WT and K10R γ2pHFAP GABAARs (yellow trace) at lysosomes. (H) pHGFP and MG-BTau measurements 
reveal surface synaptic γ2-GABAAR levels are not altered by DZP when compared against matching vehicle control 
in either  WT or K10R γ2pHFAP cells. (I) The intensity of internalized MG-BTau labeled GABAARs colocalized at 
lysosomes was enhanced in both γ2pHFAP WT and K10R cells after DZP treatment relative to their respective vehicle 
controls (*p ≤ 0.05, Student’s t-test; error bars ± S.E.M.). A signifgant increase in the area of MG-BTau lysosomal 
colocalization was also detected for γ2pHFAP K10R  neurons. Scale bars in μm: E=5; F=1;G=1. 
 
tagged α2pH (65) as a donor fluorophore and a red fluorescent protein (RFP) tagged γ2 subunit 
(γ2RFP) as an acceptor. FRET is an accurate measurement of molecular proximity at distances of 
10-100 Å and is highly efficient if donor and acceptor are within the Förster radius, typically 30-
60 Å (3-6 nM), with the efficiency of FRET being dependent on the inverse sixth power of 
intermolecular separation (303). Synaptic GABAARs exist as five subunits assembled in γ2-α-β-
α-β order forming a heteropentameric ion channel (Fig. 17A). We first expressed α2pH and γ2RFP 
in neurons and examined their ability to participate in intermolecular FRET. Photobleaching of the 
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acceptor γ2RFP channel enhanced donor α2pH signal (Supplementary Figure 4; (270)), confirming 
energy transfer from α2pH to γ2RFP. Next, we confirmed measurable FRET only occurs between 
α2pH/γ2RFP in surface GABAAR at synaptic sites; FRET was blocked with quenching of donor α2pH 
when the extracellular pH was reduced from 7.4 to 6.0 (Fig.17A,B). Following FRET assay 
validation, α2pH/γ2RFP GABAAR neurons were treated for 24 h with vehicle or DZP and examined 
for total synaptic α2pH and γ2RFP fluorescence as well as the γ2 FRET signal (Fig. 17C). These 
studies identified a DZP-induced reduction in synaptic α2 (-12.6%), synaptic γ2 (-14.3%) and 
diminished association of α2 with γ2 in synaptic GABAARs as measured by decreased FRET γ2 
signal (-10.6%) (Fig. 17D). In summary, this sensitive FRET method indicates that cortical 
neurons show a similar susceptibility for α2 subunit downregulation by BZD treatment as seen in 
hippocampal neurons (169). Furthermore it identifies a DZP-induced decrease in a specific pool 
of surface synaptic BZD-sensitive γ2-GABAAR. 
To gain additional mechanistic insight into the molecular mechanisms controlling 
phosphorylation and degradation of gephyrin observed in Fig. 11 and 12, we performed a DZP 
time series experiment to measure changes in expression or activation of the gephyrin regulating 
kinases ERK, GSK3β, and CDK5. CDK5 and GSK3β phosphorylate gephyrin at the Ser270 site 
(74, 75), while ERK phosphorylates a neighboring Ser268 residue (73). We first measured ERK 
activation by examining ERK phosphorylation across time points. DZP treatment caused a 
significant decrease in ERK phosphorylation at 45 min (-50.2%), 3 h (-44.5%) and 6 h (-51.2%), 
with a recovery in phosphorylation to vehicle levels occurring around 12 h and 24 h (Figure 5A,B). 
Total ERK levels were unchanged after DZP, except for a significant enhancement in expression 
at the 12 h time point, coinciding with recovery of ERK phosphorylation. We did not detect a 
change in the phosphorylation or total levels of GSK3β (Fig.18C,D) or expression of CDK5 
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Figure 17. Intermolecular FRET Reveals Decreased Synaptic α2/γ2 Surface GABAARs after DZP.  
(A) Diagram and time-series images of cortical neurons expressing donor α2pH (green) and acceptor γ2RFP during 
imaging and with imaging saline at pH 7.4 and pH 6.0. Surface α2pH (green) signal and intermolecular FRET (teal) 
between α2/γ2 subunits occurs at pH 7.4, but is eliminated by brief wash with pH 6.0 extracellular saline and 
quenching of the α2pH donor pHGFP fluorescence. (B) Quantification of relative FRET at pH 7.4 and pH 6.0 (n = 20 
synapses). (C) Neurons α2pH (green) and γ2RFP (red) were treated with vehicle or DZP for 20-28 h +/- and then 
subjected to live-imaging. For each cell, an initial image used 488 nm laser excitation to identify surface α2pH and 
FRET γ2RFP. A second image was taken immediately afterwards to acquire γ2RFP total levels (561 nm laser 
excitation). Dendritic lengths show multiple synaptic clusters with α2/γ2 surface GABAARs. (D) Synaptic cluster 
intensity quantification of α2pH, γ2RFP and FRET γ2RFP (at least 15 synapses per cell; n = 335-483 synapses; 6 
independent cultures). Image scale bars = 2 μm (*p ≤ 0.05, **p < 0.01, ****p < 0.0001, paired t-test (B), Student’s 
t-test (D); error bars ± S.E.M.). 
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(Fig. 18E,F). This data suggests that kinases involved in gephyrin phosphorylation at Ser270 do 
not demonstrate global changes after DZP, suggesting that the kinases may be recruited to 
gephyrin, or that an unknown phosphatase responsible for dephosphorylating Ser270 is inhibited 
after DZP exposure. Conversely, ERK inactivation by DZP is predicted to decrease 
phosphorylation of the functionally relevant Ser268 site of gephyrin, which has also been 
implicated in gephyrin synaptic remodeling (73). Gephyrin point mutant studies suggest reduced 
phosphorylation at Ser268 coupled with enhanced Ser270 phosphorylation, or the inverse, 
promotes calpain-1 degradation and scaffold remodeling (73). This data provides evidence that a 
known kinase pathway responsible for fine-tuning GABAAR synapse dynamics (304) and scaffold 
(73) is robustly inactivated by DZP. 
We previously found 24 h BZD exposure reduces the amplitude of miniature inhibitory 
postsynaptic currents (mIPSCs) (169), suggesting changes in synaptic GABAAR function. Having 
identified both reductions in full-length gephyrin (Fig. 11,12) and BZD sensitive GABAARs (Fig. 
12, 15), we next tested if DZP treatment altered the synaptic retention properties of gephyrin and/or 
GABAARs. Neurons expressing γ2pHFAP and RFP-gephyrin were used for live-imaging 
fluorescence recovery after photobleaching experiments (FRAP) to measure synaptic and 
extrasynaptic exchange following exposure to vehicle, 1 µm DZP, 5 µm Ro 15-1788, or DZP + 
Ro 15-1788. After an initial image was taken, dendrites were photobleached, and signal recovery 
was measured every 2 min over 30 min at synaptic sites and extrasynaptic regions (Fig. 19A 
synapses panel; Fig.19B larger dendritic region with white arrows denoting extrasynaptic region). 
MG-BTau dye was added directly after the photobleaching step to immediately re-identify the 
photobleached surface synaptic GABAARs, and improve spatial measurements (Fig. 19B). These 
experiments revealed synaptic γ2 turnover rates were nearly doubled in DZP treated neurons, a 
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process reversed by Ro 15-1788 co-treatment (Fig. 19C). DZP also accelerated gephyrin synaptic 
exchange rates compared to vehicle, with Ro 15-1788 co-treatment restoring exchange to control 
levels. No significant correlation was found between cluster area measured and fluorescence 
recovery rates of γ2 and gephyrin across all conditions, suggesting synaptic exchange rate is 
independent of cluster size (data not shown). Moreover, no statistical difference was found in γ2 
or gephyrin extrasynaptic exchange rates (Fig.19D). These findings suggest concurrent reduction 
of gephyrin and GABAAR synaptic confinement is a compensatory response to mitigate prolonged 
DZP potentiation of GABAARs.  
 
 
Figure 18. Gephyrin Regulating Kinases Following DZP Treatment.  
DIV 16 cortical neurons were treated with vehicle (V) or DZP (D) at multiple time points. Known kinase regulators 
of gephyrin synaptic clustering were tested for total protein levels and activation status with phospho-specific 
antibodies as indicated. (P)ERK and total ERK (A,B), (P)GSK3β and total GSK3β (C,D) and CDK5 (E,F) western 
blot and quantification (n = 4 independent cultures). DZP inhibited ERK phosphorylation across multiple time points 
while GSK3β activation and total levels did not change. CDK5 total levels were also unchanged by DZP treatment. 






















Figure 19. Prolonged DZP Exposure Accelerates γ2 GABAAR and Gephyrin Synaptic Exchange.  
(A) Neurons expressing γ2pHFAP (green) and RFP-gephyrin (red) were treated with vehicle or DZP for 20-28 h +/- 
Ro 15-1788 for the last 1-2 h. Neurons were imaged at 37°C in constant presence of treatment. Initial image of 
dendrites taken prior to photobleaching (Pre-bleach), then imaged post-bleach (t0) every 2 min for 30 min. Images of 
dendritic regions show synaptic cluster sites (yellow boxes) and extrasynaptic regions. (B) 10 nM MG-BTau dye 
(blue) was added immediately after bleaching events in A to resolve bleached γ2pHFAP GABAARs and provide spatial 
accuracy for time series measurements. Panels show enlargement of vehicle dendritic regions identified in A. Yellow 
boxes indicate synaptic clusters and arrows indicate extrasynaptic region seen by pHGFP fluorescence in pre-bleach 
(green) followed by post-bleach labeling with MG-Btau (blue). (C, D) Fluorescence recovery of γ2 GABAAR and 
gephyrin measured at synaptic sites and extrasynaptic sites from A. Synapse = γ2pHFAP cluster colocalized with 
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gephyrin cluster. Int. = fluorescence intensity. Image scale bars = 1 μm (*p ≤ 0.05, **p < 0.01, ***p < 0.001, ****p 
< 0.0001, two-way ANOVA; Tukey’s multiple comparisons test; 4-8 synapses and one 10 µm extrasynaptic region 
per cell; n = 51-56 synapses from 16 neurons per treatment; 4 independent cultures; error bars ± S.E.M.). 
 Label-Free Quantitative Proteomics of γ2 GABAAR Following DZP Injection In 
Vivo 
We next sought to observe DZP-induced changes in receptor trafficking in vivo. As an 
orthogonal approach, we utilized label-free quantitative proteomics to measure changes in the 
quantities of proteins associated with γ2-GABAARs in the cortex of mice after DZP. Cortical tissue 
was collected from DZP- or vehicle-treated mice 12 h post injection, lysed, and 
immunoprecipitated with anti-γ2 subunit antibody or IgG control. Following label-free mass 
spectrometry analysis, spectrum counts were used to assess relative abundance of γ2-associated 
proteins. A total of 395 proteins were identified using our inclusion criteria: minimum of two 
peptides; identified in at least three samples overall or in two of three samples in a specific 
treatment group; demonstrated at least 3:1 enrichment over IgG control across at least three 
samples overall (Dataset 1; not included). The relative abundance of γ2-GABAAR associated 
proteins in the DZP group compared to vehicle was used to determine which proteins were 
increased (Table 1) or decreased (Table 2). As a result we identified 46 proteins with elevated 
levels of interaction with γ2-GABAARs, including 10 proteins that were only found in the DZP 
treated group (Table 1, not found in vehicle samples, NF-V). Notably, we found a significant (p < 
0.05) increase in γ2 association with 14-3-3 protein family members tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein gamma (also known as 14-3-3γ) 
and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon (also 
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known as 14-3-3ε), the phosphatase protein phosphatase 3 catalytic subunit alpha (also known as 
calcineurin/PPP3CA) and a near significant increase in the GABAAR α5 subunit (p = 0.057), 
suggesting DZP induced changes in GABAAR surface trafficking (305, 306), synaptic retention 
(162, 180, 182, 183, 307), and receptor composition (308). In contrast, 23 proteins were found to 
co-immunoprecipitate with γ2 less in DZP animals relative to control, seven of which were only 
present in the vehicle treatment group (Table 2, not found in DZP, NF-DZP). Interestingly, the 
calcium-sensitive kinase CaMKIIα, which can regulate GABAAR membrane insertion, synaptic 
retention and drug binding properties (26, 70-72), was found to be significantly decreased in 
interaction with γ2-GABAAR following DZP injection in vivo. 
To better understand the consequences of the DZP-induced shift in the γ2-GABAAR 
protein interaction network, protein fold change data was subjected to core Ingenuity Pathway 
Analysis (IPA). Top enriched canonical pathways with –log(p-value) > 6.2 are shown in Figure 
20. Notably, GABA receptor signaling pathways were highly enriched, as expected, although IPA 
was unable to determine pathway activation status by z-score analysis. γ2-GABAAR association 
with proteins involved in 14-3-3 mediated signaling and Ras homolog gene family, member A 
(RhoA) signaling pathways were greatly increased after DZP (Fig. 20A, orange), while interaction 
with proteins involved in eukaryotic initiation factor 2 (EIF2) signaling and sirtuin signaling 
pathways were reduced (Fig. 20A, blue) relative to vehicle. We further examined alterations in 
functional network association relevant to receptor trafficking by checking the predicted activation 
status of select pathways when only using proteins which were found to be increased or decreased 
(Table 1, 2). Fig. 20B lists γ2-GABAAR major functional pathways found to be altered by DZP, 
contributing to processes such as endocytosis (z-score = 2.626), organization of cytoskeleton (z-
score = 0.672), and development of neurons (z-score = -0.293). Significant protein changes (p < 
 87 
0.05) conserved between two or more pathways include decreased γ2-GABAAR association with 
CAMKIIα and CDK5 and enhanced association with calcineurin/PPP3CA, the intracellular 
trafficking protein RAB35 and the cytoskeletal protein NEFH (also known as heavy neurofilament 
protein). As an additional measurement, we performed gene ontology (GO) database analysis of 
proteins which were found to be increased in DZP treated mice relative to vehicle control (Table 
3). GO analysis identified enrichment in γ2 association with proteins involved in intracellular 
trafficking and cellular localization biological pathways after DZP, consistent with IPA analysis 
findings. Taken together, these results suggest DZP modifies intracellular and surface trafficking 
















Table 1. Proteins Demonstrating Increased Association with γ2-GABAARs after DZP In Vivo by Mass 
Spectrometry.  
Ratio DZP/V is fold change in DZP animals’ peptide spectral counts (SC) relative to control vehicle treated animals. 




Value UniProtKB Gene ID Entrez Gene Name Location Type(s) 




9.5 4.3E-02 P12960 CNTN1 contactin 1 Plasma Membrane enzyme 
7.0 5.9E-02 P11276 FN1 fibronectin 1 Extracellular Space enzyme 
5.4 2.7E-02 E9Q4P0 KXD1 KxDL motif containing 1 Cytoplasm other 
5.4 3.1E-02 Q62277 SYP synaptophysin Cytoplasm transporter 
5.0 5.0E-03 Q9QXY6 EHD3 EH domain containing 3 Cytoplasm other 
5.0 7.8E-02 P48774 GSTM3 glutathione S-transferase mu 3 Cytoplasm enzyme 
4.9 1.9E-05 P38647 HSPA9 heat shock protein family A (Hsp70) member 9 Cytoplasm other 
4.7 6.4E-02 Q91V41 RAB14 RAB14, member RAS oncogene family Cytoplasm enzyme 
4.2 6.4E-02 P48758 CBR1 carbonyl reductase 1 Cytoplasm enzyme 
4.2 7.2E-02 Q8K3F6 KCNQ3 potassium voltage-gated channel subfamily Q member 3 
Plasma 
Membrane ion channel 
4.2 3.3E-02 A0A0R4J036 Nefm neurofilament, medium polypeptide 
Plasma 
Membrane other 
4.0 7.9E-02 Q921I1 TF transferrin Extracellular Space transporter 
3.8 8.6E-02 Q9CYZ2 TPD52L2 tumor protein D52 like 2 Cytoplasm other 
3.3 4.2E-02 Q99KI0 ACO2 aconitase 2 Cytoplasm enzyme 
2.6 8.0E-02 Q9EQF6 DPYSL5 dihydropyrimidinase like 5 Cytoplasm enzyme 
2.4 2.2E-02 P56480 ATP5F1B ATP synthase F1 subunit beta Cytoplasm transporter 
2.4 9.2E-02 P46096 SYT1 synaptotagmin 1 Cytoplasm transporter 
2.4 3.7E-02 Q6P1J1 CRMP1 collapsin response mediator protein 1 Cytoplasm enzyme 
2.2 3.8E-02 Q9DB20 ATP5PO ATP synthase peripheral stalk subunit OSCP Cytoplasm transporter 
1.9 N.A. P61027 RAB10 RAB10, member RAS oncogene family Cytoplasm enzyme 
1.8 9.6E-02 P63017 HSPA8 heat shock protein family A (Hsp70) member 8 Cytoplasm enzyme 
1.8 1.8E-02 P63011 RAB3A RAB3A, member RAS oncogene family Cytoplasm enzyme 
1.8 1.3E-02 P17426-2 AP2A1 adaptor related protein complex 2 subunit alpha 1 Cytoplasm transporter 
1.7 9.1E-02 P18760 CFL1 cofilin 1 Nucleus other 
       
 89 
Table 1. Continued 
1.7 8.2E-02 Q9Z2I9 SUCLA2 succinate-CoA ligase ADP-forming beta subunit Cytoplasm enzyme 
1.7 4.0E-02 P63328 PPP3CA protein phosphatase 3 catalytic subunit alpha Cytoplasm phosphatase 
1.7 7.1E-02 Q8R191 SYNGR3 synaptogyrin 3 Plasma Membrane other 
1.6 5.7E-02 Q8BHJ7 GABRA5 
gamma-aminobutyric acid type A 
receptor alpha5 subunit 
Plasma 
Membrane ion channel 
1.6 1.8E-02 O35129 PHB2 prohibitin 2 Cytoplasm transcription regulator 
1.6 1.6E-02 P61982 YWHAG 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein 
gamma (14-3-3 gamma) 
Cytoplasm other 
1.5 5.3E-02 P07901 HSP90AA1 
heat shock protein 90 alpha family class 
A member 1 Cytoplasm enzyme 
1.5 7.8E-03 P67778 PHB prohibitin Nucleus transcription regulator 
1.5 8.1E-02 Q3UGC7 EIF3J eukaryotic translation initiation factor 3 subunit J Cytoplasm 
translation 
regulator 
1.5 7.5E-02 Q8VEM8 SLC25A3 solute carrier family 25 member 3 Cytoplasm transporter 
1.3 3.3E-02 P60710 ACTB actin beta Cytoplasm other 
NF-V 7.9E-04 P62259 YWHAE 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein 
epsilon (14-3-3 epsilon) 
Cytoplasm other 
NF-V 1.0E-02 P63044 VAMP2 vesicle associated membrane protein 2 Plasma Membrane other 
NF-V 1.6E-02 P46660 INA internexin neuronal intermediate filament protein alpha Cytoplasm other 
NF-V 3.7E-02 Q9QYM9 TMEFF2 transmembrane protein with EGF like and two follistatin like domains 2 Cytoplasm other 
NF-V 4.1E-02 Q6PHN9 RAB35 RAB35, member RAS oncogene family Cytoplasm enzyme 
NF-V 6.0E-02 P19246 NEFH neurofilament heavy Cytoplasm other 
NF-V 6.3E-02 Q9CZ13 UQCRC1 
ubiquinol-cytochrome c reductase core 
protein 1 Cytoplasm enzyme 
NF-V 1.2E-06 Q9CQQ7 ATP5PB ATP synthase peripheral stalk-membrane subunit b Cytoplasm transporter 
NF-V 2.8E-06 P80317 CCT6A chaperonin containing TCP1 subunit 6A Cytoplasm other 






Table 2. Proteins Demonstrating Decreased Association with γ2-GABAARs after DZP In Vivo by Mass 
Spectrometry.  
Ratio DZP/V is fold change in DZP animals’ peptide SC relative to control vehicle treated animals. NF-DZP = not 
found in DZP samples. N = 3 animals per treatment condition, p < 0.1, t-test. 
Ratio 
DZP/V P-Value UniProtKB Gene ID Entrez Gene Name Location Type(s) 
0.2 3.4E-02 P62717 RPL18A ribosomal protein L18a Cytoplasm other 
0.2 3.9E-02 P62874 GNB1 G protein subunit beta 1 Plasma Membrane enzyme 
0.2 4.2E-02 Q60900-2 ELAVL3 ELAV like RNA binding protein 3 Nucleus other 
0.2 5.8E-02 Q920I9 WDR7 WD repeat domain 7 Cytoplasm other 
0.3 2.0E-02 P53026 RPL10A ribosomal protein L10a Nucleus other 
0.3 3.4E-02 Q91VM5 Rbmxl1 RNA binding motif protein, X-linked like-1 Nucleus other 
0.4 6.9E-02 P49312 Hnrnpa1 heterogeneous nuclear ribonucleoprotein A1 Nucleus other 
0.4 8.5E-02 Q8BG05 Hnrnpa3 heterogeneous nuclear ribonucleoprotein A3 Nucleus transporter 
0.4 7.9E-02 Q922F4 TUBB6 tubulin beta 6 class V Cytoplasm other 
0.5 5.2E-02 P62334 PSMC6 proteasome 26S subunit, ATPase 6 Nucleus peptidase 
0.5 2.9E-04 P11798 CAMK2A calcium/calmodulin dependent protein kinase II alpha Cytoplasm kinase 
0.5 3.6E-02 E9PV14 EPB41L1 erythrocyte membrane protein band 4.1 like 1 
Plasma 
Membrane other 
0.7 6.8E-02 P16330 CNP 2',3'-cyclic nucleotide 3' phosphodiesterase Cytoplasm enzyme 
0.7 7.6E-02 O35643 AP1B1 adaptor related protein complex 1 subunit beta 1 Cytoplasm transporter 
0.8 1.4E-02 P68369 TUBA1A tubulin alpha 1a Cytoplasm other 
0.8 8.0E-02 P52480 PKM pyruvate kinase M1/2 Cytoplasm kinase 
NF-DZP 1.5E-02 P61358 RPL27 ribosomal protein L27 Cytoplasm other 
NF-DZP 3.5E-02 Q9Z1X4-3 ILF3 interleukin enhancer binding factor 3 Nucleus transcription regulator 
NF-DZP 5.5E-02 Q80UJ0 ELAVL2 ELAV like RNA binding protein 2 Cytoplasm other 
NF-DZP 2.8E-06 Q3UHB8 CCDC177 coiled-coil domain containing 177 Other other 
NF-DZP 2.8E-06 P49615 CDK5 cyclin dependent kinase 5 Nucleus kinase 
NF-DZP 2.8E-06 Q6ZWV3 RPL10 ribosomal protein L10 Cytoplasm translation regulator 
NF-DZP 2.8E-06 Q9CQ69 UQCRQ ubiquinol-cytochrome c reductase complex III subunit VII Cytoplasm enzyme 
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Figure 20. Ingenuity Pathway Analysis Reveals Shifts in Protein Interaction Networks After DZP Exposure.  
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(A) Canonical pathways found to be enriched with γ2-GABAARs and differentially expressed following DZP 
administration in vivo. Enriched pathways with –log(p-value) greater than 6.2 were considered as calculated by 
Fisher's exact test right-tailed. Values to right of bars represent pathway activation z-score. Positive z-score represents 
predicted upregulation of a pathway (orange), negative z-score predicts inhibition (blue), z-score = 0 represents no 
change in pathway (white), while not determined (N.D.) conveys the analysis program was unable to determine a 
significant change (grey). Intensity of color represents size of z-score value. (B) Functional network association of 
select pathways when using proteins which were found to be increased or decreased with a p < 0.1. Major functional 
pathways altered by DZP include endocytosis (z-score = 2.626), organization of cytoskeleton (z-score = 0.672), and 
development of neurons (z-score = -0.293). Significant protein changes (p < 0.05) conserved between two or more 
pathways include decreased γ2-GABAAR association with CAMKIIα and CDK5 and enhanced association with 
calcineurin/PPP3CA, the intracellular trafficking protein RAB35 and the cytoskeletal protein NEFH (also known as 
heavy neurofilament protein). Red = increased measurement, green = decreased measurement, orange = activation of 
pathway, blue = inhibition of pathway, yellow = findings inconsistent with state of downstream molecule, grey = 
effect not predicted. 
 
Table 3. GO Analysis Reveals Enrichment of Intracellular Trafficking, Transport, and Protein Localization 
Pathways after DZP.  
Proteins found to have enhanced association (p < 0.1) with γ2-GABAARs during Scaffold analysis were searched in 
the GO Ontology database for biological process pathway enrichments. PANTHER Overrepresentation test and 
Fisher’s Exact test with Bonferroni correction for multiple testing for significance. 
 
GO Biological Process 
 





transport GO:0006810 4.2 9.8E-09 
establishment of localization GO:0051234 4.0 2.5E-08 
establishment of localization in cell GO:0051649 6.8 2.0E-07 
localization GO:0051179 3.3 2.5E-07 
intracellular transport GO:0046907 7.2 1.6E-06 
regulation of localization GO:0032879 4.3 3.7E-06 
intracellular protein transport GO:0006886 9.1 7.8E-06 
regulation of transport GO:0051049 5.1 2.2E-05 
cellular localization GO:0051641 4.8 4.8E-05 
protein transport GO:0015031 6.1 2.2E-04 
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Figure 21. Biochemical Evaluation of Proteins Found to be Altered in their Association with γ2-GABAARs 
after DZP by Proteomics.  
Western blot analysis (A) of cortical tissue from mice treated with vehicle or DZP for 12 h. Quantification of 
T286/T287 (P)CaMKII and overall CaMKII α/β subunits (B), CDK5 (C), GABAAR α5 (D) subunit and calcineurin 
(CaN) (E). The α5 subunit demonstrated a global increase in protein levels after DZP, while no other proteins were 
signifigantly altered (*p ≤ 0.05, Student’s t-test; n = 4 mice per treatment; error bars ± S.E.M.). 
 
To determine if the changes in association with key proteins identified to be altered in their 
association with γ2 after DZP was a result of changes in total overall protein levels, we performed 
western blot analysis of cortical tissue from mice treated with vehicle or DZP for 12 h (Fig. 21). 
Quantification revealed that phosphorylated T286/T287 ((P)CaMKII) and overall CaMKIIα/β 
subunits, CDK5 and CaN were not significantly altered by DZP. In contrast, the α5 subunit 
exhibited a statistically significant increase in response to DZP relative to vehicle. These findings 
suggest that higher levels of expression of the α5 subunit leads to increased α5/γ2 containing 
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GABAARs, while a change in localization or interaction of CaMKIIα/β, CDK5 and CaN underlie 
the diminished association with γ2 after DZP exposure seen by proteomics. 
3.4 Discussion 
This work identifies key trafficking pathways involved in GABAAR neuroplasticity in 
response to initial DZP exposure. Using a combination of biochemical and imaging techniques, 
we identified total γ2 subunit levels are diminished in response to 12-24 h of DZP exposure in 
vitro and in vivo. Concurrent with the decrease in the overall γ2 pool, we found DZP treatment 
enhanced ubiquitination of this subunit. Use of an innovative optical sensor for BZD sensitive 
GABAAR (γ2pHFAP) in combination with MG dye pulse-labeling approaches revealed DZP 
exposure moderately enhanced targeting of surface γ2-GABAARs to lysosomes. Live-imaging 
experiments with pH 7.4 NH4Cl revealed increased intracellular receptor pools, providing further 
evidence that DZP enhances γ2-GABAAR lysosomal accumulation, a response reversed by BZD 
antagonist Ro 15-1788 treatment. We used novel intersubunit FRET based live-imaging to identify 
that surface synaptic α2/γ2 GABAARs were specifically decreased after DZP, suggesting these 
receptor complexes were subjected to ubiquitination, lysosomal targeting, and degradation. In 
addition to DZP modulation of receptor trafficking, the postsynaptic scaffolding protein gephyrin 
demonstrated significant plasticity including increased Ser270 phosphorylation and production of 
gephyrin proteolytic fragments, concurrent with a decrease in total and membrane full-length 
gephyrin levels and ERK inactivation. Given the fundamental role of gephyrin in scaffolding 
GABAARs and regulating synaptic confinement, we used simultaneous FRAP live-imaging of 
receptors and scaffold in neurons to monitor inhibitory synaptic dynamics. We found ~24 h DZP 
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exposure accelerates both the rate of gephyrin and GABAAR exchange at synapses as shown by 
enhanced fluorescence recovery rates. Control experiments using the BZD antagonist Ro 15-1788 
were able to reverse the DZP induced loss of synaptic confinement, reducing gephyrin and 
GABAAR mobility back to vehicle levels. Finally, we used label-free quantitative mass 
spectrometry and bioinformatics to identify key changes in γ2-GABAAR protein association in 
vivo suggesting alterations in trafficking at the cell surface and intracellularly. Collectively, this 
work defines a DZP-induced reduction of gephyrin scaffolding coupled with increased synaptic 
exchange of gephyrin and GABAARs. This dynamic flux of GABAARs between synapses and the 
extrasynaptic space was associated with enhanced γ2-GABAAR accumulation in intracellular 
vesicles and γ2-GABAAR subtype specific lysosomal degradation. We propose DZP treatment 
alters these key intracellular and surface trafficking pathways ultimately diminishing 
responsiveness to DZP. 
Numerous classical studies have examined gene and protein expression adaptations in 
GABAAR subunits after BZD exposure with minimal agreement that a specific change occurs (32, 
33, 46).  Here molecular mechanistic insight is provided, through direct measurements of enhanced 
ubiquitination of the γ2 subunit (Fig. 12), lysosomal targeting (Fig. 14,15), reduced surface 
synaptic α2/γ2 GABAAR levels (Fig. 17), and reduced synaptic confinement (Fig. 19) of DZP-
sensitive GABAARs. Together this suggests BZD exposure primarily decreases synaptic retention 
of γ2 containing GABAAR while downregulating surface levels of the α2 subunit. Ubiquitination 
of the γ2 subunit by the E3 ligase Ring Finger Protein 34 (RNF 34) (170) is the only currently 
known mechanism targeting internalized synaptic GABAARs to lysosomes (159). Due to the 
requirement of the γ2 subunit in all BZD-sensitive GABAARs, it is likely that ubiquitination of the 
γ2 subunit is a contributing factor for increased lysosomal-mediated degradation in response to 
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DZP, although not required (Fig. 16). Despite a small decrease in the γ2 total protein, changes in 
surface levels were not significant by biochemical approaches, consistent with evidence that γ2-
GABAAR surface levels are tightly regulated to maintain baseline inhibition and prevent 
excitotoxicity. For example, in heterozygous γ2 knockout mice a 50% reduction in γ2 levels 
appears to be compensated by increased cell surface trafficking, resulting in only an approximately 
25% reduction in BZD binding sites in the cortex and a limited reduction in synaptic GABAAR 
clusters (309, 310). In contrast, homozygous γ2 knockout mice show a complete loss of behavioral 
drug response to BZD and over 94% of the BZD sites in the brain (GABA binding sites unchanged) 
and early lethality (311). Similarly, studies have shown that prolonged GABAAR agonist or BZD 
application increases γ2 GABAAR internalization in cultured neurons, with inconsistent changes 
in surface GABAAR levels detected (160, 312). Importantly, by using high sensitivity surface 
GABAAR intersubunit FRET measurements we were able to detect a decrease in BZD sensitive 
α2/γ2 GABAARs (Fig. 17).  
The role of inhibitory scaffolding changes in responsiveness to BZD has been largely under 
investigated. Phosphorylation of gephyrin at Ser270 is mediated by CDK5 and GSK3β, while a 
partnering and functionally relevant Ser268 site is regulated by ERK (73). DZP time series 
experiments revealed a global decrease in ERK phosphorylation but not GSK3β, without a change 
in total kinase levels of ERK, GSK3β  or CDK5 over the course of the assay (except 12 h ERK) 
(Fig.  18). A previous model by Tyagarajan SK, et al. (2013) using gephyrin point mutants at 
Ser268 and Ser270 suggested that enhanced Ser270 phosphorylation coupled with decreased 
Ser268 phosphorylation by ERK promotes gephyrin remodeling and calpain-1 degradation. This 
is consistent with the ERK inactivation measured in our data and the increase in gephyrin Ser270 
phosphorylation demonstrated by immunofluorescence after DZP (Fig. 11), enhanced gephyrin 
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degradation and decreased full-length gephyrin levels (Fig. 11,12). Calpain-1 mediated gephyrin 
cleavage can occur within 1 minute in hippocampal membranes (313), and cleavage products are 
increased following in vitro ischemia at 30 min and up to 48 hours following ischemic events in 
vivo (295). Gephyrin cleavage may be occurring at earlier time points than the DZP 24 h mark 
measured here (Fig. 12 F,G), coinciding with ERK dephosphorylation as early as 45 min (Figure 
5A,B). One limitation of our results is that measuring total and phospho levels of these kinases 
does not directly address changes in association or regulation of gephyrin, although it does provide 
an additional piece of evidence supporting gephyrin cleavage by calpain-1 and scaffold 
remodeling. Accordingly, our previous work found 30 min treatment with the GABAAR agonist 
muscimol in immature neurons (depolarizing) leads to ERK/BDNF signaling and decreased 
Ser270 phosphorylated gephyrin levels at synapses and overall (304). Thus, ERK activation status 
negatively correlates with the level of phosphorylation at gephyrin Ser270. 
Recent work has demonstrated 12 h DZP treatment of organotypic hippocampal slices 
expressing eGFP-gephyrin causes enhanced gephyrin mobility at synapses and reduced gephyrin 
cluster size (314). Here we found the synaptic exchange rate of γ2 GABAARs and gephyrin to be 
nearly doubled at synapses in cortical neurons after ~24 h DZP exposure (Fig. 19). γ2 extrasynaptic 
fluorescence recovery in DZP treated neurons was variable but also trended towards an increase 
relative to controls (Fig. 19), which could be a result of increased diffusion of receptors out of the 
synaptic space. This effect occurred coincident with the formation of truncated gephyrin cleavage 
products (Fig. 12), which has previously been shown to decrease γ2 synaptic levels (295). These 
findings are also consistent with our previous work showing RNAi gephyrin knockdown doubles 
the rate of γ2-GABAAR turnover at synaptic sites (54). Later quantum dot single particle tracking 
studies confirmed γ2 synaptic residency time is linked to gephyrin scaffolding levels (252). 
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Importantly, GABAAR diffusion dynamics also reciprocally regulate gephyrin scaffolding levels 
(307), suggesting gephyrin and GABAARs synaptic residency are often functionally coupled. 
Accordingly, γ2 subunit and gephyrin levels both decrease in responses to other stimuli including 
status epilepticus (315) or prolonged inhibition of IP3 receptor-dependent signaling (180). 
Additionally, chemically-induced inhibitory long-term potentiation (iLTP) protocols demonstrate 
gephyrin accumulation occurs concurrent with the synaptic recruitment of GABAARs within 20 
min (287). Collectively, these proteins display a high degree of interdependence across different 
experimental paradigms of inhibitory synapse plasticity occurring over minutes to days.  
Increasing receptor synaptic retention enhances synaptic currents, while enhanced receptor 
diffusion via decreased scaffold interactions reduces synaptic currents. For example, reduction of 
gephyrin binding by replacement of the α1 GABAAR subunit gephyrin binding domain with non 
gephyrin binding homologous region of the α6 subunit results in faster receptor diffusion rates and 
a direct reduction in mIPSC amplitude (285). Similarly, enhanced diffusion of GABAARs 
following estradiol treatment also reduces mIPSCs in cultured neurons and in hippocampal slices 
(316). In contrast, brief DZP exposure (< 1h) reduces GABAAR synaptic mobility (69) without a 
change in surface levels (70), consistent with initial synaptic potentiation of GABAAR 
neurotransmission by DZP. Together with our current findings, this suggests post-translational 
modifications on GABAAR subunits or gephyrin that enhance receptor diffusion are a likely key 
step leading to functional tolerance to BZD drugs.  
It is a significant technical challenge to examine dynamic alterations in receptor trafficking 
occurring in vivo. To overcome this we examined changes in γ2-GABAAR protein association 
following DZP injection in mice using quantitative proteomics and bioinformatics analysis. This 
work revealed shifts toward γ2-GABAAR association with protein pathway networks associated 
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with endocytosis and organization of cytoskeleton (Fig. 20B, Table 3), confirming similar 
fluctuations in membrane and intracellular trafficking occur in vivo and in vitro after DZP. We 
also found that shifts in association of proteins involved in the development of neurons (CaMKIIα, 
CDK5, NEFH, calcineurin/PPP3CA) suggested an inhibition in this pathway after DZP (Fig. 20B). 
When considering all protein hits between vehicle and DZP, γ2-GABAAR association with 
proteins involved in 14-3-3 mediated signaling and RhoA signaling pathways were greatly 
increased after DZP (Fig. 20A, orange), while interaction with proteins involved in EIF2 signaling 
and sirtuin signaling pathways were reduced (Fig. 20A, blue). 14-3-3 proteins are heavily linked 
in GABAAR intracellular to surface trafficking (305, 306), and the RhoA signaling pathway is 
directly involved in actin cytoskeleton organization (317) and α5-GABAAR anchoring (106), 
providing further evidence of GABAAR shifts in membrane and cytosolic trafficking after DZP 
exposure.  
Recent inhibitory synapse proteomics studies have identified a number of new protein 
synaptic constituents or modulators of GABAAR function (87, 318-321). We show here that 
proteins known to have roles in synaptic function and trafficking of membrane receptors show 
changes in their association with γ2-receptors. For example, the calcium-sensitive kinase 
CaMKIIα was found to be significantly decreased in interaction with γ2-GABAAR following DZP, 
which can regulate GABAAR membrane insertion, synaptic retention and drug binding properties 
(119, 178, 287, 322) (Table 2). Calcineurin/PPP3CA has been recognized as a key regulator of 
GABAAR synaptic retention and plasticity (162, 180, 182, 183, 307) and has been linked to the 
response to DZP in vitro (312). Here we provide the first evidence that DZP exposure enhances 
the association of calcineurin with γ2-GABAARs in vivo. Furthermore, DZP was found to enhance 
γ2 association with 14-3-3 protein family members (Table 1), which are known mediators of 
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GABAAR surface and intracellular trafficking (305, 306). α5 subunit coassembly with γ2 (Table 
1) and overall levels (Fig. 21) were elevated after DZP. Interestingly, the α5 subunit is required 
for the development of BZD sedative tolerance in mice (308). It is notable that our proteomic 
studies are in part limited by the specificity of our antibody used and general downstream effects 
of reduced neuronal activity. Future follow up studies using the DZP site antagonist R015-1788 
will be needed to dissect the individual roles of proteins found to be significantly altered in their 
association with GABAAR, and their physiological and pharmacological importance to BZD 
tolerance and inhibitory neurotransmission. 
Through application of novel and highly sensitive fluorescence imaging approaches 
combined with in vivo proteomics, we provide unprecedented resolution of GABAAR synapse 
plasticity induced by BZDs at both the level of the single neuron and cortex. Our study reveals that 
sustained initial DZP treatment diminishes synaptic BZD sensitive GABAAR availability through 
multiple fundamental cellular mechanisms: through reduction of the post-synaptic scaffolding 
protein gephyrin; shifts toward intracellular trafficking pathways and targeting of receptors for 
lysosomal degradation; and enhanced synaptic exchange of both gephyrin and GABAARs. 
Proteomic and bioinformatics studies using DZP-treated mouse brain tissue provide further 
evidence that altered γ2-GABAAR surface and intracellular trafficking mechanisms play a critical 
role to the response to DZP in vivo. These results define key events leading to BZD 
irresponsiveness in initial sustained drug exposure. Future studies utilizing this dual approach will 
address the neuroadaptations produced by long term BZD use to systematically identify the effects 
of a critical drug class that has seen a tripling in prescription numbers over the last two decades 
(323).  
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4.0 Inhibitory and Excitatory Synaptic Neuroadaptations in the Diazepam Tolerant Brain 
Joshua Lorenz-Guertin performed animal injections, sample collection, biochemistry data 
collection and analysis, behavior, mass spectrometry data analysis. Megan L. Brady performed an 
open-field behavioral assay. Sabya Das performed biochemistry experiments on tissue from seven 
day treated animals and assisted with behavioral experiments. Tija C. Jacob, Matthew J. Bambino, 
Katarina Vajn and Matthew L. MacDonald assisted with mass spectrometry data analysis. Tija C. 
Jacob and Matthew L. MacDonald built and curated SRM libraries. The Macdonald laboratory 
performed mass spectrometry experiments. Nadezda Povysheva performed electrophysiology 
experiments and analysis.  
4.1 Introduction 
BZDs are positive allosteric modulators that potentiate GABAAR inhibition by increasing 
the binding affinity of GABA and increasing channel opening frequency (32). Sustained treatment 
with BZD drugs is intimately associated with the development of tolerance, dependence, 
withdrawal and addiction (33). BZD efficacy diminishes after prolonged or high dose acute 
exposure (271, 272), with tolerance to the sedative/hypnotic effects and anti-convulsant properties 
forming most quickly (46, 273-275). Since the development of BZDs in the early 1960s, intense 
research efforts have attempted to understand the adaptive response to BZDs. Direct comparison 
of these studies has proved challenging due to inconsistent findings likely as a result of 
methodological differences (33). Regardless, three important key characteristics were identified: 
BZD drugs demonstrate reduced affinity for the GABAAR after prolonged exposure (allosteric 
uncoupling; described in section 3.1), the effects of BZD could be reversed by concurrent treatment 
with the BZD site antagonist flumazenil (including behavioral dependence, withdrawal and 
tolerance (324-326)), and DNA/RNA level changes of GABAAR subunit expression are 
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inconsistent across experimental models (32). Considering these findings en masse, it is likely that 
rapidly tunable post-translational modifications, protein levels of GABAAR subunits, or other non-
GABAAR inhibitory synapse components, may provide important mechanistic information 
underlying BZD irresponsiveness. For instance, BZD potentiation of recombinant GABAARs in 
HEK293 cells is reduced when γ2 subunit Ser327 residue is phosphorylated (150) and 7-14 days 
of DZP treatment in rats causes increased phosphorylation at this site (327). Moreover, protein 
level changes in GABAAR subunit composition dictates the ability to bind BZD drugs (2), impacts 
localization at synapses and interacting proteins (328) and determines general channel properties 
(329). GABAARs exist primarily in heteropentamers composed of two α, two β and a γ2 subunit, 
possibly containing two different α subunits, which impacts receptor pharmacology (330-332). As 
stated in previous sections, α1/2/3/5 subunits directly adjacent to γ2 form the BZD binding pocket, 
while α4 and α6 are BZD insensitive. Notably, α4/β/γ2 GABAARs exist in small α subunit 
heterogeneous populations (333, 334), and increased expression of these BZD-insensitive 
GABAARs could shift receptor pharmacology and contribute to tolerance by reducing BZD 
binding.  
Neurotransmission relies on a delicate balance of both inhibitory and excitatory input, and 
thus synaptic neuronal proteins involved in both of these processes are likely involved in the 
response to BZDs. Excitatory glutamatergic receptors consist of ionotropic and metabotropic 
subtypes. Ionotropic glutamate receptors are heteromeric ligand-gated cation channels inwardly 
permeable to K+, Na+, or Ca2+ ions following glutamate binding. The NMDA (N-methyl-D-
aspartate) receptor class is crucial for synaptic plasticity and is comprised of two obligatory 
GluN1 subunits and two GluN2/3 subunits with differing regulatory characteristics. The 
predominant GluN2 isoforms are GluN2A and GluN2B. GluN2B is predominantly expressed in 
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the early postnatal brain and remains open longer after activation compared to GluN2A, which is 
expressed at higher levels later in over development (335). As a result, NMDA receptor function 
and role in synaptic plasticity is closely correlated with dynamic changes in the composition of 
GluN2 subunit isoforms. AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-4-propionic acid) 
receptors are heterotetrameric ligand-gated ion channels composed of multiple subunits (GluR1-
4). AMPA receptors are also important for the establishment of long-term excitatory potentiation 
and synaptic plasticity. AMPA receptors exhibit faster kinetics and lower glutamate affinity than 
NMDA receptors, thus the balance of AMPA/NMDA receptors is key to neuronal excitatory 
neurotransmission for short-term integration of synaptic inputs and long-term transformation of 
circuits (336-338).  
Glutamatergic sensitization or upregulation has been postulated to be important in the 
development of BZD tolerance and addiction/withdrawal (339), as excessive excitation could 
require BZDs to be administered persistently or at higher doses to achieve the intended therapeutic 
effect. Early mouse studies using the AMPA antagonist GYKI 52466 and the NMDA receptor 
antagonist CPP revealed BZD withdrawal syndromes occur in separate AMPA and NMDA 
dependent phases (340). NMDAR current has also been shown to be decreased two days post 
cessation of one week treatment with the BZD flurazepam in CA1 hippocampal neurons, although 
this effect could be reversed by treatment with the non-competitive NMDAR  antagonist MK-801 
one day after BZD cessation (299). Multiple studies support the role of enhanced NMDA receptor 
function in withdrawal behaviors (341-343) and upregulation of GluN1 and GluN2B NMDAR 
subunits after DZP by [3H]MK801 binding and biochemistry (344, 345). Moreover, MK801 and 
ifenprodil (GluN2B subtype NMDAR antagonist) suppressed withdrawal-induced 
 104 
pentylenetetrazole (PTZ) seizure susceptibility in DZP treated mice (342), cumulatively 
supporting the idea of NMDAR upregulation in response to DZP withdrawal.  
Fewer studies have focused on the role of NMDAR contribution to the formation BZD 
tolerance. Importantly, NMDARs are implicated in tolerance to a number of other pharmacological 
drug classes including opioids (346), ethanol (347) and barbiturates (348). Some behavioral data 
suggests co-administration of the highly potent NMDAR competitive antagonist CPP, but not the 
AMPAR antagonist GYKI 52466, prevents development of DZP sedative behavioral tolerance in 
mice (349). MK801 also prevented the development of tolerance to locomotor effects (350) of 
DZP in rats, while tolerance to the anticonvulsant response of the BZD lorazepam was moderately 
prevented by CPP in mice (341). Interestingly, lorazepam reduced binding of the BZD binding site 
agent [3H]flumazenil in multiple brain regions, an effect that was not reversed by CPP co-
treatment, suggesting downregulation of GABAARs was not reversible by NMDAR inhibition. 
This finding could imply distinct contributions of GABAARs and NMDARs to neuroadaptations 
in BZD tolerance.  
Understanding the role of both GABAergic and glutamatergic contributions in BZD 
withdrawal and tolerance studies has been limited by using non-comprehensive experimental 
approaches. Moreover, these studies lack insight about the key molecular signaling networks 
undermining functional changes in synaptic function. To gain a more holistic perspective of the 
neuroadaptive changes occurring during BZD tolerance, we analyzed inhibitory and excitatory 
synaptic protein levels and function by biochemical and electrophysiology approaches in mice 
who demonstrate DZP sedative tolerance behaviorally. To generate a more complete 
understanding of DZP-induced neuroplasticity, we used state of the art selected reaction 
monitoring (SRM) mass spectrometry to quantify over 500 proteins, interrogating glutamatergic, 
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GABAergic and other signaling pathways. No existing studies have used a high-throughput 
quantitative and targeted proteomics based method to reveal the complex neuroadaptations of the 
BZD tolerant rodent brain. We assessed our proteomic findings using bioinformatics analysis to 
determine changes in activation states of key biological pathways to predict changes in cellular 
activity and function. Collectively our findings reveal complex alterations in both synaptic 
inhibitory and excitatory neurotransmission that share overlapping mechanisms with ethanol and 
opiate tolerance. 
4.2 Methods and Materials 
 Mice 
All experiments were approved by the Institutional Animal Care and Use Committee of 
the University of Pittsburgh and conducted in accordance with the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals. C57BL/6J 8-10 week old male mice 
(Jackson Laboratory) were maintained on a reverse 12 h dark/light schedule. Mice were habituated 
to the University of Pittsburgh animal facility for at least three days prior to initiation of 
experiments. Mice were housed under 12 h light/dark cycles and had ad libitum access to food.  
 Diazepam Treatment and Open-Field Behavior Assay 
Mice were randomly assigned to vehicle (40% PEG, 10% EtOH, 5% Na Benzoate, 1.5 % 
Benzyl alcohol) or DZP (Hospira) treatments. All animals received a saline injection at day -1 and 
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vehicle injection at day 0. On day 1, mice received either a DZP (10mg/kg) or vehicle injection 
and this treatment continued once daily for seven days in the morning. Mice were injected with 
vehicle or DZP approximately 45 min prior to testing for locomotor activity in an open field using 
automated activity monitors (Med Associates, St Albans, VT). Mice were allowed to freely explore 
the chamber for 20 min during which time ambulatory distance traveled was recorded. Brain tissue 
was immediately collected and flash frozen following day 7 behavior studies where applicable. 
Mice that were only used for biochemistry experiments were given the same dosing regimen, 
including a dose approximately 45 min prior to sacrifice (two treatments total for 24 h timepoint 
mice and four treatments total for 72 h timepoint mice). 
 Antibodies 
Primary antibodies: rabbit GAPDH (WB) (14C10, Cell Signaling); rabbit CaMKII α/β 
Phospho Thr286 (WB) (p1005-286, Phosphosolutions); rabbit CaMKII pan (WB) (4436, Cell 
Signaling); rabbit GluN1 (WB) (5704, Cell Signaling); mouse GluN2B (WB) (610417, BD 
Biosciences); rabbit GluN2A (WB) (1500, Phosphosolutions), rabbit GABAAR α1 subunit (WB) 
(06-868, Millipore); rabbit GABAAR α4 subunit (WB) (845-GA4C, Phoshposolutions); rabbit 
GABAAR α5 subunit (WB) (2224503, Synaptic Systems); rabbit GABAAR β3 subunit (WB) (863-
GB3C, Phoshposolutions); rabbit γ2 GABAAR subunit (WB) (224003, Synaptic Systems); rabbit 
gephyrin (WB) (sc-14003, Santa Cruz); rabbit KIR3.2 (WB) (APC-006, Alomone Labs). 
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 Subcellular Fractionation 
Subcellular fractionation was performed as previously described (351). Mouse cortical 
tissue was homogenized using a dounce homogenizer in homogenization buffer (HB) (in mM): 20 
Tris-HCl, 2 EDTA, 640 Sucrose, 40 Na pyrophosphate, 20 NaF, 40 β-glycerophosphate, 4 
Na₃VO₄, Sigma protease inhibitor cocktail (adjusted to pH 7.4 with NaOH at 4°C).  After 
homogenization, samples were spun 1000rcf for 10mins at 4°C. The supernatant was removed and 
was either stored (Total) or used for subcellular fractionation. Samples were spun at 15,000 rcf for 
30 min at 4°C. The supernatant was removed and the pellet was resuspended in 496 µL H20 with 
protease inhibitor and sat on ice for 15 min. 3.75 µL 1M HEPES NaOH was then added and lysis 
continued on ice for 15 min. Samples were then spun for 20 min at 25,000 rpm at 4°C. 
Supernatant was discarded and 75 µL HB was added followed by addition of 75 µL 2x Triton 
buffer (final concentration in mM): 20 Tris-HCl, 2 EDTA, 2 EGTA, 20 NaF, 4 Na₃VO₄, Sigma 
protease inhibitor cocktail). Samples were sonicated at 25%, 3 pulses, 5s each under ice to dissolve 
the pellet.  150 µL 1x Triton buffer (with 1% Triton X-100) was then added and incubated for 30 
min on ice. Next, samples were spun 100,000 rcf for 60 min at 4°C; the supernatant (extrasynaptic 
fraction) was removed and stored on ice. The pellet was homogenized in HB and sonicated, 
followed by the addition of 1% SDS prior to storage at -80°C (Synaptic). The extrasynaptic 
fraction was concentrated using acetone precipitation overnight, followed by homogenization in 
HB, sonication, and addition of 1% SDS. Samples were run using SDS-PAGE and transferred to 
nitrocellulose membrane. Samples were probed with primary antibody overnight followed by the 
appropriate horseradish peroxide (HRP)-coupled secondary antibody.  
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 Electrophysiological Recordings 
Experiments were performed on prefrontal cortex (PFC) slices from 3-7 month old 
C57BL/6J male mice. Mice were deeply anesthetized with chloral hydrate and decapitated. The 
brain was quickly removed and immersed in ice-cold pre-oxygenated artificial cerebrospinal fluid 
(ACSF). Coronal slices containing PFC were made as previously described (352). Throughout 
experiments, ACSF (31-32°C, perfused with a 95% O2/5% CO2) of the following composition was 
used (in mM): 126 NaCl, 2.5 or 10 KCl, 1.25 NaH2PO4, 1 MgSO4, 2 CaCl2, 24 NaHCO3, 10-20 
glucose; pH~7.3.  
Whole-cell recordings were performed from layer 2-3 neurons visualized by IR-DIC video 
microscopy as previously described (353). Pyramidal neurons were identified by their apical 
dendrites and triangular somata. Patch electrodes (5-10 MΩ open-tip resistance) were filled with 
a solution containing (in mM): 140 CsCl, 0.1 CaCl2, 2 MgCl2, 2.5 Phosphocreatine, 1.1 EGTA, 2 
ATP-Mg, 1 GTP-Na and 10 HEPES, adjusted to 7.2 with 1 M CsOH. Voltage and current 
recordings were performed with a Multi-Clamp 700A amplifier (Axon Instruments, Union City, 
CA). Signals were filtered at 2 kHz and acquired at a sampling rate of 10 kHz using Clampex 10.2 
software (Molecular Devices Corporation, Sunnyvale, CA). Access resistance typically was 10-20 
MΩ and remained relatively stable during experiments (≤30% increase). Corrections were made 
for liquid junction potential (-13 mV). We used: gabazine (10 μM) and picrotoxin (100 μM) to 
inhibit GABAAR; 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline (NBQX; 20 μM) to 
inhibit kainate and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs); 
D-2-amino-5-phospho-pentanoic acid (AP-5; 50 µM) to inhibit NMDARs; tetrodotoxin (TTX; 1 
µM) to inhibit voltage-gated Na+ channels; diazepam (3 µM) and GABA (20 µM) as an GABAAR 
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agonist. Gabazine, picrotoxin, GABA, diazepam, NBQX, and AP-5 were purchased from Abcam 
(Cambridge, MA); TTX from Sigma (St. Louis, MO). 
Miniature inhibitory postsynaptic currents (mIPSCs) were recorded at -70 mV in NBQX, 
AP-5, TTX. Miniature excitatory post-synaptic currents (mEPSCs) were recorded at -70 mV in 
Gabazine and TTX. Spontaneous and miniature events were analyzed using the MiniAnalysis 
Program (Synaptosoft, Decatur, GA) as previously described (353). 
To record evoked AMPA/NMDA receptor EPSC (eEPSC), a bipolar stimulating electrode 
was placed on the border of white matter and layer 6 (352) with pulses delivered at 0.1 Hz 
frequency. eEPSCs were recorded at +40 mV in the presence of gabazine to block GABAAR 
mediated currents. After eEPSCs were recorded for ~5 min, AP-5 was added to isolate AMPAR 
mediated responses. The AMPA/NMDA ratio was calculated as previously described (354). First, 
the average NMDAR current was calculated by subtracting the average isolated AMPAR current 
from the initial average eEPSC prior to AP-5 application. Second, the AMPA/NMDA ratio was 
calculated as a ratio of the peak amplitude of the currents. Amplitude of evoked synaptic responses 
was measured on averaged traces as the most positive current value compared to baseline current 
using Clampfit. 
Tonic GABAAR current was measured as the shift in baseline produced by the application 
of GABAAR blocker picrotoxin in the presence of NBQX, AP-5, TTX and GABA. The baseline 
current was measured in the Clampfit during three consecutive 0.2-min intervals before the 
application of pictrotoxin and 3 min after its application when baselines reach plateau.   
Two-tailed paired t-test was used for group comparisons using Excel (Microsoft Corp., 
Redmond, WA). Values are presented as mean ± SEM.  
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 Mass Spectrometry 
Mouse cortical tissue from 10 vehicle and 10 DZP treated mice was homogenized 
individually using a dounce homogenizer in HB (in mM): 20 Tris-HCl, 2 EDTA, 640 Sucrose, 40 
Na pyrophosphate, 20 NaF, 40 β-glycerophosphate, 4 Na₃VO₄, Sigma protease inhibitor cocktail 
(adjusted to pH 7.4 with NaOH at 4°C).  After homogenization, samples were spun 1000 rcf for 10 
min at 4°C. The supernatant (total) was used for downstream mass spectrometry. Total protein 
concentration in the homogenate preparations were assessed by micro BCA (Pierce). Targeted MS 
was performed in a similar fashion as described previously (355):10 μg homogenate or pooled 
controls were mixed with 10 μg of [13C6]brain ISTD (355) prepared from stable isotope labeling 
in mammals (SILAM) mouse cortex tissue (Cambridge Isotopes). The [13C6]lysine-labeled brain 
proteome internal standard ([13C6]brain ISTD) was prepared by homogenizing cerebral cortex 
tissue from a Stable Isotope Labeling in Mammals (SILAM) mouse (Cambridge Isotopes). These 
animals were raised on a diet in which the only source of Lysine was 13C6 labeled, resulting in near 
complete (99%) labeling of the animal proteome in three generations. Labeling efficiency of each 
[13C6]brain ISTD preparation was confirmed prior to use.  
Mass spectrometry analyses were conducted on a TSQ Quantiva triple stage quadrupole 
mass spectrometer (ThermoFisher Scientific, Location) with an Ultimate 3000 HPLC (Dionex). 
Two µl (~1 μg protein) was loaded on to a 3 µm 120A; 105mm REPROSIL-Pur C18 Picochip 
(New Objective) at 1 μl/min for 12 min and eluted at 400nl/min over a 25 min gradient from 3-
35% mobile phase B (Acetonitrile, 0.1% formic acid). Selected reaction monitoring (SRM) 
transitions were scheduled with 60 second windows. Transitions were monitored, allowing for a 
cycle time of 1 sec, resulting in a dynamic dwell time never falling below 10 msec.  The MS 
instrument parameters were as follows: capillary temperature 275°C, spray voltage 1350 V, and a 
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collision gas of 1.4 mTorr (argon).  The resolving power of the instrument was set to 0.7 Da (Full 
Width Half Maximum) for the first and third quadrupole.  Data were acquired using a Chrom Filter 
peak width of 4.0 sec.  
Method development began by building upon our previously described SRM libraries 
(355-358) with the selection of additional proteins of interest included in published 
multidimensional MS/MS analyses of synaptic enrichments from mouse and human brain tissue 
(355, 359, 360) as well as the NIST Tandem Mass Spectral Library and the library generated by 
pilot immunoprecipitation-proteomic studies of γ2-GABAARs. Targets for inclusion in the LC-
SRM/MS assay were selected with a bias toward well annotated synaptic proteins, such as 
glutamate receptors, kinases, phosphatases, vesicular fusion, amino acid metabolism, protein 
trafficking and scaffolding as well as proteins found to interact with the GABAAR. Peptides for 
proteins of interest were then filtered based on the following criteria: 1) presence of lysine and 2) 
non-redundant to a selected protein or protein group (determined by BLAST search). Acceptable 
peptide sequences, along with MS2 spectra, were imported into Skyline (361). Initially, five mass 
transitions were selected for each target peptide and its “heavy” counter-part. To ensure that the 
desired peptide was assayed, rigorous selection criteria were employed for the inclusion of peptide 
SRM transitions. Candidate “light”/“heavy” peptide SRMs were evaluated manually in Skyline 
for A) retention time, B) similar y-ion ratios (within 25%) to each other and database MS2 spectra, 
and D) a signal-to-noise ratio greater than 3. Peptide SRM pairs for which more than one identical 
peak was observed was omitted. Ultimately, 961 peptides unique to 571 proteins (or protein 
groups) were quantified in mouse samples. Statistics were performed by Student’s t-test analysis 
in Excel. 
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 Bioinformatics Analysis 
Ingenuity Pathways Analysis (IPA) (Ingenuity Systems) was used for cellular pathway 
analysis. Proteins with peptides which were found to have increased or decreased DZP/Veh ratios 
with a p < 0.1 were used for analysis. This statistical cutoff was used to achieve adequate numbers 
of proteins to be used for comparison and prediction based analysis. Duplicate proteins were 
averaged within IPA to determine relative ratio changes. Significant enrichment in protein 
networks were calculated by right tailed Fisher's exact test. Z-score analysis is a statistical measure 
of an expected relationship direction and observed protein/gene expression to predict pathway 
activation or inhibition. IPA core analysis was searched to determine direct and indirect 
relationships within 35 molecules per network and 25 networks per analysis. All data repositories 
available through IPA were used to determine experimentally observed and highly predicted 
interactions occurring in mammalian tissue and cell lines. Ratio data were converted to fold change 
values in IPA, where the negative inverse (-1/x) was taken for values between 0 and 1, while ratio 
values greater than 1 were not affected.  
 Statistics 
Relevant statistical test information is described in the figure legends or within the 




 Mice Rapidly Form Tolerance to the Sedation Actions of DZP 
We first sought to establish a model of DZP sedative tolerance in mice. All animals 
received a saline injection at day -1 and vehicle injection at day 0. On day 1, mice received either 
a DZP (10mg/kg) or vehicle injection. DZP-treated mice demonstrated sedation and a significant 
decrease in distance traveled compared to vehicle treated animals (Fig. 22). By day 3, the distance 
traveled was not significantly different between groups, indicating DZP-treated mice had become 
tolerant to the sedative effects of DZP. Similar rapidly forming behavioral tolerance to the sedative 
actions of DZP has been reported by multiple groups (47, 297, 349, 362). To confirm functional 
loss of DZP sensitivity in the cortex, we measured miniature inhibitory postsynaptic currents 
(mIPSCs) and potentiation by DZP using slice electrophysiology at the end of the seven day 
protocol (Fig. 23A). There was no significant difference between vehicle (Veh) and DZP treated 
animals mIPSC amplitude (Fig. 23B), frequency (Fig. 23C) or tau (decay) (Fig. 23D), suggesting 
no major change in pre- or post-synaptic GABAergic neurotransmission. In contrast, DZP 
potentiation (Fig. 23E) of current amplitude (Fig. 23F) and tau decay (Fig. 22G) in vehicle animals 
was significantly higher than animals treated for seven days with DZP, suggesting functional 
tolerance to the positive allosteric effects of the drug. These results are consistent with previous 
publications suggesting loss of DZP sensitivity occurs independent of changes in basal 




Figure 22. Repeated DZP Treatment Rapidly Leads to Sedative Tolerance in Mice.  
Animals were administered treatment by IP injection once daily and then tested for sedative tolerance 45min later in 
the open field behavioral test on the days indicated. All animals received a saline injection at day -1 and vehicle 
injection at day 0. Mice received either a DZP (10mg/kg) or vehicle injection on days 1-7. DZP-treated mice 
demonstrated sedation and a significant decrease in distance traveled compared to vehicle treated animals. By day 3, 
the distance traveled was not significantly different between groups, indicating DZP-treated mice had become tolerant 
to the sedative effects of DZP. Two-way ANOVA found a significant effect of time (p < 0.0001), treatment (p = 
0.0261), and a significant interaction (p = 0.0020), with a post-hoc Sidak test indicating a significant difference 




Figure 23. Repeated DZP Exposure Leads to Loss of DZP Potentiation of GABAAR Synaptic Currents.  
(A) mIPSCs in vehicle (Veh) (black and green) and DZP (blue and red) treated mice (Vhold = -70 mV). (B) mIPSC 
amplitude, (C) frequency and (D) tau were not different in DZP treated mice compared to Veh. (E,F,G) DZP 
potentiation of current amplitude and tau is signifantly larger in Veh animals relative to DZP (**p ≤ 0.01, ****p ≤ 
0.0001 Student’s t-test; n=9 per treatment group ; error bars ± S.E.M.). 
 Inhibitory Synapse Protein Levels and Localization after DZP 
We next sought to determine if GABAAR subunits involved in the sedation response to 
DZP (308, 366, 367) were altered by seven day drug treatment. Levels of gephyrin, the key 
synaptic scaffolding protein for GABAergic synapses, the DZP-insensitive GABAAR α4 subunit, 
and the highly expressed GABAAR β3 subunit were also measured. Subcellular fractionation (351) 
was used to measure the total, synaptic and extrasynaptic cortical levels of these proteins to 
determine membrane localization and overall changes (Fig. 24A,B,C). Unexpectedly, this analysis 
revealed a significant increase in the overall pool of GABAAR α1 (+71.4% ± 11.6), β3 (+48.8% ± 
7.2) and γ2 (+32.9% ± 5.7) subunits in the DZP group relative to the vehicle animals  
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Figure 24. GABAAR Subunits and Gephyrin are Altered by Seven Day DZP Treatment In Vivo.  
Mice treated IP once daily for seven days with vehicle or DZP were assessed for GABAAR subunit and gephyrin 
cortical tissue total (A), synaptic (B), and extrasynaptic levels (C) by western blot analysis. Representative blots show 
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mice 1-5 from each treatment. Quantification revealed a significant increase in the overall levels of α1, β3, γ2 subunits 
(D). Synaptic levels of (E) α1, α4 and γ2 subunits were also enhanced, while extrasynaptically α1 and α4 were 
decreased (F). DZP also increased extrasynaptic gephyrin (*p ≤ 0.05, **p < 0.01, ***p < 0.001, Student’s t-test; n = 
10 mice per treatment (experimental error resulted in n < 10 for some measurements); error bars ± S.E.M.). 
 
(Fig. 24D). An increase in α5 subunit levels also approached statistical significance (+21.4% ± 
7.6; p = 0.054). No change in α4 or gephyrin total levels was detected (Fig. 24A,D). Synaptic 
fractions revealed an enrichment of α1 (+24.1% ± 5.0), the DZP-insensitive α4 subunit (+33.4 % 
± 5.8) and γ2 (+36.6% ± 4.3) at synaptic sites (Fig. 24B,E). The enhancement of α1 and α4 subunits 
in the synaptic fraction also occurred concomitantly with a significant reduction in the 
extrasynaptic pools of these subunits (Fig. 23C,F), suggesting a recruitment of these subunits to 
synapses away from extrasynaptic sites during seven day DZP exposure. A significant increase in 
extrasynaptic gephyrin levels (+26.7% ± 4.6) was also detected, indicating inhibitory scaffold 
function or clustering may be altered as well. 
Next we performed slice electrophysiology recordings to determine if the DZP-induced 
shift of α1 and α4 subunits away from the extrasynaptic space and into the synapse would alter 
tonic inhibition. Whole-cell patch clamp recordings in cortical slices were used to measure changes 
in the tonic current. Bath application of the GABAAR pore blocker picrotoxin revealed a dramatic 
decrease in the tonic current of neurons from DZP treated mice compared to vehicle (Fig. 25). 
Whole-cell current change, measured as a difference between baseline before and after picrotoxin 
application was used for control. These experiments revealed seven day DZP exposure produces 
a shift in synaptic GABAAR composition where α4 and α1 subunits are 
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Figure 25. Tonic Inhibition is Reduced in DZP Treated Mice.  
(A) Picrotoxin-sensitive changes in holding current were used to measure tonic inhibition in cortical slices from 
vehicle or DZP treated mice. (B) Quantification revealed a signifigant reduction in DZP (n = 8) treated animals tonic 
inhibtion relative to vehicle (n = 6) injected mice (**p ≤ 0.01, Student’s t-test; error bars ± S.E.M.). 
 
elevated and a corresponding reductions of these subunits at extrasynaptic sites occurs concurrent 
with decreased baseline tonic inhibition. 
 DZP Treatment Increases NMDA Receptor Levels and Function  
Given the neuroadaptations seen in inhibitory GABAAR subunit synaptic proteins and prior 
evidence for glutamatergic system sensitization in the development of BZD tolerance, we 
hypothesized that an equivalent increase in excitation may also occur to achieve appropriate E/I 
balance in a homeostatic manner. Moreover, previous studies link enhanced NMDAR function to 
various types of drug tolerance (346-348), including evidence it has a role in DZP behavioral 
sedative tolerance (349, 350). We examined the subunit levels of this receptor after seven day DZP 
treatment. Analysis revealed increased total levels of GluN2A (+17.8% ± 4.7) and GluN2B 
(+53.7% ± 13.4) subunits in the cortex of DZP treated mice relative to vehicle (Fig. 26A,C) with 
an enrichment of GluN2A subunit (21.6 ± 4.1) at synapses (Fig. 26B, D). Collectively this data 
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suggests compensatory upregulation of excitatory receptors occurs after DZP exposure. Next we 
examined functional changes in excitatory neurotransmission by first measuring AMPA miniature 
excitatory postsynaptic currents (mEPSC) (Fig. 27A). We found no significant difference between 
treatment groups in AMPA mEPSC amplitude (Fig. 27B), frequency (Fig. 27C) and tau (Fig. 
27D), suggesting pre- and post-synaptic mechanisms regulating AMPA receptor activation were 
not altered by seven day DZP exposure. In contrast, we found that the AMPA/NMDA ratio in DZP 
treated mice was nearly half that of vehicle in evoked excitatory postsynaptic current (eEPSC) 
measurements (Fig. 27E,F), consistent with upregulation of NMDAR functional activity. Together 
these functional results, combined with biochemical data indicate GluN2A and GluN2B NMDAR 
subunit upregulation, enhanced synaptic GluN2A levels and increased NMDAR activity following 
seven day DZP injections. 
 
Figure 26. NMDA Receptor Subunit Levels are Increased by Seven Day DZP Treatment In Vivo.  
Mice treated IP once daily for seven days with vehicle or DZP were assessed for NMDA receptor subunit cortical 
tissue total (A) and synaptic (B) levels by western blot analysis. Representative blots for mice 1-5. Quantification 
revealed a significant increase in the overall levels of the GluN2A and GluN2B subunits (C). GluN2A synaptic levels 
were also found to be significantly enhanced after DZP exposure (D) (*p ≤ 0.05, **p < 0.01, Student’s t-test; n = 10 
mice per treatment (experimental error resulted in n < 10 for some measurements); error bars ± S.E.M.). 
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Figure 27. NMDAR Function is Increased in DZP Treated Mice.  
(A) AMPAR EPSC traces in vehicle (black) and DZP (red) treated animals (Vhold= -70 mV). (B) AMPAR mEPSC 
(B) amplitude, (C) frequency and (D) decay were unchanged at day seven of DZP treatment (n=6). (*p ≤ 0.05, 
Student’s t-test; error bars ± S.E.M.). (E,F) The AMPA/NMDA ratio (Vhold= +40 mV) was significantly lower (p < 
0.05, Student's t test) in DZP treated (n = 7) compared to vehicle-treated mice (n = 8). 
 Inhibitory and Excitatory Proteins Adaptions Occur at Earlier DZP Timepoints 
To determine if key inhibitory and excitatory proteins altered after seven day DZP 
treatment are also changed at earlier stages of drug exposure, we tested the cortical tissue of mice 
treated for a  24 h period (two treatments) or 72h period (four treatments) with vehicle or DZP. 
This experiment revealed a significant increase in total GABAAR α1 (+49.5% ± 16.0), α4 (+25.3% 
± 5.5) and α5 (+32.0% ± 4.4) subunits after 24 h DZP exposure relative to vehicle (Fig. 28A,B). 
GABAAR β3 subunit, γ2 subunit, and gephyrin were not significantly altered. Increased α1 subunit 
levels persisted across 72 h of DZP treatment, while α4 and α5 subunits were not detectably 
different than vehicle. Notably, β3 and γ2 subunit overall levels were enhanced at 72 h in the DZP 
treated group, consistent with findings at day seven (Fig. 24).  
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The excitatory NMDA receptor subunit GluN2A was upregulated after 24 h of DZP 
treatment (+21.1% ± 4.4), without a detectable change in GluN1 or GluN2B subunits (Fig. 28C,D). 
In contrast, DZP elevated the GluN1 (+30.3% ± 3.3) and GluN2B (+35.2% ± 11.8) subunits after 
72 h, but the GluN2A subunit returned to vehicle levels.  
Collectively, these results suggest that GABAAR subunits found to be elevated after seven 
day DZP treatment can be detected at higher levels earlier in the DZP treatment timeline axis. 
Notably the GABAAR α1 subunit is elevated as early as the 24 h time point and persists through 
day seven. NMDA receptor subunits are also found to be differentially increased at earlier DZP 




Figure 28. Key Inhibitory and Excitatory Proteins are Upregulated at Earlier DZP Treatment Timepoints.  
Mice were treated with DZP or vehicle for 24 h (two doses) or 72 h (four doses). Total cortical lysates of GABAAR 
subunits and gephyrin (A,B) and NMDAR subunits (C,D) were examined by western blot. Representative blots for 
mice 1-2 from each treatment. Quantification revealed significantly increased levels of  α1, α4 and α5 GABAAR 
subunits and NMDAR GluN2A subunit after 24 h DZP.  The α1 subunit remained elevated after 72 h DZP treatment, 
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while α4, α5 and GluN2A subuntis returned to vehicle levels. Conversely, the GABAAR subunits β3 and γ2, and 
NMDAR subunits GluN2B and GluN1, were increased at the 72 h DZP treatment time point (*p ≤ 0.05, **p < 0.01, 
***p < 0.001, Student’s t-test; n = 4 mice per treatment; error bars ± S.E.M.). 
 Quantitative Mass Spectrometry Identifies Changes in Neuronal Synaptic 
Proteome with DZP Treatment 
Changes in the major GABAAR and NMDAR subunits contributing to inhibitory and 
excitatory neurotransmission are only a small fraction of the possible signaling network altered by 
DZP treatment. To gain a more comprehensive understanding of the protein profile of a DZP 
tolerant brain, we performed a quantitative proteomic screening against 500+ key synaptic proteins 
in vehicle versus DZP treated cortical tissue. This experiment identified a total of 962 unique 
peptides across 10 vehicle and 10 DZP samples. The peptide abundance of proteins in the DZP 
group compared to vehicle was used to determine which proteins were increased (Table 4) or 
decreased (Table 5). As a result we identified 108 protein peptides with elevated levels of 
interaction in seven day DZP treated animals, while 16 protein peptides were decreased. These 
experiments revealed robust changes in the Ca2+/calmodulin-dependent protein kinase II 
(CaMKII), a dodecameric holoenzyme that regulates key processes including synaptic plasticity. 
CaMKII is expressed in four isoforms α/β/δ/γ, with α and β being the most highly expressed in the 
forebrain at a ratio of about three α per β subunit (368). Individual CAMKII subunits can have 
distinct regulatory properties (369), localization (370), and developmental expression in neurons, 
for instance the δ and γ subunits are highly and selectively expressed early in development but 
strongly decrease in expression over time (371). Here we identified highly elevated peptide levels 
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of the α, β and δ subunits in cortical tissue of DZP treated mice, suggesting a global upregulation 
of CaMKII function or activity (Table 4).  
Protein kinase C (PKC) is critical for NMDAR function and trafficking alongside 
CaMKII (372, 373), and PKC epsilon (1.20 fold increase, p = 0.0060) and gamma (1.30 fold 
increase, p = 0.026) isozymes were significantly enriched in DZP treated mice (Table 4). PKCε 
reduces GABAAR sensitivity to ethanol and BZDs in vitro and in vivo by phosphorylating the γ2 
subunit S327 residue (150), while PKCγ is critical in tolerance mechanisms to other drugs like 
opioids (374, 375). DZP also significantly increased the levels of the growth associated protein 43 
(GAP-43) (1.50 fold increase, p = 0.019) (Table 4) which is involved in excitatory neuron driven 
epileptogenesis (376), is integral for growth cone dynamics (377-379) and PKC phosphorylation 
of GAP-43 promotes excitatory long-term potentiation (380, 381). Increased levels of other pro-
excitatory synapse proteins including discs large MAGUK scaffold protein 2 (DLGAP2) (382) 
(1.20 fold increase, p = 0.027) and the protein tyrosine kinase 2 beta (FAK2/CAKβ/Pyk2) (1.30 
fold increase, p = 0.0036) were also measured. FAK2 can be recruited to excitatory synapses to 
mediate PSD-95 scaffolding maintenance, promotes NMDA receptor levels, upregulate 
NMDAR function by activating Src and is involved in long term potentiation (LTP) (383-386). 
Interestingly, DZP evoked presynaptic plasticity is also suggested by increases in 
piccolo peptides (1.60 fold increase, p = 0.033), which functions as a large scaffold protein that 
redundantly contributes to the synaptic vesicle readily releasable pool with bassoon (387). 
Importantly, combined knockdown of piccolo and bassoon does not affect basic synaptic vesicle 
release (387, 388). The synaptotagmin 7 (SYT7) and 1 (SYT1) proteins were also enriched in 
DZP treated animals. SYT7 is a major regulator of the readily releasable neurotransmitter pool 
and was recently identified to work postsynaptically with SYT1 in hippocampal neurons as 
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redundant Ca2+-sensors for Ca2+-dependent exocytosis of AMPA-receptors during LTP (389), 
although no change in mEPSCs was detected. Combined knockout of SYT1 and SYT7 is needed 
to block LTP, and SYT1/SYT7 double knockout does not alter mEPSCs, suggesting no change 
in baseline synaptic AMPAR activity, consistent with our electrophysiology data showing no 
changes in AMPAR mEPSC after DZP (Fig. 27). Elevated peptide levels of the membrane 
trafficking RAB3A protein (1.10 fold increase, p = 0.0036) were also measured, which regulates 
exocytosis of synaptic vesicles  and is the most abundant RAB in the brain (390). Conversely, 
DZP animals exhibited decreased Dynamin 3 expression (Table 5), which is a large GTPase 
crucial for presynaptic endocytosis and neurotransmission (391), is a component of the 
metabotropic glutamate receptor excitatory postsynapse (392), and mediates developmental 
synaptogenesis (393). 
Cyclic nucleotide (namely cAMP and cGMP) levels are tightly regulated by 
phosphodiesterases (PDEs) (394) and we identified a DZP-induced enrichment (1.40 fold 
increase, p = 0.042) of the PDE2 enzyme which is particularly key for the regulation of 
performance and cognitive functions (395, 396) and inhibition of this enzyme is a key target 
for ongoing cognitive therapies (397). Interestingly, a decrease in the GABAAR subunit beta 
family (isoform 1/2/3) was determined by our analysis (Table 5). Our biochemical data predicts a 
significant increase in β3 subunit levels, suggesting a decrease in either isoform β1 and/or β2, 
which is consistent with multiple studies showing decreased β2 subunit mRNA after BZD 
exposure (32). We were unable to detect a statistically significant difference in other GABAAR 
subunits or NMDAR subunits using our quantitative proteomics method in part due to variability 





Table 4. Protein Peptides Demonstrating Increased Levels after DZP Treatment by Mass Spectrometry.  
Ratio D/V is fold change in DZP animals’ relative peptide levels to control vehicle treated animals, t-test. Significant 
(p < 0.05) and near significant results (p < 0.1) shown. 
D/V P-Value Uniprot Entrez Gene Name Peptide Sequence Location Type(s) 
1.6 3.27E-02 Q9QYX7 piccolo presynaptic cytomatrix protein 
ASPVPAPAEPPP
QK Cytoplasm transporter 
1.6 6.57E-04 P28652 calcium/calmodulin dependent protein kinase II beta FYFENLLAK Cytoplasm kinase 
1.6 4.01E-02 Q9R0N7 synaptotagmin 7 VDLTQMQTFWK Cytoplasm transporter 
1.6 5.28E-02 O35136 neural cell adhesion molecule 2 IIELSQTTAK 
Plasma 
Membrane other 
1.5 5.61E-02 P55095 glucagon AQDFVQWLMNTK Cytoplasm other 
1.5 1.63E-03 Q6PHZ2 calcium/calmodulin dependent protein kinase II delta QETVDCLK Cytoplasm kinase 
1.5 3.69E-04 P11798 calcium/calmodulin dependent protein kinase II alpha 
FTEEYQLFEELG
K Cytoplasm kinase 
1.5 2.98E-04 P11798 calcium/calmodulin dependent protein kinase II alpha 
AGAYDFPSPEW
DTVTPEAK Cytoplasm kinase 
1.5 3.46E-04 P11798 calcium/calmodulin dependent protein kinase II alpha VLAGQEYAAK Cytoplasm kinase 






1.4 1.11E-03 P28652 calcium/calmodulin dependent protein kinase II beta 
FTDEYQLYEDIG
K Cytoplasm kinase 
1.4 3.70E-03 Q6PHZ2 calcium/calmodulin dependent protein kinase II delta 
FTDEYQLFEELG
K Cytoplasm kinase 
1.4 1.49E-03 P11798 calcium/calmodulin dependent protein kinase II alpha ITAAEALK Cytoplasm kinase 
1.4 1.16E-03 P11798 calcium/calmodulin dependent protein kinase II alpha 
VTEQLIEAISNGD
FESYTK Cytoplasm kinase 





1.4 1.44E-02 P46096 synaptotagmin 1 LTVVILEAK Cytoplasm transporter 
1.4 4.26E-02 Q922S4 phosphodiesterase 2A EFFSQGDLEK Cytoplasm enzyme 
1.4 6.94E-02 Q6P9K8 CASK interacting protein 1 VGYFPSSLGEAIVK Nucleus 
transcription 
regulator 
1.4 6.25E-02 Q80Z24 neuronal growth regulator 1 CYLEDGASK Plasma Membrane other 







K Cytoplasm enzyme 
1.3 6.86E-02 Q9CS84 neurexin 1 SADYVNLALK Plasma Membrane transporter 
1.3 4.93E-02 Q9Z140 copine 6 SDPFMEIYK Plasma Membrane transporter 
1.3 5.14E-02 P60879 synaptosome associated protein 25 FCGLCVCPCNK 
Plasma 
Membrane transporter 
1.3 3.60E-03 Q9QVP9 
protein tyrosine kinase 2 
beta/proline-rich tyrosine 
kinase 2 
DMPHNALDK Cytoplasm kinase 
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Table 4. Continued 
 
1.3 8.31E-02 P46660 
internexin neuronal 
intermediate filament protein 
alpha 
NLQSAEEWYK Cytoplasm other 
1.3 1.61E-02 P08551 neurofilament light NMQNAEEWFK Cytoplasm other 
1.3 7.76E-02 P06837 growth associated protein 43 EGDGSATTDAAPATSPK 
Plasma 
Membrane other 
1.3 3.20E-02 Q8CHH9 septin 8 SLSLGGHVGFDSLPDQLVSK 
Extracellul
ar Space other 
1.3 4.17E-02 Q8R3V5 SH3 domain containing GRB2 like, endophilin B2 VEEFLYEK Cytoplasm other 
1.3 3.92E-02 P46096 synaptotagmin 1 VPYSELGGK Cytoplasm transporter 
1.3 9.14E-02 O35526 syntaxin 1A HSAILASPNPDEK Cytoplasm transporter 
1.3 8.00E-03 Q9Z1G4 ATPase H+ transporting V0 subunit a1 
QAEIENPLEDPV
TGDYVHK Cytoplasm transporter 
1.3 2.63E-02 P63318 protein kinase C gamma GSDELYAIK Cytoplasm kinase 
1.2 8.66E-02 A2A9R6 ELAV like RNA binding protein 4 DANLYVSGLPK Cytoplasm 
translation 
regulator 
1.2 2.72E-02 Q8BJ42 DLG associated protein 2 SSWSTLTVSQAK 
Plasma 
Membrane other 
1.2 7.60E-03 Q9JME5 adaptor related protein complex 3 subunit beta 2 LLTQYVLSLAK Cytoplasm transporter 
1.2 1.22E-02 Q8BUV3 gephyrin TLIINLPGSK Plasma Membrane enzyme 
1.2 8.44E-02 Q922S4 phosphodiesterase 2A ATDQVVALACAFNK Cytoplasm enzyme 
1.2 9.81E-02 P46097 synaptotagmin 2 VFLLPDK Cytoplasm transporter 
1.2 2.11E-02 Q3TXX4 solute carrier family 17 member 7 YIEDAIGESAK 
Plasma 
Membrane transporter 
1.2 2.51E-02 P25444 ribosomal protein S2 TYSYLTPDLWK Cytoplasm other 
1.2 9.67E-02 P53994 RAB2A, member RAS oncogene family YIIIGDTGVGK Cytoplasm enzyme 
1.2 1.51E-02 P46460 N-ethylmaleimide sensitive factor, vesicle fusing ATPase GILLYGPPGCGK Cytoplasm transporter 
1.2 6.90E-02 Q9CQC9 secretion associated Ras related GTPase 1B LVFLGLDNAGK Cytoplasm enzyme 
1.2 1.14E-02 P35276 RAB3D, member RAS oncogene family LVDIICDK Cytoplasm enzyme 




Membrane ion channel 
1.2 5.96E-03 P16054 protein kinase C epsilon DFIWGVIGK Cytoplasm kinase 
1.2 6.29E-02 P58281 OPA1 mitochondrial dynamin like GTPase VVVVGDQSAGK Cytoplasm enzyme 
1.2 8.40E-03 Q91V41 RAB14, member RAS oncogene family 
TGENVEDAFLEA
AK Cytoplasm enzyme 
1.2 7.25E-02 Q9WUK2 






1.2 4.51E-02 Q8BMS1 
hydroxyacyl-CoA 
dehydrogenase trifunctional 
multienzyme complex subunit 
alpha 
FVDLYGAQK Cytoplasm enzyme 
1.2 5.28E-02 P63318 protein kinase C gamma ITDFGMCK Cytoplasm kinase 
1.2 6.06E-02 Q925E7 protein phosphatase 2 regulatory subunit Bdelta 
FLESPDFQPNIA
K Nucleus other 
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Table 4. Continued 
 
1.2 3.69E-02 P46460 N-ethylmaleimide sensitive factor, vesicle fusing ATPase TTIAQQVK Cytoplasm transporter 
1.2 2.70E-02 Q91V92 ATP citrate lyase FGGALDAAAK Cytoplasm enzyme 
1.2 6.57E-02 P31324 
protein kinase cAMP-
dependent type II regulatory 
subunit beta 
VVDVIGTK Cytoplasm kinase 
1.2 1.59E-02 Q80TJ1 calcium dependent secretion activator DIVTPVPQEEVK 
Plasma 
Membrane other 
1.2 7.03E-02 P60766 cell division cycle 42 WVPEITHHCPK Plasma Membrane enzyme 
1.2 4.32E-02 P47857 phosphofructokinase, muscle VLVVHDGFEGLAK Cytoplasm kinase 
1.2 2.73E-02 P28474 alcohol dehydrogenase 5 (class III), chi polypeptide GTAFGGWK Cytoplasm enzyme 
1.2 8.97E-02 Q6PGN3 doublecortin like kinase 2 TAHSFEQVLTDITEAIK Cytoplasm kinase 
1.1 6.85E-03 Q9CVB6 actin related protein 2/3 complex subunit 2 IIEETLALK Cytoplasm other 
1.1 7.61E-02 O08539 bridging integrator 1 LNQNLNDVLVSLEK Nucleus other 
1.1 2.42E-02 Q76MZ3 protein phosphatase 2 scaffold subunit Aalpha VLELDNVK Cytoplasm phosphatase 
1.1 7.81E-03 P62761 visinin like 1 STEFNEHELK Cytoplasm other 
1.1 7.33E-02 P17710 hexokinase 1 FLLSESGSGK Cytoplasm kinase 
1.1 4.10E-02 P14869 ribosomal protein lateral stalk subunit P0 TSFFQALGITTK Cytoplasm other 
1.1 5.69E-02 O88935 synapsin I IHGEIDIK Plasma Membrane transporter 
1.1 5.65E-02 O88935 synapsin I TYATAEPFIDAK Plasma Membrane transporter 
1.1 2.83E-02 P63011 RAB3A, member RAS oncogene family LVDVICEK Cytoplasm enzyme 
1.1 4.81E-02 Q62351 transferrin receptor DAWGPGAAK Plasma Membrane transporter 
1.1 5.65E-02 Q63844 mitogen-activated protein kinase 3 
DVYIVQDLMETD
LYK Cytoplasm kinase 
1.1 9.08E-02 Q9CQE8 RNA transcription, translation and transport factor NFIVWLEDQK Nucleus other 
1.1 8.04E-02 P11499 heat shock protein 90 alpha family class B member 1 YESLTDPSK Cytoplasm enzyme 
1.1 2.01E-02 P17710 hexokinase 1 NILIDFTK Cytoplasm kinase 
1.1 2.48E-02 Q63844 mitogen-activated protein kinase 3 APEIMLNSK Cytoplasm kinase 
1.1 9.53E-02 Q8K0T0 reticulon 1 SVLQAVQK Cytoplasm other 
1.1 9.69E-02 Q76MZ3 protein phosphatase 2 scaffold subunit Aalpha LTQDQDVDVK Cytoplasm phosphatase 
1.1 9.26E-02 P70168 karyopherin subunit beta 1 SSAYESLMEIVK Nucleus transporter 
1.1 5.94E-02 P62827 RAN, member RAS oncogene family LVLVGDGGTGK Nucleus enzyme 





YDDMATCMK Cytoplasm other 
1.1 7.56E-02 P39053 dynamin 1 LQSQLLSIEK Cytoplasm enzyme 
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1.1 7.43E-02 P68368 tubulin alpha 4a TIGGGDDSFTTFFCETGAGK Cytoplasm other 
1.1 9.39E-02 P40124 
cyclase associated actin 
cytoskeleton regulatory 
protein 1 
NSLDCEIVSAK Plasma Membrane other 
1.1 2.46E-02 P62631 eukaryotic translation elongation factor 1 alpha 2 QLIVGVNK Cytoplasm 
translation 
regulator 
1.1 1.16E-02 P49615 cyclin dependent kinase 5 DLLQNLLK Nucleus kinase 
1.1 4.38E-02 Q7TMM9 tubulin beta 2A class IIa INVYYNEAAGNK Cytoplasm other 
1.1 9.45E-02 P05213 tubulin alpha 1b SIQFVDWCPTGFK Cytoplasm other 
1.1 6.81E-02 Q8CHC4 synaptojanin 1 NQTLTDWLLDAPK Cytoplasm phosphatase 
1.1 2.10E-02 P68369 tubulin alpha 1a GHYTIGK Cytoplasm other 
1.1 9.94E-02 P39054 dynamin 2 LQSQLLSLEK Plasma Membrane enzyme 
1.1 3.91E-02 P84078 ADP ribosylation factor 1 DAVLLVFANK Cytoplasm enzyme 
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Table 5. Protein Peptides Demonstrating Decreased Levels after DZP Treatment by Mass Spectrometry.  
Ratio D/V is fold change in DZP animals’ relative peptide levels to control vehicle treated animals, t-test. Significant 
(p < 0.05) and near significant results (p < 0.1) shown. 
 
To gain a more complete understanding of the functional outcome of DZP-induced changes 
in the synaptic proteome, we subjected our quantitative proteomics data to IPA bioinformatics 
analysis. Top enriched canonical pathways with –log(p-value) > 6.2 are shown in (Fig. 29A). 
Analysis determined the synaptogenesis signaling pathway to be the most abundantly enriched and 
was predicted to be robustly upregulated as determined by z-score analysis. Synaptic LTP and 
CREB signaling in neurons pathways were also found to be activated, suggesting increased 
synaptic remodeling and strengthening of excitatory synapses, consistent with increased peptide 
levels for actin related protein 2/3 complex subunit 2 (ARP 2/3) (Table 4), an important driver of 
D/V P-Value Uniprot Entrez Gene Name Peptide Sequence Location Type(s) 
0.6 1.65E-02 Q8BZ98 dynamin 3 RPLVLQLVTSK Cytoplasm enzyme 




Membrane ion channel 
0.7 5.99E-02 P61027 RAB10, member RAS oncogene family SFENISK Cytoplasm enzyme 
0.7 2.21E-02 Q9D6M3 solute carrier family 25 member 22 
GAAVNLTLVTP
EK Cytoplasm transporter 
0.7 8.23E-02 P84096 ras homolog family member G YLECSALQQDGVK Cytoplasm enzyme 
0.7 7.25E-02 Q60597 oxoglutarate dehydrogenase VIPENGPAAQDPHK Cytoplasm enzyme 
0.7 3.36E-02 P63038 heat shock protein family D (Hsp60) member 1/HSP60 GIIDPTK Cytoplasm enzyme 
0.8 8.65E-02 P35436 glutamate ionotropic receptor NMDA type subunit 2A FSYIPEAK 
Plasma 
Membrane ion channel 





0.9 9.43E-02 P15105 glutamate-ammonia ligase ACLYAGVK Cytoplasm enzyme 
0.9 6.64E-02 Q02053 ubiquitin like modifier activating enzyme 1 QFLDYFK Cytoplasm enzyme 
0.9 7.17E-02 P05063 aldolase, fructose-bisphosphate C 
DNAGAATEEFI
K Cytoplasm enzyme 
0.9 9.88E-02 Q9D051 pyruvate dehydrogenase E1 beta subunit 
VVSPWNSEDA
K Cytoplasm enzyme 
0.9 9.71E-02 Q8BG32 proteasome 26S subunit, non-ATPase 11 
EQSILELGSLL
AK Cytoplasm other 
0.9 1.71E-02 P35979 ribosomal protein L12 QAQIEVVPSASALIIK Nucleus other 
0.9 5.53E-02 P19096 fatty acid synthase AGLYGLPK Cytoplasm enzyme 
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dendritic spine maturation and synapse unsilencing (399). Predicted activation of other interesting 
pathways including 14-3-3 mediated signaling, melatonin signaling and Huntington’s disease 
signaling was also observed.  
We further examined alterations in functional network association by checking the 
predicted activation status of select pathways when only using proteins which were found to be 
increased or decreased with a p < 0.1 (Table 4,5). Functional network association of key biological 
pathways (Fig. 29B) predicted activation of the release of neurotransmitter (z-score = 3.112), 
development of neurons (z-score = 2.886), and long-term potentiation (z-score = 1.902) pathways 
in DZP mice relative to vehicle control. Significant protein changes (p < 0.05) conserved between 
two or more pathways include increased peptide levels of CaMKII subunits α/β, PRKCG (PKCγ) 
and RAB3A. Taken together, these results suggest seven day DZP treatment in vivo results in 
synaptic remodeling, pre- and post-synaptic plasticity and strengthening of excitatory synapses. 
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Figure 29.  IPA Analysis Reveals Activation of Key Biological Networks Following DZP Treatment. 
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 (A) Canonical pathways found to be differentially expressed following DZP administration in vivo. Enriched 
pathways with –log(p-value) greater than 6.2 were considered as calculated by Fisher's exact test right-tailed. Values 
to right of bars represent pathway activation z-score. Positive z-score represents predicted upregulation of a pathway 
(orange), negative z-score predicts inhibition (blue), z-score = 0 represents no change in pathway (white), while not 
determined (N.D.) conveys the analysis program was unable to determine a significant change (grey). Intensity of 
color represents size of z-score value. (B) Functional network association of select pathways when using proteins 
which were found to be increased or decreased with a p < 0.1. Major functional pathways altered by DZP include 
release of neurotransmitter (z-score = 3.112), development of neurons (z-score = 2.886), and long-term potentiation 
(z-score = 1.902). Significant protein changes (p < 0.05) conserved between two or more pathways include increased 
peptide levels of CaMKII subunits α/β, PRKCG (PKCγ) and RAB3A. Red = increased measurement, green = 
decreased measurement, orange = activation of pathway, blue = inhibition of pathway, yellow = findings inconsistent 
with state of downstream molecule, grey = effect not predicted. 
 Western Blot Analysis of CaMKII Activation and Levels 
To further validate the observed increase in CaMKII subunit peptide levels after DZP 
treatment in our proteomics data (Table 4), we performed western blot analysis on the cortical 
tissue of these mice. As an additional measure we also examined activation of CaMKII based on 
the phosphorylation state of the Thr286/287 residue, which is important for autonomous activation 
of the kinase (400), targeting to specific subcellular domains such as excitatory synapses (401) and 
regulation of LTP (402, 403). These experiments were unable to detect a statistical difference in 
the total α/β/δ or Thr286/287 phosphorylation levels of α/β CaMKII (Fig. 30A,B). The inability to 
measure a change in CaMKII subunit levels equivalent to that seen in mass spectrometry 
experiments could be a result of the constraints of western blot analysis when considering antibody 
detection limitations and single molecular weight band measurements that may not 
comprehensively represent all forms of a protein including splice variants or various post-
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translational modifications (368). Collectively, further tests will be needed to confirm that the 
alterations in CaMKII observed after DZP by proteomics are not false positive findings. 
 
 
Figure 30. Western Blot Analysis was Unable to Detect a Change in CaMKII Subunit Expression after DZP.  
Mice treated seven days with vehicle or DZP were assessed for phosphorylation status of CaMKII Thr286/287 residues 
and total CaMKII subunit cortical tissue levels (A). (B) Quantification revealed no change in phosphorylation or 
subunit levels of CaMKII (Student’s t-test; n = 10 mice per treatment; error bars ± S.E.M.). 
4.4 Discussion 
The neuroadaptive signature of a DZP tolerant brain has been elusive for researchers in 
part due to experimental limitations. Herein we find mice with tolerance to the sedative actions of 
DZP have modified GABAAR subunit protein levels and localization in the cortex, highlighted by 
the DZP-insensitive α4 subunit and the highly abundant α1 subunit moving away from the 
extrasynaptic space into the synapse (Fig. 24). Slice electrophysiology experiments confirmed 
DZP insensitivity in animals treated for seven days with this drug, while no significant change in 
mIPSC amplitude was detected between treatments (Fig. 23). This suggests the total numbers of 
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GABAARs at synapses are not changed but a modification of the receptor pharmacological profile 
had occurred, consistent with increased incorporation of α4 into γ2 GABAARs. Further supporting 
this proposed shift in GABAAR subtypes away from the extrasynaptic space, DZP treated animals 
demonstrated a marked reduction in tonic inhibitory current (Fig. 25). Biochemical analysis of 
cortical tissue further revealed an enrichment of NMDAR subunits GluN2A and GluN2B (Fig. 
26), culminating with an decrease in AMPA/NMDA ratio in slice electrophysiology studies 
without a change in AMPA mEPSCs (Fig. 27), suggesting overall increased NMDAR activity. 
Examining total levels of key inhibitory and excitatory proteins at earlier DZP treatment time 
points identified increases in GABAAR β3, γ2 and NMDAR GluN2B subunit by day three of DZP 
exposure, concomitant with behavioral sedative tolerance (Fig. 28). Quantitative proteomic 
experiments screening hundreds of pivotal synaptic proteins in the cortex of vehicle versus DZP 
treated mice revealed upregulation of a number of proteins involved in synaptogenesis and 
remodeling, excitatory LTP and drug tolerance (Table 4 and Fig. 29). The most robust increase 
found by mass spectrometry was the pro-excitatory CaMKII kinase α/β/δ subunit levels (Table 4), 
where all measured peptides were elevated by around 1.5 fold (number of peptides for CaMKII 
kinase α/β/δ subunits were 4/2/2). Our inability to detect this by western blot analysis is likely due 
to methodological limitations including antibody specificity, limitations in sensitivity of 
measurements with highly abundant proteins, and single molecular weight band measurements 
(Fig. 30). In summary, our work demonstrates DZP sedative tolerance is associated with synaptic 
GABAAR compositional changes, increased NMDAR levels and activity, enhanced expression of 
positive NMDAR modulators and synapse remodeling and excitatory synapse strengthening. 
These findings are clear factors that would contribute to a hyperexcitable and DZP-insensitive 
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brain state promoting symptoms observed during BZD withdrawal: heightened seizure 
susceptibility, anxiety, panic, and sleep disturbances.  
One key finding in this study was the apparent shift in the α4 subunit to the synapse away 
from the extrasynaptic space. The α4 subunit does not bind classical BZD agonists like DZP, and 
receptor function is enhanced, rather than inhibited, by antagonists/inverse agonists at the BZD 
binding site and also is sensitive to modulation by neurosteroids, anesthetics, and ethanol (1, 219, 
302, 404). Interestingly, the expression of the α4 subunit is highly malleable to a number of stimuli 
including alcohol exposure withdrawal (219, 405-407), progesterone-withdrawal (408, 409), 
social isolation in rats (410), electroshock seizures (411), absence seizures induced by gamma-
hydroxybutyric acid (412) and pilocarpine-induced seizures (413). Chronic intermittent ethanol 
(CIE) treatments leads to a reduced behavioral hypnotic response to BZDs, associated with 
increased α4 and γ2 total levels and decreased decay time of GABAAR-mediated mIPSCs and 
potentiation by DZP (407). Similarly, we identified a DZP-induced increase in synaptic α4 and γ2 
subunit levels by western blot analysis (Fig. 24) coupled with minimal potentiation by DZP in 
electrophysiology studies (Fig. 23). Dorsal ganglion cells (DGCs) from temporal lobe epilepsy 
animal models also show diminished DZP responsiveness following accumulation of α4 at 
synaptic sites (414). Furthermore, electrophysiology recordings in hippocampal slices found an 
extrasynaptic to synaptic switch of α4 appears after CIE, demonstrating potentiation by RO 15-
4513, which acts as a partial agonist at α4/γ2 GABAARs, but functions as an inverse agonist at 
receptors with classical BZD pharmacology (α1/α2/α5β2). This was further confirmed by electron 
microscopy studies identifying increased α4 but not δ subunit within GABAergic synapses. It is 
important to note RO 15-4513 has high selectivity for the α5 subunit over other alpha subunits, 
and is used as a relatively selective marker for α5-GABAAR subtypes (415-417). Interestingly, 
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rapid ethanol tolerance paradigms examining CA1 area slices show increased surface synaptic α4 
levels, decreased DZP enhancement of mIPSCs and faster mIPSC kinetics after ethanol withdrawal 
(219). As the quantitative proteomic data here identified increased expression of the PKCε and 
PKCγ isoforms (Table 4), this suggests a PKC mediated mechanistic link between increased 
synaptic α4 subunit observed biochemically (Fig. 24) and the decrease in tonic inhibition by 
electrophysiology (Fig. 25) after DZP. Future studies examining the synaptic composition of 
GABAARs in vivo will be needed to fully elucidate the role of α4 in DZP insensitivity. 
Surprisingly, a similar extrasynaptic to synaptic accumulation was seen with the α1 
subunit, which also demonstrated increased overall levels (Fig. 24). The majority of BZD-sensitive 
GABAARs in the brain contain the α1 subunit (418). The DZP sedative response is mediated by 
the α1 subunit as demonstrated by studies using knock-in mice expressing an α1 subunit H101R 
mutation, which disrupts BZD binding (366). Increased BZD-sensitive γ2-GABAAR 
internalization and trafficking in vivo has been implicated with sustained DZP exposure (270). 
Accordingly, increased expression of PKCγ (Table 4) in DZP treated mice may promote increased 
α1-GABAAR internalization, as is seen with ethanol treatment (149). An elevated rate of 
extrasynaptic endocytosis of α1 receptors may also provide context to the observed reduction in 
GABAAR tonic current (Fig. 25). Additionally, the increase in total and synaptic GABAAR γ2 
subunit levels observed biochemically (Fig. 24, Fig. 28) may be an adaptive response to rescue 
inhibition as a result of augmented endocytosis rates of α1-GABAARs and lead to incorporation 
of atypical GABAAR subtypes (α4/γ2) at synapses. 
Enhanced inhibition via DZP-mediated GABAAR potentiation would likely result in a 
homeostatic upregulation of excitation to restore E/I balance. Importantly, over the last twenty 
years, the majority of studies have focused on hippocampal plasticity found following 2 days of 
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BZD withdrawal, leaving the BZD adapted cortex before drug withdrawal relatively 
uncharacterized. Due to the many confounds and changes induced with the evolving 
hyperexcitability of the withdrawal state and the prolonged removal of BZD drugs, the 
glutamatergic receptor adaptations shown for sedative tolerance here may be distinct from 
withdrawal studies. For example, NMDAR currents are reduced in two day flurazepam withdrawn 
rats in the CA1 hippocampus (299, 419), potentially due to reduced GluN2B but not GluN2A 
receptor levels (420), while AMPAR-mediated miniature excitatory postsynaptic current (mEPSC) 
amplitude are diminished after one and two-day withdrawal (299, 421). Behaviorally, AMPAR 
current amplitude and anxiety-like behavior measured in the elevated plus-maze in one-day FZP-
withdrawn rats is enhanced (422). GluN2B levels are not decreased after one day of flurazepam 
withdrawal, suggesting down regulation of NMDAR function does not occur until later (423). 
Conversely, a single in vivo dose of DZP increased the AMPA/NMDA current ration in ventral 
tegmental area dopaminergic neurons that lasted up to 72 hours, suggesting brain region and time-
dependent plasticity (354).  
Here we identify in a seven day DZP treatment sedative tolerance paradigm, where animals 
are not in a withdrawal state, enhanced cortical NMDAR subunit levels by western blot analysis 
(Fig. 26) and decreased AMPA/NMDA amplitude ratio without changes in AMPA mEPSCs  (Fig. 
27), suggesting selectively increased NMDAR function. In agreement, behavioral data suggests 
co-administration of the highly potent competitive antagonist NMDAR CPP, but not the AMPAR 
antagonist GYKI 52466, prevents development of sedative behavioral tolerance after DZP in mice 
(349). MK801, a non-competitive NMDAR agonist also prevents the development of tolerance to 
locomotor effects (350) of DZP. These findings are consistent with a generalized role of increased 
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NMDAR function in tolerance to a number of pharmacological drug classes including opioids 
(346), ethanol (347) and barbiturates (348). 
To gain a more holistic understanding of the mechanisms leading to DZP tolerance, both 
directly and indirectly related to the changes observed in our biochemical and electrophysiology 
findings, we performed a quantitative proteomics screen against 500+ key synaptic proteins. We 
found a enrichment in a number of kinase pathways associated with increased NMDAR function 
including elevated CaMKII subunit levels (424), PKC isozymes (372, 373) and protein tyrosine 
kinase 2 beta (383-385). Interestingly, CaMKII inhibition in two-day flurazepam withdrawn rats 
reverses increased AMPAR single-channel conductance (425). This was later connected to 
CaMKIIα-mediated GluA1 Ser831 phosphorylation in the postsynaptic density of two-day FZP-
withdrawn rats without changes in (P)T286 CaMKIIα levels (426). This may suggest a general 
increase in CAMKII levels during both tolerance and withdrawal. This increase in CaMKII 
appears to occur after prolonged DZP treatment, as a single dose decreased transcript levels of 
CAMKIIα in mice cortex (427), and our lab found decreased association of GABAARs with 
CAMKIIα 12h following DZP injection (270).  
Interestingly we found both the PKCγ isoform and CaMKII subunits to be increased after 
seven day DZP treatment. Multiple studies implicate both of these kinases as essential for the 
generation and maintenance of opioid tolerance and dependence (374, 428-435). PKC activation 
by 4beta-phorbol-12,13-dibutyrate (PDBu; 100nM, 10 min) in endogenous GABAARs of NT2-N 
neurons caused a rightward shift of the concentration-response curve for DZP positive allosteric 
enhancement without affecting the maximal response, suggesting decreased allosteric coupling of 
DZP and GABA sites (436). Our proteomic studies also found elevated PKCε isozyme levels after 
DZP (Table 4), which has been described to reduce GABAAR sensitivity to ethanol and BZDs in 
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vitro and in vivo by acting at a γ2 S327 residue (150) and negatively regulates cell surface 
GABAARs levels through the membrane fusion ATPase N-ethylmaleimide-sensitive factor (NSF) 
(437). Importantly, a significant increase in NSF protein peptides after DZP exposure was also 
seen (Table 4). Both PKCγ and PKCε knock‐out mice exhibit altered ethanol potentiation of 
GABAAR mediated Cl– flux (438), where chronic ethanol consumption decreases association of 
PKCγ association with α1 but increases its association with α4 (439). Short (4 h) ethanol exposure 
induces internalization of α1-containing GABAARs (149) coinciding with an increase in surface 
levels of the α4 subunit (440) with both adaptations occurring in a PKCγ dependent manner. 
Notably, PKCγ is recruited to the membrane after opioid exposure (441, 442) and PKCγ kinase 
mutant mice demonstrate reduced tolerance (374) and blocks delayed pronociceptive sensitivity  
to opioid agents (375). Herein we observed increased α1 subunit and PKCγ levels after seven days 
DZP treatment, suggesting an increase in surface GABAAR populations undergoing drug-induced 
endocytosis and intracellular trafficking in agreement with our previous findings at earlier DZP 
treatment time points (270).  
We further analyzed our proteomics data by using IPA bioinformatics analysis to 
determine changes in pathway activation or enrichment. Canonical pathway analysis revealed 
strong predicted activation of synaptogenesis signaling, synaptic LTP and CREB signaling in 
neurons pathways (Fig. 29A). Individual biological pathway assessment suggested the release 
of neurotransmitter, development of neurons, and long-term potentiation favored an activated state 
(Fig. 29B). Statistically significant protein peptide changes with the most robust difference 
between DZP and vehicle animals support these changes including growth cone regulator GAP-
43 (377-379), the Ca2+-sensors Syt1 and Syt7 that contribute to both presynaptic synaptic vesicle 
ready releasable pool and postsynaptic trafficking to support LTP (443), piccolo (387), dynamin-
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3 (391) and RAB3A (390) and the critical phosphodiesterase enzyme PDE2 (395, 396). The 
collective bioinformatics and proteomics analysis supports synaptic plasticity, in part through 
NMDAR pathway upregulation and function. 
Here we leverage a comprehensive experimental approach utilizing behavioral testing, 
biochemistry, quantitative proteomics and electrophysiology to examine the neuronal adaptions 
occurring in response to DZP tolerance in vivo. Our study reveals complex alterations in both 
inhibitory and excitatory neurotransmission that have similar profiles to ethanol and opiate 
tolerance. We find an increase in the synaptic levels of α1, γ2 and the DZP-insensitive α4 subunit, 
resistance to DZP potentiation and no change in GABA mIPSC amplitude or frequency. Moreover, 
an increase in NMDAR levels and function was observed by western blot analysis and by 
electrophysiology. These changes occurred coincidently with an increase in the levels of multiple 
CaMKII subunits and the PKCγ isozyme, known positive regulators of NMDAR function. These 
results define key aspects of the neuroadaptive signature of a brain with sedative BZD tolerance. 
Future studies will need to identify if other BZD class drugs with different pharmacokinetic and 
pharmacodynamics profiles relative to DZP elicit similar changes found here. Moreover, the FDA 
approved NMDAR inhibitor memantine poses an interesting candidate to inhibit or reverse the 
DZP induced adaptations, as it has been show to alleviate some negative side effects resulting from 
opioid (444) and alcohol intake (445, 446). Advancing our understanding and identifying possible 
targets for treatments for the neuroadaptations produced by long-term BZD are critical for clinical 
care considering that during the last two decades prescription dosage and/or length of treatment 
has steadily risen (323).  
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5.0 Final Conclusions 
A deeper molecular understanding of the factors influencing the pharmacological profile 
of GABAARs is crucial for current clinical practices and future drug development. GABAAR 
regulatory mechanisms including trafficking, post-translational modifications and composition 
directly and dynamically tune receptor activity and function during neuronal scaling. Herein we 
investigated the compensatory neuroadaptations occurring after initial and prolonged treatment 
with the highly utilized clinical drug, DZP, where functional and behavioral tolerance to DZP has 
occurred. This work included the generation and characterization of a novel dual reporter 
GABAAR optical tool with multiple imaging based applications. The γ2pHFAP construct aided our 
ability to detect elusive trafficking changes in receptors after initial DZP and an in vitro epilepsy 
paradigm, and this tool will remain highly useful for future studies into GABAAR trafficking 
regulation. The comprehensive use of advanced imaging techniques, biochemistry and label-free 
quantitative proteomics revealed a complex array of trafficking and regulatory mechanisms 
dampening inhibitory synapse function in response to one day DZP exposure. Compromised 
gephyrin scaffolding, increased internalization and lysosomal targeting of select GABAAR 
subtypes, and enhanced γ2-GABAAR association with intracellular and surface trafficking protein 
mediators in vivo defined this work.  
Many classical studies have attempted to solve the molecular fingerprint of a BZD tolerant 
brain, but conclusive evidence remains undetermined due to differences in research paradigm, 
brain-region and experimental tool limitations (32). Our work utilized a comprehensive 
experimental strategy in a behaviorally-validated DZP tolerance model to measure protein level 
changes in inhibitory and excitatory receptors, functional validation by electrophysiology and a 
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targeted synaptic proteome screening. These findings revealed alterations in subunit specific 
synaptic and extrasynaptic GABAAR localization coupled with a general increase in GABAAR 
subunits. Additionally, we identified enhanced NMDAR subunit levels and function, and an 
upregulation of proteins regulating neuronal remodeling, development, and excitatory synapse 
strengthening. The use of SRM based quantitative proteomic methods afforded us detection of a 
number of key kinase mediators altered by DZP including CAMKII and PKC subtypes that have 
also been determined to be important in the adaptive drug response to ethanol and opiates. 
Importantly, we identified a unique response profile between early and sustained DZP treatment, 
including opposing changes in GABAAR subunit levels and the inhibitory scaffolding protein 
gephyrin. This work highlights the necessity of multiple experimental approaches and emphasizes 
the importance of understanding drug effects at different stages of treatment exposure. Current 
clinical and new GABAAR modulating therapies will have to strongly consider the short- and long-
term consequences of manipulating GABAAR function and the brains fundamental mechanisms to 
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